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ABSTRACT 
Migration of circulating leukocytes into extravascular tissues is required for the 
effective functioning of the immune system, being essential to such processes as 
inflammation, and lymphocyte recirculation between the blood, secondary 
lymphoid tissues and non-lymphoid tissues. Extravasating leukocytes first 
adhere to the lumenal surface of the vascular endothelium, migrate between (cv""ti., .. ·ch.\ ,) '/ 
the endothelial cells, and penetrate the subendothelial basement membrane. 
Leukocyte-endothelial adhesive interactions have been well characterised at the 
molecular level, however the mechanisms by which leukocytes penetrate the 
subendothelial basement membrane are less clear. Several studies suggest that 
activated leukocytes secrete hydrolytic enzymes which degrade the basement 
membrane. Following evidence that cell surface localization of degradative 
enzymes may be an important means of regulating ECM degradation by 
metastatic tumour cells, and that lysosomal enzymes can be expressed on the 
cell surface via mannose 6-phosphate receptors (MPRs), Parish and coworkers 
proposed that leukocyte extravasation mav be dependent on the cell surface 
expression of degradative lysosomal enzymes. They subsequently showed that 
mannose 6-phosphate (M6P) and castanospermine, both inhibitors of the 
lysosomal enzyme-MPR interaction, are potent inhibitors of passively-induced 
experimental autoimmune encephalomyelitis (EAE) and adjuvant arthritis in 
rats. As development of disease in these animal models is dependent on the 
passage of transferred T cells from the circulation into the appropriate tissue, 
the anti-inflammatory effects of these compounds were proposed to result from 
their ability to prevent the binding of lysosomal enzymes to cell surface MPRs 
on extravasating T cells. The aim of this thesis was to test the hypothesis, 
proposed by Parish et al. (1990), that cell surface expression of lysosomal 
enzymes via MPRs contributes to degradation of the subendothelial basement 
membrane by extravasating leukocytes. 
The MPRs include two receptors, designated MPR-300 and MPR-46 on the basis 
of Mr, which are expressed predominantly on intracellular membranes, with 
approximately 10°/o at the plasma membrane. They recognise a M6P marker 
common to all lysosomal enzymes, and mediate their transport to lysosomes by 
both an intracellular and endocytic pathway. Newly synthesized lysosomal 
enzymes are bound by MPR-300 and MPR-46 in the Golgi apparatus, and 
transported to a prelysosomal compartment, from which they are packaged 
into lysosomes. Enzymes may also be secreted, either through failure to bind 
MPRs in the Golgi, or directly by means of MPR-46. Extracellular lysosomal 
enzymes can be recaptured and endocytosed by MPR-300 expressed at the cell 
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surface. Secretion of lysosomal enzymes from the cell, and subsequent binding 
to celLsurface MPR-300, are thus central to our hypothesis. , 
If MPR-300 is involved in the cell surface expression of degradative enzymes by 
extravasating leukocytes, then disruption of ligand binding to this receptor 
should reduce the ability of these cells to degrade the subendothelial basement 
membrane, by analogy with the proposed action of M6P in EAE and adjuvant 
arthritis. The first part of this study aimed to specifically prevent lysosomal 
enzyme binding to cell surface MPR-300, using monoclonal antibodies (mAbs) 
specific for this receptor. Chapter 2 describes an assay for detecting cell surface 
MPR-300, based on the binding and endocytosis of a fluorecein-labelled, M6P-
rich polysaccharide (PPME). This assay was used to identify a rat cell line 
expressing MPR-300 on the plasma membrane, for use in screening hybridoma 
supernatants for antibodies specific for the extracellular portion of MPR-300. 
As this assay was dependent on binding of a M6P-bearing ligand, it also 
established a method for screening antibodies for their ability to inhibit ligand 
binding to MPR-300. In Chapter 3, a panel of 12 monoclonal antibodies specific 
for the extracellular portion of rat MPR-300 were produced. Using the PPME 
binding and uptake assay, their ability to disrupt ligand binding to cell surface 
MPR-300 was assessed. None interfered with ligand binding to a significant 
degree, precluding their use in examining the consequences of inhibiting cell 
surface binding of lysosomal enzymes on the ability of T cells to induce EAE in 
vivo, or to degrade ECM components in vitro. 
The second part of this study involved a comparison of the cell surface 
expression of MPR-300 in resting and activated T cells. As activated, but not 
resting, T cells enter the central nervous system (CNS) and induce EAE, Parish 
and coworkers proposed that the cell surface expression of lysosomal enzymes 
may be increased by activation, thus contributing to the enhanced invasive 
capacity of these cells. Lysosomal enzyme expression at the cell surface could 
be increased through an activation-induced upregulation of MPR-300 on the 
plasma membrane, thus providing additional binding sites for extracellular 
enzymes. In addition, the extracellular pool of lysosomal enzymes available for 
binding could be raised through an increase in the expression of MPR-46 in the 
Golgi, as this receptor participates in the secretion of newly synthesized 
1 ysosomal enzymes. 
The study described in Chapter 4 compared the cell surface expression of MPR-
300 on resting and activated T lymphocytes from a variety of sources, using one 
of the mAbs specific for rat MPR-300 prepared in Chapter 3. No MPR-300 was 
detectable on the cell surface of rat lymphocytes from secondary lymphoid 
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tissues or the peritoneal cavity, or on rat and human peripheral blood 
leukocytes, with the exception of human neutrophils. Expre~sion of MPR-300 
was induced on the plasma membrane of rat T cells by several activating 
stimuli. MPR-300 was expressed on the surface of splenic T cells after 3-4 days 
stimulation with Con A, although similar treatment did not affect human 
peripheral blood T cells. MPR-300 was also detected on the plasma membrane 
of activated T cells present in a thioglycollate-induced inflammatory peritoneal 
exudate. These observations demonstrate that unstimulated T cells do not 
express MPR-300 at the cell surface, and support the proposal that it's 
expression can be induced by activating stimuli, consistent with the hypothesis 
that expression of lysosomal enzymes on the plasma membrane of activated T 
cells facilitates their degradation of the subendothelial basement membrane 
and entry into extravascular tissues. 
Endothelial cells are known to provide activating signals to adherent 
leukocytes, producing such effects as integrin-mediated tight binding, which 
enhance their capacity to extravasate and enter the extravascular tissue. In 
Chapter 5, endothelial cells were examined for their ability to induce MPR-300 
expression on the plasma membrane of adherent T cells. Expression of MPR-
300 at the surface of T lymphocytes, both resting and Con A-stimulated, was 
assessed after adhesion to endothelial cell monolayers. Neither resting or 
stimulated human peripheral blood T cells expressed MPR-300 initially, and 
adhesion to human umbilical vein endothelial (HUVE) cells had no affect on 
the resting T cells. Con A-stimulated cells, however, showed a marked, 
transient increase in MPR-300 expression after adhesion, demonstrating that 
endothelial cells can induce the upregulation of MPR-300 on T cells. The 
inability of endothelial cells to induce MPR-300 expression on resting cells 
suggested that two signals are required, such that interaction with endothelium 
provides a second signal to cells which have been pre-activated. 
This suggested a re-evaluation of the conclusion drawn in Chapter 4, that 
activating stimuli directly induce expression of MPR-300 on the surface of T 
lymphocytes. A requirement for both a pre-activating and an endothelial-
derived signal is compatible with MPR-300 expression by activated peritoneal 
exudate lymphocytes, as these cells entered the peritoneal cavity from the 
circulation and so have had the opportunity to interact with the vascular 
endothelium. It can also be reconciled with the expression of MPR-300 on Con 
A-stimulated rat T cells. Interaction with rat brain microvascular endothelium 
did not induce further MPR-300 expression on these cells, suggesting that 
human and rat T cells may interact differently with Con A, such that Con A 
X 
supplied the rat T cells with both the activating and otherwise endothelial-
derived signals. 
The demonstration that endothelial cells can induce the upregulation of MPR-
300 on pre-activated T cells suggests a modification to the hypothesis proposed 
by Parish et al. (1990). Expression of MPR-300 does appear to be restricted to 
recently activated T cells, consistent with the proposal that the activated, more 
invasive phenotype corresponds with the ability to express lysosomal enzymes 
at the cell surface, however activation alone may be insufficient to induce this 
change. Activation may prime circulating T cells, enabling them to later 
upregulate MPR-300 expression in response to an endothelial-derived signal. 
This is an attractive possibility as it correlates with the increased invasive 
potential of activated T cells, but restricts cell surface expression of MPR-300, 
and potentially lysosomal enzymes, to T cells in contact with the vascular 
endothelium. This limits the ability to degrade the subendothelial basement 
membrane by a lysosomal enzyme-dependent mechanism to T cells that have 
commenced the process of extravasation. 
Xl 
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1.1 Introduction 
Migration of leukocytes from the bloodstream into extravascular tissues is 
essential for the effective functioning of the immune system. A principal 
function of the immune system is to protect the host against microbial invasion, 
and its defensive role involves continuous surveillance of lymphoid and non-
lymphoid tissues for the presence of foreign antigen, followed by proliferation 
and differentiation of antigen-specific cells, and dissemination of effector cells 
to sites of antigen exposure. Lymphocytes are the major participants in this 
process, as they determine the specificity of the immune response, and their 
response to antigen orchestrates its effector limb. Naive lymphocytes 
constantly recirculate between the blood and the secondary lymphoid tissues, 
an important means of exposing potentially reactive lymphocytes to the full 
spectrum of antigen entering the body. Once activated, effector or memory 
lymphocytes also enter peripheral tissues in small numbers, presumably for the 
purpose of immune surveillance, as well as in response to low level antigenic 
challenges. The most spectacular induction of leukocyte migration into tissues, 
however, occurs during an inflammatory response, in which neutrophils, 
monocytes and lymphocytes migrate into injured or infected tissues on a large 
scale. Leukocyte migration also contributes to some less desirable effects of the 
immune response, such as chronic inflammation, cell-mediated autoimmune 
disease and graft rejection (Vachula and Epps, 1992). 
Leukocyte migration into extravascular tissues has been studied largely in the 
context of lymphocyte recirculation, and inflammation, the major features of 
which are outlined below. 
1.2 Leukocyte migration into extravascular tissues 
1.2.1 Lymphocyte recirculation 
Lymphocytes recirculate continuously through the various tissues of the body, 
entering from the blood and leaving via the lymph. Since very few 
lymphocytes recognise any specific antigen, this constant movement is 
necessary to give the entire range of receptor specificities the opportunity to 
contact antigen. Lymphocyte migration also disseminates the effector and 
memory cells produced in a local immune response to other regions of the 
body, ensuring systemic immunity. The recirculation pathway is dependent on 
the cell type and its differentiation state. B cells, for example, migrate 
preferentially to mucosa-associated lymphoid tissues, while T cells favour 
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peripheral lymph nodes. Naive cells recirculate between all secondary 
lymphoid tissues, but once activated, effector and memory cells also migrate to 
non-lymphoid sites in a highly tissue-specific manner. This field has been 
reviewed recently by Butcher (1986), Duijvestijn and Hamann (1989), Mackay 
(1991), Mackay (1992), (Mackay (1993a), Picker and Butcher (1992), and 
Yednock and Rosen (1989). 
Naive or virgin lymphocytes preferentially migrate to secondary lymphoid 
tissues (Mackay, 1991), such as the spleen, peripheral lymph nodes (PLNs) and 
non-encapsulated mucosa-associated lymphoid tissues (MALT; including the 
Peyer's patches in the lamina propria of the small intestine, tonsils in the 
pharynx, and lymphoid follicles in the appendix and upper airways) (Abbas et 
al., 1991). The PLNs and MALT are the termination point of the afferent 
lymphatics which drain lymph from most tissues, carrying with it antigens that 
have entered the body through skin or mucosal surfaces, while the spleen 
filters the blood, accumulating antigens that have entered the vascular system 
(Picker and Seigelman, 1993). These lymphoid tissues thus act as a collection 
point for both lymphocytes and antigens, bringing them together in the 
presence of specialized antigen presenting cells in an environment suited to the 
activation of naive lymphocytes (Mackay, 1993a). Lymphocytes enter 
lymphoid tissues_across high endothelial venules (HEV), specialized regions of 
the vasculature which selectively mediate high levels of extravasation . After 
about 18-20 h in the lymph node, lymphocytes that fail to contact antigen leave 
with the efferent lymph and return to the bloodstream via the thoracic duct 
(Mackay, 1991). Naive cells are thought to recirculate between the various 
secondary lymphoid tissues until they either respond to their specific antigen 
or die. 
Lymphocytes that encounter specific antigen within the lymphoid tissues 
differentiate into effector or memory cells, and return to the circulation with 
markedly different recirculation properties. Firstly, they migrate to non-
lymphoid tissues, both constitutively at very low levels Ganossy et al., 1989; 
Mackay et al., 1990; Rannie and Donald, 1977), and at much higher levels 
during inflammation (Pitzalis et al., 1988; Pitzalis et al., 1991; Saltini et al., 1990). 
Secondly, homing is tissue-specific, with distinct subsets of cells recirculating 
through particular organs or tissues; this preference may be for the 
tissue/lymphatic bed in which they were first activated (Picker and Butcher, 
1992). Many investigators have shown two distinct pools of recirculating 
lymphocytes, one associated with peripheral lymph nodes,and the other with 
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gut-associated lymphoid tissues (Peyers patches and mesenteric lymph nodes). 
Lymphoblasts obtained from PLNs and injected intravenously into recipient 
animals return preferentially to the PLNs (Griscelli et al., 1969; McDermott and 
Bienenstock, 1979), whereas lymphoblasts from the thoracic duct, mesenteric 
lymph nodes or intestinal lymph migrate to gut mucosa and gut-associated 
lymphoid tissue (Gowans and Knight, 1964; Griscelli et al., 1969; Hall et al., 
1979; McDermott and Bienenstock, 1979; Rose et al., 1976). Small lymphocytes 
from the efferent intestinal lymph also relocalize to gut-associated lymphoid 
tissues and efferent intestinal lymph (Chin and Hay, 1980; Scollay et al., 1976). 
Several studies also suggest the existence of a lung-homing population of 
lymphoblasts and small lymphocytes (McDermott and Bienenstock, 1979; 
Spencer and Hall, 1984). Tissue-selective homing properties may enhance the 
efficiency of the immune system by targeting immune surveillance to tissues 
similar to those where antigen first entered the body; they may also reduce 
opportunity for autoimmune cross-reactions with self-antigens from other 
tissues (Picker and Butcher, 1992). 
Tissue-selectivity is regulated, at least in part, by selective lymphocyte-
endothelial cell recognition. Homing receptors are expressed on specific 
subpopulations of T cells, and recognise vascular addressins expressed on the 
endothelium. Re_cent work suggests that the local microenvironment at the 
time of lymphocyte activation in lymphoid tissue influences the expression of 
tissue-selective homing receptors (Picker et al., 1993a; Picker et al., 1993b ). L-
selectin has been identified as a homing receptor for PLN-homing cells, and the 
a.4~7 integrin LP AM-1 for mucosal homing cells. The former binds a 50 kDa 
glycoprotein expressed on PLN HEV endothelial cells, while the most likely 
ligand for LPAM-1 is a 55-65 kDa glycoprotein specifically expressed by HEVs 
in Peyer's patches and mesenteric lymph nodes (reviewed by Jutila (1994)) . 
Homing mechanisms for migration of lymphocytes into inflamed skin and 
inflamed synovium have also been described. E-selectin acts as a vascular 
addressin on the endothelium of chronically inflamed skin, and binds a skin-
associated subset of memory/ effector T cells defined by expression of the 
cutaneous lymphocyte-associated (CLA) antigen (Picker et al., 1991), which acts 
as a homing receptor (Berg et al., 1991). T cell entry into the inflamed synovium 
may also involve a synovial vascular addressin Galkanen et al., 1986; Salmi and 
Jalkanen, 1992). 
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1.2.2 Inflammation 
Inflammation generally occurs as a defensive response to injury, and is 
commonly initiated by microbial infection, as well as mechanical trauma and 
toxins. It is a localised reaction which seeks to eliminate the inciting agent and 
restore the tissue to a normal state (Callin et al., 1992). Most forms of 
inflammation involve both humoral and cellular components of the immune 
system, and antigen may be recognised as "foreign" by specific or non-specific 
means. Non-specific recognition (ie. recognition of carbohydrates, denatured 
proteins or endotoxins) can be mediated by tissue phagocytes or the alternative 
complement pathway. Tissue macrophages respond by phagocytosis of the 
offending material and release of inflammatory cytokines such as IL-1, TNF 
and IL-8 (Muller-Eberhard, 1989; Wright, 1992). Microbes which activate the 
alternative complement pathway are opsonized with C3b, which enhances 
phagocytosis, and leads to formation of the membrane attack complex; in the 
process, the pro-inflammatory fragments C3a, C4a and CSa are released (Abbas 
et al., 1991; Wright, 1992). Specific recognition is mediated by antigen-specific 
immunoglobulins or T cell receptors. The former activate the complement 
cascade, mainly by the classical pathway (Feinstein et al., 1986). Complement 
fragments, CSa in· particular, attract granulocytes and mononuclear phagocytes 
to the site of antibody deposition. These recognize antibody-coated target cells 
via Fe or complement receptors, leading to phagocytosis (Wright, 1992). T cell 
recognition of antigen, presented by tissue macrophages in association with 
MHC molecules, may induce a cell-mediated response, in which circulating 
phagocytic cells (neutrophils and monocytes) are induced to enter the infected 
tissue by T cell-derived cytokines such as IL-1 and TNF (Abbas et al., 1991). 
Both modes of recognition initiate the release of proinflammatory substances, 
such as cytokines, prostaglandins and leukotrienes released by cells 
participating in inflammatory processes (Baggiolini et al., 1992; Davies and 
MacIntyre, 1992; Dinarello, 1992; Lam and Austen, 1992), or complement-
derived peptides (Abbas et al., 1991). These mediators alter blood flow, 
increase vascular permeability, activate vascular endothelium, and promote the 
migration of circulating neutrophils and monocytes into tissues. These 
phagocytic cells mediate the actual destruction of antigens (Callin et al., 1992). 
The infiltration of leukocytes into extravascular tissue, and their subsequent 
activation, are central events in most forms of inflammation (Callin et al., 1992). 
The cellular infiltrate is composed of neutrophils and/ or mononuclear cells, 
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depending on the nature of the inflammatory stimulus and the age of the lesion 
(Beekhuizen and van Furth, 1993; Issekutz et al., 1981). Neutrophils generally 
predominate initially, due to a large but short-lived influx which peaks within 
in a few hours of the onset of inflammation. As the life-span of neutrophils 
within the tissue is short, monocytes, which enter more slowly, come to 
predominate at later stages. Lymphocytes are usually a minor component of 
the acute inflammatory exudate (van Furth et al., 1979; Issekutz and Movat, 
1980; Issekutz et al., 1981; Paz and Spector, 1962). Chronic inflammation, which 
may derive from an unresolved acute inflammatory reaction 
is also characterized by leukocyte infiltration of extravascular tissue. 
The cellular infiltrate consists mainly of mononuclear phagocytes, lymphocytes 
and plasma cells, although neutrophils and eosinophils may also be present 
(Gallin et al., 1992; MacSween and Whaley, 1992). 
1.2.3 Leukocyte migration into non-inflamed, non-lymphoid tissues 
The bulk of leukocyte emigration into extravascular tissues occurs in the 
lymphoid tissues and at sites of inflammation. There is, however, some 
movement of blood monocytes into non-lymphoid tissues under steady-state 
conditions (Beekhuizen and van Furth, 1993). There they differentiate into 
either free- or fixed-tissue macrophages (MacSween and Whaley, 1992), and act 
as phagocytic scavengers (Johnston, 1988). Free-tissue macrophages migrate 
through the loose connective tissues of the peritoneum, lymphoid tissues, 
pulmonary alveoli and brain (microglia), while the fixed-tissue macrophages 
remain within a single organ, such as the sinusoids of the liver (Kupffer cells), 
spleen and bone marrow, and the lymphatic sinuses of lymph nodes 
(MacSween and Whaley, 1992). 
Entry of lymphocytes into normal, non-lymphoid tissues occurs at a low level, 
demonstrated by the small amount of radioactivity found in tissues such as 
kidney, muscle, brain and skin after intravenous injection of labelled thoracic 
duct lymphocytes (Rannie and Donald, 1977), and the correspondingly low 
numbers of lymphocytes found in the afferent lymph draining all tissues except 
liver and gut mucosa. There are, for example, 200-800 lymphocytes/mm3 in 
the afferent lymph draining skin or muscle, compared with is 2, 000-4, 
OOO/mm3 in efferent lymph or blood (Parrott and Wilkinson, 1981). Migration 
into non-lymphoid tissues is largely restricted to small lymphocytes with 
effector/memory phenotype, and lymphoblasts. Lymphocytes of the 
effector/ memory phenotype have been isolated from the afferent lymph in 
sheep (Mackay et al., 1990; Smith et al., 1970). Blast cells isolated from in vivo 
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stimulated lymphoid tissues and injected into syngeneic recipients distribute 
between the lung, liver, spleen and skin in the case of PLN-derived cells, or 
enter the lamina propria of the gut in the case of blast cells derived from 
mesenteric lymph nodes. Lymphocytes activated in vitro by lectins and other 
mitogens behave similarly (reviewed by Hamann and Rebstock, 1993), and 
antigen-stimulated T cell blasts have been observed to enter the central nervous 
system (Hickey et al., 1991; Ludowyk et al., 1992). These cells subsequently e :· h ,- d~e 
; ,._ oy .51s O return to the draining lymph nodes via the afferent lymphatics, and eventually 
to the blood via the efferent lymph. Constitutive migration of effector/ memory 
lymphocytes and blast cells into non-lymphoid tissues may constitute an 
immune surveillance mechanism, whereby antigen-primed lymphocytes are 
able to respond promptly to recall antigens as soon as they enter the body 
(Mackay, 1991). 
1.3 The barrier to leukocyte migration: structure of the venular 
wall 
Entry of circulating leukocytes into extravascular tissues requires penetration 
of the vascular wall. In general, leukocyte extravasation is believed to occur in 
the postcapillaiy venular segments of the microvasculature (Marchesi, 1961). 
Post-capillary v~nules are similar in structure to capillaries, although larger, 
consisting of a single layer of endothelial cells overlying a thin, continuous 
basement membrane, and encased by a periendothelial sheath of pericytes, 
collagen fibres and a few elastic tissue fibres (Marchesi and Florey, 1960; 
Simionescu et al., 1975). 
Specialized post-capillary venules support the migration of lymphocytes into 
lymph nodes and the MALT of the gut and lungs. These are known as high-
endothelial venules (HEVs) due to their cuboidal, plump cell morphology 
(Anderson et al., 1976; reviewed by Kraal et al., 1987). HEVs are a permanent 
feature of lymphoid tissues, however their number and length vary with local 
immune activity (Anderson et al., 1975; Hendriks et al., 1987), and HEV-like 
structures often develop at sites of chronic inflammation Galkanen et al., 1986; 
Oppenheimer-Marks and Ziff, 1986). HEV morphology varies between species; 
endothelial cells in rats and guinea pigs are less cuboidal than those of mice 
and humans, while in sheep, HEVs are not discemable at all (Kraal et al., 1987). 
In the rat, HEVs are lined by polygonal endothelial cells, separated by 
intercellular gaps of 200-400 A, and joined by tight junctions near their apical 
and basal surfaces. This endothelium rests on a basement membrane. A 
complex sheath of connective tissue surrounds the venule, consisting of two or 
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three layers of overlapping reticular plates which are also covered by basement 
membrane, and are linked to the underlying stroma of the lymph node by 
collagen fibres (Anderson et al., 1976; Wenk et al., 1974). 
1.3.1 Endothelial cells 
Endothelial cells line all the blood vessels of the body, forming an interface 
between blood and tissues. In most tissues, they form a continuous monolayer 
of tightly connected cells, exceptions being highly specialized endothelium in 
liver, spleen and bone marrow, where the monolayer is discontinuous (Smith et 
al., 1989). Morphologically, endothelial cells are relatively homogeneous. They 
are flattened, polygonal, elongated cells, approximately 25-50 µm long, 10-15 
µm wide, and 3 µm thick near the nucleus, with the long axis oriented in the 
direction of the bloodflow. Regional differences include some variation in size 
and thickness, and in relative content of organelles and vesicles (reviewed by 
Thorgeirsson and Robertson, 1978). 
Endothelial cells are connected by tight junctions, which contribute to their 
barrier function, and in some cases are also connected by gap junctions, which 
permit communication between cells (Alberts et al., 1986; Huttner et al., 1973; 
Simionescu et al., 1975). Each segment of the circulation has a characteristic 
arrangement of ·intercellular junctions. Arterial and arteriolar endothelial cells 
are joined by a composite system of tight junctions and gap junctions, while 
capillaries and post-capillary venules have tight junctions only (Simionescu et 
al., 1975; Simionescu et al., 1976). Post-capill~ry venules have the least 
organised endothelial junctions (Simionescu et al., 1975), which may be a factor 
in their being the favoured entry point for leukocytes during inflammation. 
Tight junctions create a diffusion barrier in the plasma membrane (Alberts et al., 
1986), and the lumenal and ablumenal membranes of endothelial cells are 
chemically and functionally distinct. The lumenal membrane is non-adhesive 
under normal conditions, allowing the free flow of blood cells, while the 
ablumenal membrane firmly adheres to the basement membrane, anchoring the 
cell to the subendothelial extracellular matrix (Defilippi et al., 1993). 
1.3.2 The extracellular matrix and basement membranes 
The extracellular matrix (ECM) is an intricate network of macromolecules 
which fills the extracellular space in tissues, and includes the basement 
membranes and connective tissue stromas. At the molecular level, it consists 
largely of proteoglycans which form a highly hydrated, gel-like framework in 
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which structural (collagen and elastin) and adhesive (fibronectin and laminin) 
fibrous proteins are embedded. The proteoglycan gel permits the diffusion of 
nutrients, metabolites and hormones between capillaries and tissue cells. 
Collagen fibres strengthen and organise the matrix, elastin fibres provide 
resilience, and adhesive proteins mediate cell attachment (Alberts et al., 1986; 
Shimizu, 1991). 
Basement membranes are specialized extracellular matrices found in most 
multicellular animal species. They are produced by epithelial cells, endothelial 
cells and many mesenchymal cells, forming a thin, but tough, sheet-like 
structure at the interface of cell layers and the underlying connective tissue 
(Fig. 1.1) (Vracko, 1974; Yurchenco and Schnittny, 1990). Basement membranes 
also completely surround adipocytes, muscle cells and Schwarm cells 
(Abrahamson, 1986), as well as some organs such as the kidney (Alberts et al., 
1986). The basement membrane provides physical support for cells and cell 
layers (Vracko, 1974); acts as a selective molecular sieve between tissue 
compartments, which impedes the passage of cells and macromolecules; and 
functions in the regulation of cell growth, attachment and differentiation 
(Yurchenco and Schnittny, 1990). Most basement membranes have at least 
three morphologically distinct layers, discernible by electron microscopy. The 
lamina lucida, approximately 40-60 nm in thickness, lies directly beneath the 
plasma membrane of the overlying cell layer. The central lamina densa, or 
basal lamina, is an electron dense layer of similar thickness. The outer layer is 
known as the lamina fibroreticularis or sub-lamina densa. Fine strands of 
fibrillar material connect the basal lamina and overlying cell membranes, and 
in some cases anchor also it to the underlying connective tissue (Abrahamson, 
1986). 
Although the precise composition of the basement membrane varies between 
tissues, all contain type IV collagen, the glycoproteins laminin and entactin, and 
proteoglycans (Alberts et al., 1986; Schultz, 1991): 
Type IV collagen is unique to basement membranes, and unlike other ECM 
collagens (types I-III), does not form fibrils. Instead rod-like monomers 
associate by their C-terminal domains to form head-to-head dimers, while 
tetramers form by lateral association of N-terminal regions (Fig. 1.2) (Mignatti 
and Rifkin, 1993; Timpl, 1989). 
Laminin is a flexible, cross-shaped glycoprotein, consisting of three polypeptide 
chains held together by disulfide bridges (Fig. 1.2). It has binding sites for 
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Fig. 1.1 
Scanning electron micrograph of the basement membrane in the cornea of 
a chick embryo. Epithelial cells (E) have been removed to expose the 
upper surface of the basement membrane (BL). A network of collagen 
fibrils (C) interacts with the lower surface. 
Photograph from Alberts et al., (1986). 
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Fig. 1.2 Scale diagrams of basement membrane macromolecules. 
a. Type IV collagen monomers form a triple-stranded helical rod, terminating in a 
globular C-terminal domain. 
b. Type IV collagen tetramers form by lateral association between N-terminal 
segments arranged alternately in parallel and antiparallel fashion. Networks of 
collagen IV may also form by crosslinking of tetramers at the globular C-terminal 
domains and by lateral associations along the arms. 
c. Heparan sulfate proteoglycan showing three heparan sulfate chains bound to a 
smaller core protein. Larger forms also exist. 
d. Laminin 
e. Entactin 
Adapted from Abrahamson (1986), Timpl (1989), Yurchenko and Schittny (1990) 
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interstitial and type IV collagens, heparan sulfate, entactin, and cell surface 
laminin receptors. The latter mediate cell-matrix interactions, and influence cell 
attachment, spreading, growth and differentiation (Timpl, 1989; Timpl and 
Dziadek, 1986). 
Entactin (also called nidogen) is a sulfated glycoprotein, consisting of a 
globular domain connected to a thin tail, which terminates in a second, smaller 
globular domain, forming a characteristic dumbell shape. It binds to the centre 
of the cross-shaped laminin molecule, to fibronectin, and to the globular 
domain of type IV collagen (Mignatti and Rifkin, 1993). 
Proteoglycans are high Mr structures consisting of a protein core covalently 
bound to as many as 100 glycosaminoglycan (GAG) chains (reviewed by Kjellin 
and Lindahl, 1991). GAGs are long, linear polysaccharides composed of 
repeating disaccharide units, one residue of which is always an aminosugar. 
Seven types of GAG can be distinguished on the basis of sugar residues, and 
number and location of sulfate groups: hyaluronic acid (which is not linked to a 
protein core), chondroitin 4-sulfate, chondroitin 6-sulfate, dermatan sulfate, 
heparan sulfate, heparin and keratan sulfate (Alberts et al., 1986). Heparan 
sulfate is most common GAG found in basement membranes (Hassell et al., 
1986; Heremans et al., 1989; Ruoslahti, 1988), although small amounts of 
chondroitin sulfate and hyaluronic acid are also present (Lemkin and 
Farquahar, 1981). GAGs adopt highly extended, random-coil structures, 
occupying a huge volume relative to their mass. Being highly charged, GAGs 
are also strongly hydrophilic and form hydrated gels, thus they fill most of the 
extracellular space and provide mechanical support to tissues (Alberts et al. 
1986; Mignatti and Rifkin, 1993). 
According to current models, the basement membrane is a polygonal 
meshwork of polymerized type IV collagen and laminin, bridged by entactin 
and associated with heparan sulfate proteoglycans (Ratner, 1992; Schultz, 1991; 
Yurchenco and Schnittny, 1990). A schematic representation of the three 
dimensional structure of the three major components, collagen type IV, laminin 
and heparan sulfate proteoglycan (HSPG), is depicted in Fig. 1.3. Type IV 
collagen provides mechanical suppport by forming a sheet-like, polygonal 
framework through covalently stabilized N- and C-terminal and lateral 
associations. Laminin self-associates through terminal domain interactions to 
form a second lattice within the collagen framework. These two networks are 
connected by entactin, whose C-terminal domain binds both laminin and type 
IV collagen. Proteoglycans are firmly anchored in the basement membrane; the 
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Fig. 1.3 
Schematic representation of the three dimensional structure of the three 
major components of the basement membrane: type IV collagen (black), 
laminin (red) and heparan sulfate proteoglycan (blue). Type IV collagen 
and laminin form double polymer networks. Heparan sulfate 
proteoglycan complexes interact with collagen and laminin through their 
polyanionic sidechains. 
Adapted from Yurchenco and Schittney (1990). 
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protein cores bind one another to form oligomers, while GAG chains bind 
weakly to laminin and type IV collagen (Yurchenco and Schnittny, 1990). The 
high negative charge of sulfated GAG chains is important in controlling 
basement membrane permeability to charged macromolecules (Kanwar, 1984), 
and also has a charge-sieving effect, as these polyanionic chains possess large 
spheres of hydration which leave very little free space in the basement 
membrane, allowing passage to small macromolecules only (Yurchenco and 
Schnittny, 1990). 
1.4 Leukocyte extravasation 
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Leukocyte extravasation through the wall of the post-capillary venule consists 
of at least three consecutive events (Fig. 1.4), the first being adhesion to the 
endothelium. The vascular endothelium, described as the gatekeeper of the 
tissues (Pober and Cotran, 1990a), forms the primary interface between the 
bloodstream and the tissues of the body, playing an important role in 
regulating the traffic of circulating cells and metabolites across the vessel wall 
(Defilippi et al., 1993). Leukocytes adhere to the endothelium despite 
considerable shear forces generated by the blood flow (Luscinskas et al., 1994). 
Extensive study in recent years has revealed some of the molecular mechanisms 
involved in leukocyte-endothelial adhesion; these will be further discussed in 
Section 1.5 .1. 
Adhesion is followed by transmigration through the endothelial cell 
monolayer. The adherent leukocyte initially extends a pseudopod into the 
endothelium, followed by the rest of the cell. In some cases, the migrating 
leukocyte is also enveloped by endothelial cytoplasmic extensions (Shaw, 1980; 
Williamson and Grisham, 1961). It has been a matter of some controversy as to 
whether migration occurs through the body of the endothelial cell, or whether 
the point of entry is an interendothelial cell junction, but it is now generally 
believed that leukocytes pass between endothelial cells (Anderson and 
Anderson, 1976; Schoefl, 1972; van Ewijk et al., 1975; Yamaguchi and Schoefl, 
1983). The leading edge of the migrating leukocyte tends to be arrested at 
either the subendothelial basement membrane or the periendothelial cell layer 
until most or all of the leukocyte has passed beneath the endothelium, after 
which any defect in the endothelial layer is sealed (Hurley and Xeros, 1961; 
Schoefl, 1972; Shaw, 1980). The barrier function of the endothelium is 
preserved during transmigration, due to close interaction between the 
peripheral membranes of migrating leukocytes and endothelial cells, although 
Endothelial cell 
Fig. 1.4 
Basement 
membrane 
lntercellular 
junction 
Neutrophil 
adhering to 
endothelium 
Transmigration between 
endothelial cells 
Neutrophil breaking 
through basement 
membrane into 
tissue space 
Stages in the extravasation of neutrophils (or other leukocytes) 
through the vascular wall. Adapted from Bartlett (1993). 
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sustained migration of cells across the vascular wall can result in some leakage 
of plasma (Schoefl, 1972). 
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Once beneath the endothelium, the infiltrating cell must pass through the 
basement membrane. Migrating cells appear to "pause" in the space between 
the endothelium and periendothelial structures, both inside and outside the 
basement membrane, with the pressure of the leukocyte distorting the 
overlying endothelium (Hurley and Xeros, 1961; Marchesi and Florey, 1960; 
Zweifach, 1955). As early as 1960, it was suggested that leukocytes may have 
more difficulty passing through the basement membrane and periendothelial 
connective tissue than through the endothelium, and the possibility that they 
secrete enzymes which "soften up the cells and tissues through which 
emigration occurs" was raised (Marchesi and Florey, 1960). In one study, a new 
basement membrane formed between the emigrating cell and the endothelium 
while the original basement membrane disintegrated, releasing the lymphocyte 
into the extravascular space (Williamson and Grisham, 1961). In other studies, 
however, emigrating cells have been observed to pass through small holes in 
the basement membrane (Hurley and Xeros, 1961; Shaw, 1980). Once the 
infiltrating cell has passed, the endothelial cells reconstruct an intact monolayer 
of tightly connected cells, and repair any damage done to the basement 
membrane (Huber and Weiss, 1989). 
In contrast to other endothelia, lymphocytes migrating across HEVs appear not 
to be seriously impeded by the subendothelial basement membrane. Scanning 
electron micrographs of HEVs show that migrating lymphocytes accumulate 
between endothelial cells and pericytes. As basement membrane material has 
rarely been observed between lymphocytes and pericytes, the periendothelial 
sheath is likely to be the major obstacle to lymphocyte migration across HEV s 
(Marchesi and Gowans, 1964; Wenk et al., 1974). 
1.5 The molecular basis of extravasation 
1.5.1 Adhesion to the vascular endothelium 
Until recently it was believed that circulating leukocytes migrate into 
extravascular tissues in response to chemoattractants produced at sites of 
inflammation (Goldstein et al., 1977). Leukocytes were thought to "sense" the 
presence of a pathogen via specific chemoattractant receptors: once exposed to 
the chemoattractant within the vasculature, leukocytes were activated, 
becoming more adhesive for endothelium, and followed the "trail" of the 
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chemoattractant into the extravascular space. The role of the endothelium in 
this model was one of passive retraction, permitting the leukocytes to pass 
through (Cronstein and Weissman, 1993). 
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Recent work has shown that the endothelium actually plays a very active role 
in leukocyte extravasation, expressing adhesion molecules specific for counter-
receptors on circulating leukocytes. Diapedesis under non-inflammatory 
conditions is relatively restricted: recirculating lymphocytes enter lymph nodes 
by binding to and migrating across HEVs; blood monocytes leave the 
circulation at a low frequency to become tissue macrophages (van Furth, 1986); 
and lymphocytes also enter non-lymphoid, non-inflamed tissues at a low rate 
Oanossy et al., 1989; Mackay et al., 1990; Rannie and Donald, 1977). During 
inflammation, however, the endothelium lining the postcapillary venule is 
activated by cytokines and other mediators produced in the extravascular 
tissue, inducing or upregulating expression of adhesion molecules (Munro et 
al., 1989). According to this revised model, circulating leukocytes, which 
constitutively display receptors for endothelial adhesion molecules, adhere 
transiently to the stimulated endothelium. Once bound, they receive an 
activation signal, delivered by cytokines or cell surface interactions, which 
enables them to adhere more tightly, and migrate through the endothelial 
monolayer. Once in the extra vascular tissue, leukocytes follow a 
chemoattractant gradient toward the inciting pathogen (Butcher, 1991; 
Cronstein and Weissman, 1993; Osborn, 1990). 
The adhesion molecules involved in leukocyte-endothelial interactions belong 
to three major classes: selectins, integrins and the immunoglobulin superfamily. 
A primary interaction between a selectin and its carbohydrate ligand is largely 
responsible for the initial binding of leukocytes to endothelium; this is a 
relatively unstable interaction and leads to leukocyte "rolling" along the vessel 
wall. Activation of adherent leukocytes leads to functional activation of ~1 and 
~2 integrins, which adhere to members of the immunoglobulin superfamily on 
endothelial cells in an interaction which is stable under shear force, and leads to 
the complete arrest of leukocyte movement over the endothelium (Fig. 1.5). 
Integrin activation can be triggered by selectin-mediated binding (Lo et al., 
1991), and by a variety of chemoattractants and stimulants, such as IL-8 
(Detmers et al., 1990), PAF, CSa and endotoxin (Pober and Cotran, 1990b; 
Tonnesen et al., 1989), that might be displayed on the endothelial surface. 
These adhesive interactions, and the properties of the selectins, integrins and 
immunoglobulin superfamily, have been extensively reviewed by Butcher 
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Fig. 1.5 Model for the adhesion mechanisms underlying the migration of circulating leukocytes 
into extravascular tissues. · 
a) Selectins initiate rolling contacts between leukocytes and endothelium, allowing time for the leukocytes to 
become exposed to locally released signaling molecules. 
b) Integrins on the activated leukocytes mediate shear-resistant attachment and transendothelial migration 
Adapted from Bartlett (1993), Springer (1990) and Shimizu et al. (1991). 
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(1991), Dustin and Springer (1991), Hogg (1991), Hogg (1992), Hynes (1992), 
Mackay (1993), Pardi et al. (1992), Pober and Cotran (1991b), Schweighhoffer 
and Shaw (1992), Shimizu et al. (1992), Sonnenberg (1993), Tanaka et al. (1993c), 
Vestweber (1993), and Zimmerman et al. (1992), and further discussion is 
beyond the scope of this review. 
1.5.2 Transmigration across the endothelial barrier 
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The molecular mechanisms involved in transmigration between the endothelial 
cells are less well understood than the adhesion process. Several in vivo (Arfors 
et al., 1987; von Andrian et al., 1991) and in vitro studies (Hakkert et al., 1990; 
Kavanaugh et al., 1991; Muller and Weigl, 1992; Smith et al., 1988) have 
implicated leukocyte integrins in this process, as antibodies specific for 
integrins or their endothelial counter-receptors block transmigration. P AF 
receptor antagonists and anti-IL 8 antibodies also block neutrophil 
transmigration in vitro (Kuijpers et al., 1992). It is not certain, however, whether 
these effects on transmigration result from blocking the earlier step of tight 
adhesion (Muller et al., 1993). Platelet/ endothelial cell adhesion molecule 1 
(PECAM-1; CD31), a member of the lg superfamily (Newman et al., 1990), 
appears to have a role in mediating transmigration. Expressed on monocytes, 
neutrophils and on a subset of T lymphocytes (Ohto et al., 1985; Stockinger et 
al., 1990; Tanaka et al., 1992b ), it is also concentrated in the junctions between 
endothelial cells (Muller et al., 1989). Muller et al. (1993) demonstrated a 
homophilic interaction between endothelial and leukocyte CD31, which was 
required for the transendothelial migration of neutrophils and monocytes. 
These investigators proposed several mechanisms by which CD31 might 
contribute to the transmigration process: (a) CD31 may serve as an adhesion 
molecule, binding the leukocyte tightly during its passage through the 
endothelial junction; (b) an apical-basal gradient of CD31 could exist through 
the endothelial junction, acting as a haptotactic gradient to produce directed 
migration of leukocytes through the junction; (c) CD31 could enhance integrin-
mediated binding during passage through the endothelial junction, as ligation 
of CD31 with antibody has been shown to activate ~1 and J32 integrins; and (d) 
adhesion of endothelial CD31 to leukocyte CD31 may help maintain the tight 
apposition of these cells during transmigration and control the efflux of cells 
and soluble molecules. 
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1.5.3 Passage of leukocytes through the subendothelial basement 
membrane 
Having passed through the endothelial lining of the vasculature, migrating 
leukocytes must then penetrate the subendothelial basement membrane. Most 
studies concerning leukocyte entry into tissues have concentrated on the 
adhesion step; few have considered the basement membrane as a serious 
barrier. Since it regulates the passage of plasma proteins and other 
macromolecules from the capillaries into tissues (Vracko, 1974), it is reasonable 
to suppose that it also obstructs the path of extravasating leukocytes. This has 
long been recognised in the field of tumour metastasis, where mechanisms 
involved in the degradation of basement membranes and interstitial stroma by 
invading tumour cells have been extensively studied. 
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According to current models of extravasation (Fig. 1.6) (Liotta, 1986; Ratner, 
1992), the invading cell attaches to the ECM via specific adhesion molecules, 
which bind reversibly to matrix components such as laminin (in the basement 
membrane) or fibronectin (in the connective tissue stroma). Once anchored, the 
cell secretes (o~ induces host cells to secrete) proteolytic and glycolytic 
enzymes. These appear to play a vital role.by clearing a path for the cell 
through the dense meshwork of the ECM, as well as by more subtle means, 
such as reversing adhesive contacts and possibly degrading ECM components 
into motility-stimulating fragments. The final step involves cell locomotion 
into the region of the matrix modified by hydrolysis. Continued movement of 
the cell may take place by cyclic repetition of these steps, implying that 
hydrolysis of ECM components must be tightly regulated in a temporal and 
spatial fashion with respect to cell attachment and migration. Insufficient 
degradation would prevent forward movement, while excessive degradation 
would result in a loss of the substratum needed for cell attachment to the ECM 
(Stetler-Stevenson et al., 1993). 
1.6 Hydrolytic enzymes and basement membrane degradation 
The role of hydrolytic enzymes in ECM degradation has been studied most 
comprehensively in the context of tumour growth and metastasis. Once cancer 
cells detach and escape from the primary tumour, they move through 
connective tissue stroma and basement membranes at many key points in the 
metastatic cascade, for example during entry or exit from blood vessels, the 
invasion of muscle or nerve, and in traversing epithelial boundaries (Liotta, 
1986). A number of studies have shown that metastatic tumour cells have the 
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Fig. 1.6 Three step model for tumour cell invasion of the extracellular 
matrix. 
Schematic diagram (not to scale) showing invasion of the basement membrane. 
1. Tumour cell attachment to matrix components, such as laminin. 
2. Local degradation of the matrix by tumour cell-associated proteinases. These 
may degrade attachment proteins as well as the structural proteins of the matrix. 
3. Tumour cell locomotion into the region of the membrane modified by 
proteolysis. Continued invasion of the extracellular matrix may take place by 
cyclic repetition of these three steps. 
Adapted from Liotta (1986). 
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capacity to degrade basement membrane (Henry et al., 1983; Liotta et al., 1981; 
Salo et al., 1982; Salo et al., 1983), and that degradation correlates with 
metastatic potential (Liotta et al., 1977; Liotta et al., 1980; Nakajima et al., 1984; 
Starkey et al., 1984). An array of hydrolytic enzymes have been implicated in 
ECM degradation, reflecting the composition of this complex structure. As 
several ECM components, particularly the collagens and GAGs, have unique 
requirements for their degradation, dissolution of the matrix requires a variety 
of hydrolases acting simultaneously or sequentially on the different 
components. The proteinases implicated in ECM degradation by invasive 
tumour cells can be subdivided into three classes: (i) serine proteinases, (ii) 
matrix metalloproteinases (MMPs) and (iii) cysteine proteases. Endo- and 
exoglycosidases also contribute to ECM degradation by hydrolyzing the 
proteoglycan GAG chains (Mignatti and Rifkin, 1993; Ratner, 1992). 
1.6.1 Serine proteases 
15 
The serine proteases include plasminogen activators (urokinase-type and 
tissue-type), elastase and cathepsin G. Of these, urokinase-type plasminogen 
activator (uPA) is the best characterized, and considerable evidence points to 
it's involvement in invasive processes (revi~wed by Mignatti and Rifkin, 1993; 
Mullins and Rohrlich, 1983; Saksela and Rifkin, 1988). uP A converts the 
zymogen plasminogen, a plasma protein found in relatively high amounts 
throughout the body (Robbins and Summaria, 1970), to plasmin. Plasmin has a 
broad, trypsin-like substrate specificity, and can degrade several ECM 
components, including fibronectin, laminin, and the protein core of 
proteoglycans (Werb et al., 1980). It also activates certain pro-
metalloproteinases (Eaton et al., 1984; Werb et al., 1977), as well as latent 
elastase (Chapman and Stone, 1984). 
uP A is secreted as a proenzyme (pro-uP A) which binds to a specific cell surface 
receptor (uP A-R), a heavily glycosylated protein linked to the plasma 
membrane by a glycosyl-phosphatidylinositol anchor (Estreicher et al. , 1989; 
Roldan et al., 1990). Receptor-bound pro-uPA is converted to its active form by 
limited proteolysis (Dano et al., 1985; Petersen et al., 1988). This can be 
accomplished by trace amounts of plasmin, and probably other proteinases, as 
uP A is activated in vitro by a membrane-bound serine proteinase on 
transformed chicken fibroblasts (Berkenpas and Quigley, 1991), and by the 
cysteine proteinase cathepsin B (Kobayashi et al., 1991). As active uP A 
increases plasmin levels, the production of uPA generates a self-maintained 
feedback loop of pro-uP A and plasminogen activation (Fig. 1.7). The levels of 
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Fig. 1.7 Activation of urokinase-type plasminogen activator. 
Abbreviations: uP A (urokinase-type plasminogen activator), uP A-R (uP A receptor), PAI (plasminogen activator inhibitor), 
- - - ...,._ activation. 
Adapted from Mignatti and Rifkin (1993). 
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plasminogen in the extravascular space are quite high, hence the initial 
activation of a small amount of uPA can rapidly lead to high local 
concentrations of plasmin (Mignatti and Rifkin, 1993). uP A binds to its 
receptor with high affinity, and as uP A-R is not internalized or downregulated 
in response to ligand binding, remains active on the cell surface for several 
hours (Vassalli et al., 1985). Plasminogen also binds to a cell surface receptor 
(Plow et al., 1986), and both pro-uPA and plasminogen bind to heparin and 
heparan sulfate proteoglycans in the ECM, indicating that they co-localize on 
the cell surface and/ or in the ECM. Activation of the uPA-plasmin system and 
the resulting plasmin activity are thus focussed on insoluble substrates 
(Mignatti and Rifkin, 1993). 
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uP A activity is controlled at three levels: (i) gene transcription, which is 
upregulated by tumour promoters, oncogenes, cAMP, retinoids, prostaglandins 
and ultraviolet light (Dano et al., 1985); (ii) proenzyme activation; and (iii) 
inhibition by specific tissue inhibitors. PA-producing cells often produce PA 
inhibitors (PAI), members of a family of serine proteinase inhibitors (serpins) 
(Mignatti and Rifkin, 1993). Three PAis have been identified: PAl-1 is 
produced by a variety of cell types and is also present in plasma, PAl-2 is 
expressed largely by cells of the monocyte-macrophage lineage, and protease 
nexin 1 (PN-1) is produced by cultured fibroblasts and several other cell types 
(Kruithof, 1988). As with pro-uPA itself, expression of the PAis is regulated by 
a number of biological agents, including tumour promoters and and growth 
factors (Mignatti and Rifkin, 1993). The PAis bind and inactivate uPA (Saksela 
and Rifkin, 1988), blocking the pro-uPA - uPA - plasmin feedback loop, and 
also trigger the clearance of inactive enzymes from the cell surface, as uPA:R-
uPA:P AI complexes are internalized and degraded (Baker et al., 1980; Cubellis 
et al., 1990; Low et al., 1981; Mignatti and Rifkin, 1993). 
1.6.2 Matrix metalloproteinases 
Matrix metalloproteinases (MMP) are a family of zinc metalloenzymes which 
are secreted as latent pro-enzymes and activated by proteolytic cleavage of an 
N-terminal domain (reviewed by Kleiner and Stetler-Stevenson, 1993; Mignatti 
and Rifkin, 1993; Schultz, 1991; Stetler-Stevenson, 1990; Stetler-Stevenson et al., 
1993). Those which have been correlated with the metastatic potential of 
transformed cells can be subdivided into three classes: (i) interstitial 
collagenase (MMP-1), (ii) type IV collagenases, including 72 kDa gelatinase 
(MMP-2) and 92 kDa gelatinase (MMP-9), and (iii) stromelysins, including 
stromelysin-1 (MMP-3), stromelysin-2 (MMP-10) and matrilysin (MMP-7). The 
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substrate specificities of these metalloproteinases overlap somewhat. 
Interstitial collagenase degrades collagen types I-III, VII and X. The type IV 
collagenases degrade basement membrane (type IV) collagen, collagen types V, 
VII and X, gelatin and fibronectin, but not the interstitial collagens (types I-III). 
Stromelysins have the broadest substrate specificity, cleaving collagen types IV, 
V, VIII and IX, fibronectin, laminin, elastin, and the protein core of 
proteoglycans (Mignatti and Rifkin, 1993; Schultz, 1991). Between them, the 
MMPs are capable of degrading all the structural components of the ECM, with 
the exception of the proteoglycan GAG chains and hyaluronic acid (Woolley, 
1993). 
As with uP A, MMP activity is regulated at three levels: (i) gene transcription, 
(ii) pro-enzyme activation, and (iii) inhibition by specific tissue inhibitors. 
MMPs are not constitutively expressed, instead transcription is induced by 
such agents as tumour promoters, growth factors and oncogene products 
(reviewed by (Mignatti and Rifkin, 1993). The pro-enzyme form is activated by 
proteolytic cleavage of an amino terminal fragment (Stetler-Stevenson, 1990); in 
vivo this is accomplished for most of the MMP family by plasmin or other 
metalloproteinases. MMPs initially activated by plasmin can in turn activate 
other pro-enzyme molecules, creating an amplification loop similar to the 
feedback mechanism of pro-uP A and plasmin activation (Mignatti and Rifkin, 
1993). Other activation mechanisms also exist, for example, the 72 kDa 
gelatinase appears to be activated by a poorly characterised cell surface 
receptor/ activator system distinct from the uP A system (Kleiner and Stetler-
Stevenson, 1993). Fully activated enzymes are regulated by binding of specific 
inhibitors, the TIMPs (tissue inhibitor of metalloproteinases), which appear to 
be members of a multigene family. Expression of these inhibitors is modulated 
by growth factors, hormones and cytokines. TIMP-1 and TIMP-2 bind non-
covalently to active forms of all the MMPs, and to the latent forms of gelatinase 
A and B respectively, apparently controlling the activation of these two 
proenzymes (Kleiner and Stetler-Stevenson, 1993; Mignatti and Rifkin, 1993; 
Stetler-Stevenson, 1990). 
Activation of MMPs and the uP A-plasmin system is thought to initiate a 
cascade of proteolytic events, which generates a broad spectrum of proteolytic 
activities (Figure 1.8). The uP A-plasmin system plays a key role in the 
proposed cascade. The activated form of uP A can rapidly convert the high 
concentrations of plasminogen found in most tissues to plasmin. Plasmin plays 
a dual role, directly degrading ECM components, as well as activating pro-
procollagenases 
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collagenases and pro-stromelysins. Activation of even a small amount of uPA 
can thus generate high local concentrations of broad spectrum proteinases 
(plasmin and stromelysins) and enzymes with more restricted substrate 
specificity (interstitial and type IV collagenases), which together are capable of 
degrading most of the protein components of the ECM (Mignatti and Rifkin, 
1993). 
1.6.3 Cysteine proteinases (lysosomal cathepsins) 
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Cysteine proteinases are a class of endo- and exopeptidases whose catalytic 
activity depends on the reactive thiol of a cysteine residue at the active site. In 
general, they are intracellular enzymes, present in the lysosomes or cytosol, 
however their release by living cells has been documented in a few pathological 
conditions (Mignatti and Rifkin, 1993). They include enzymes able to activate 
pro-collagenases, directly degrade collagen and digest the protein core of 
proteoglycans (Delaisse et al., 1980; Eeckhout and Vaes, 1977; Etherington, 1976; 
Etherington and Evans, 1977; Gohda and Pitot, 1981). Cysteine proteinases 
implicated in tumour metastasis include the lysosomal cathepsins Band L 
(reviewed by Sloane et al., 1987). Cathepsin B is the better studied of the two, 
and has endopeptidase activity against a variety of proteins, including such 
ECM components as proteoglycans (Morris.on et al., 1973), laminin (Weiss et al., 
1990) and collagen types I-IV (Burleigh et al., 1974; Etherington and Evans, 
1977; Maciewicz et al., 1989). It can also activate latent collagenases (Eeckhout 
and Vaes, 1977), and both soluble and receptor-bound forms of pro-uPA 
(Kobayashi et al., 1991). Cathepsin Lis known to release type IV collagen from 
intact basement membrane (Maciewicz et al., 1989). 
While cathepsins Band Lare usually considered to be intracellular lysosomal 
enzymes, their overexpression and secretion has been associated with 
metastatic activity in tumour cells. Intracellular expression of cathepsin B in 
B16 melanoma sublines correlates with increased metastatic activity (Rochefort 
et al., 1987; Sloane et al., 1981; Sloane et al., 1982), and a cathepsin B-like cysteine 
protease is secreted by cultured cells from malignant human breast tumours 
(Recklies et al., 1980). A latent form of cathepsin Lis released from H-ras 
transformed murine fibroblasts (Denhardt et al., 1987; Gal and Gottesman, 
1986a; Gal and Gottesman, 1986b ), however its role in tumour cell invasion is 
unclear. Both cathepsins are enriched in the plasma membranes of metastatic 
B16 melanoma cells (Rozhin et al., 1987; Rozhin et al., 1989; Sloane et al., 1986), 
and cathepsin Bin the plasma membranes of malignant and transformed 
human epithelial cell lines (Krepela et al., 1987; Pietras and Roberts, 1981b; 
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Sylven et al., 1974), rodent tumour cells (Sloane et al., 1987), squamous 
carcinoma cells (Pietras and Roberts, 1981a), and an invasive murine bladder 
carcinoma cell line (Weiss et al., 1990). 
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It remains unclear whether secreted cathepsins contribute to basement 
membrane degradation in vivo, as they are released as precursors which require 
proteolytic cleavage to become fully active, and appear in most studies to have 
limited activity at physiological pH (Briozzo et al., 1988; Denhardt et al., 1987; 
Maciewicz et al., 1989; Mort and Recklies, 1986; Rochefort, 1990; Rochefort et al., 
1990). There are, however, suggestions that tumour cells can modify their 
surroundings to produce an acidic microenvironment, which may facilitate 
auto-activation of the pro-enzymes, and one study reported the ability of 
tumour cells to process secreted pro-enzymes to the mature, active form 
(Maciewicz et al., 1989). In spite of this, it is questionable whether secreted 
cathepsin B, whether active or latent, is related to tumour cell invasion, as the 
levels released do not necessarily correlate with the invasive potential of the 
cells (Sloane et al., 1987). Several investigators have proposed instead that the 
plasma membrane-associated form may be more important (Persky et al., 1986; 
Sloane et al., 1987). Cathepsin B present at the cell surface of tumour cells 
appears to be in an ·active form, with a hig~er pH optimum and greater stability 
at neutral pH than lysosomal cathepsin B (Rozhin et al., 1987; Weiss et al., 1990), 
and the specific activity of cathepsins Band Lin the plasma membrane fraction 
of B16 melanoma cells increases with metastatic potential (Rozhin et al., 1989; 
Sloane et al., 1986). 
1.6.4 Glycosidases 
Proteoglycan GAG chains are an important structural element of basement 
membranes. They contribute to the architecture of the basement membrane by 
enhancing interactions between its protein components (Paulsson et al., 1986) 
while protecting them against proteolytic attack (Chiarugi, 1982; Nakajima et 
al., 1988), and to its sieving properties by their polyanionic charge (Yurchenco 
and Schnittny, 1990). The hydrophilic GAGs form hydrated gels with a huge 
volume relative to their mass, filling most of the space within the protein 
meshwork of the ECM (Mignatti and Rifkin, 1993), thus their dissolution in 
advance of an invading cell should in itself facilitate forward movement, and in 
addition make the protein scaffold more accessible to the action of proteinases. 
Degradation of GAGs requires the action of specific glycosidases, for example, 
hyaluronidase for hyaluronic acid and heparanase for heparan sulfate (Mignatti 
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and Rifkin, 1993). Heparan sulfate is the most prominent GAG associated with 
basement membrane proteoglycans, and so it is significant that a heparanase 
activity has been associated with metastatic tumour cells. This activity was 
identified as an endo-~-D-glucuronidase which cleaves heparan sulfate at 
specific intra-chain sites (reviewed by Nakajima et al., 1988). Release of low Mr 
heparan sulfate fragments from subendothelial ECM in vitro correlates with 
metastatic potential in B16 melanoma (Kramer et al., 1982; Nakajima et al., 1983; 
Nakajima et al., 1986; Ricoveri and Cappelletti, 1986), murine lymphoma 
(Vlodavsky et al., 1983), rat rhabdomyosarcoma (Becker et al., 1986), and murine 
fibrosarcoma (Ricoveri and Cappelletti, 1986). Furthermore, there is good 
correlation between the heparanase-inhibitory activity of various heparin 
preparations and other sulfated polysaccharides, and their anti-metastatic 
activity in vivo (Coombe et al., 1987; Irimura et al., 1986; Parish et al., 1987; 
Vlodavsky et al., 1988). These data have been taken to implicate heparanase 
activity in degradation of basement membrane by extravasating tumour cells. 
1.6.5 Basement membrane degradation by leukocytes 
The invasive behaviour of tumour cells is believed to arise from a loss of 
control over the invasive phenotype expressed in a restricted manner by 
normal cells, such as by endothelial cells du.ring angiogenesis, or leukocytes 
entering inflamed tissues (Stetler-Stevenson et al., 1993). On this basis, 
emigrating leukocytes are likely to share molecular mechanisms with tumour 
cells, albeit under different control processes. Mounting evidence suggests that 
leukocytes, like tumour cells, secrete enzymes capable of degrading basement 
membrane components. 
Several in vitro studies have shown that activated murine T cells secrete the 
serine protease MTSP-1 (murine T cell-specific serine proteinase) (Ebnet et al., 
1991; Simon et al., 1991), which degrades type IV collagen (Simon et al., 1991), 
fibronectin (Simon et al., 1988) and sulfated proteoglycans (Simon et al., 1987; 
Vettel et al., 1991), and activates pro-uPA (Brunner et al., 1990). A serine 
protease (HuTSP-1) secreted from activated human T cells (Fruth et al., 1987; 
Wood et al., 1988) also catalyses the conversion of pro-uPA to its active form, 
and thus may trigger the enzymatic cascade initiated by plasminogen 
activation (Brunner et al., 1990). No correlation between these activities and 
invasive behaviour in vivo has actually been demonstrated, however several 
protease inhibitors reduce the perivascular infiltration of mononuclear cells in a 
T cell-mediated experimental autoimmune disease (Brosnan et al., 1980). 
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Activated T cells also secrete a heparanase activity capable of releasing heparan 
sulfate fragments from ECM in vitro (Fridman et al., 1987; Naparstek et al., 1984; 
Savion et al., 1984; Vettel et al., 1991), as do freshly isolated neutrophils and 
activated peritoneal macrophages (Matzner et al., 1985; Savion et al., 1987; 
Savion et al., 1984). In vivo studies have implicated heparanase expression in 
the infiltration of circulating T cells into DTH reactions (Lider et al., 1990), 
experimental autoimmune lesions and allografts (Lider et al., 1989; Willenborg 
and Parish, 1988; reviewed by Vlodavsky et al., 1992), highlighting its potential 
importance in basement membrane degradation. 
The degradative enzymes secreted by invasive tumour cells are believed to 
contribute to a cascade in which multiple proteinases act in concert with one 
another and/ or activate other proteinases with different specificities. Such a 
spectrum of proteolytic activity has not yet been demonstrated for leukocytes, 
however MSTP-1 and heparanase appear to act sequentially in the degradation 
of ECM-associated proteoglycans by T cells in vitro. Purified MTSP-1 releases 
high Mr sulfated proteoglycans from the ECM, which are further degraded into 
small fragments by the heparanase, while heparanase alone degrades intact 
ECM poorly (Vettel et al., 1991). Prior proteolysis is also required for release of 
low Mr heparan· sulfate fragments by neutrophil and macrophage heparanases 
(Matzner et al., 1985; Savion et al., 1987). Thus, the products of proteolysis 
provide a more accessible substrate for the heparanase. In the context of the 
intact basement membrane, the two enzymes are proposed to act 
synergistically, such that proteolytic activity exposes the proteoglycan heparan 
sulfate side chains, providing a more accessible substrate for the heparanase. 
In turn, removal of GAG chains from the ECM exposes the collagen network, 
increasing its susceptibility to proteolysis (David and Bernfield, 1979). 
Degradation of matrix GAGs could thus facilitate the complete degradation of 
the ECM by collagenases (Simon et al., 1987; Vettel et al., 1991). In this context, 
it is significant that purified MTSP-1 degrades purified type IV collagen, and 
also activates pro-uP A, which contributes to ECM proteolysis by the generation 
of plasmin from matrix-associated plasminogen. This in turn activates a 
matrix-associated type IV pro-collagenase (Vettel et al., 1991). Thus, the initial 
action of MSTP-1 and heparanase on ECM components, combined with their 
ability to recruit additional proteolytic enzymes, may lead to the complete 
dissolution of the basement membrane. 
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1.7 Localization of basement membrane-degrading enzymes 
Regulation of ECM degradation is a key co~cept when considering the invasive 
behaviour of leukocytes or tumour cells. As described in Section 1.5.3, cell 
migration through the ECM is thought to proceed by a cyclic process of 
attachment to ECM components, extension of pseudopodia around which 
extensive degradation occurs, and movement of the cell into the cleared space. 
Invasive cells must therefore degrade ECM in a highly organized manner, both 
spatially and temporally, as uncontrolled lysis of the matrix would remove the 
substratum needed for continued cell attachment (Liotta, 1986; Liotta, 1990). 
Several investigators have observed the focal dissolution of fibronectin or 
reconstituted ECM in regions of contact with adherent cells, both in vitro (Chen 
and Chen, 1987; Chen et al., 1984; Kramer et al., 1986) and in vivo (Crissman et 
al., 1985), with degradation particularly marked adjacent to pseudopodia 
extended in the direction of cell locomotion. These studies illustrate that 
degradative activity can be concentrated at discrete points over the cells' 
surface. 
The ability of tumour cells to secrete inhibitors for many of the proteases they 
produce offers one means for localized control over ECM degradation. 
Plasminogen activators, for example, are inhibited by P Als and 
metalloproteinases by TIMPS. Thus, invading cells may regulate proteolysis by 
controlling the local balance between enzyme and inhibitor molecules, and 
varying it at different points on the cell surface. At points of forward 
protrusion, the balance could be towards net proteolysis, while at points of 
attachment to the substratum, proteolysis might be inhibited (Liotta, 1990). In 
support of this, Chen (1992) observed basement membrane degradation by 
transformed cells at sites of contact with pseudopodia but not at adhesive foci, 
and found P AI-1 at sites of attachment but not on pseudopodia. Thus, P Als 
may be differentially expressed across the cell surface, so as to minimize ECM 
degradation at sites of adhesion, and to permit it where degradation is 
required. 
A second means of controlling the extent of ECM degradation is offered by the 
cell surface expression of hydrolytic enzymes, thereby limiting cleavage of 
matrix components to the immediate vicinity of the cell. Enzyme activity could 
be localised further by restricting expression to specific parts of the cell 
membrane, much as was suggested for enzyme inhibitors. While some studies 
have demonstrated degradative activity in the conditioned medium of 
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activated leukocytes (Fridman et al., 1987; Vettel et al., 1991; Vlodavsky et al., 
1992), others have shown matrix degradation to require contact between cells 
and ECM. Parish et al. (1992) found that while intact or heat-killed metastatic 
rat mammary adenocarcinoma cells degraded ECM in vitro, sonicated or 
detergent-solubilized cells, and culture supernatants did not. Likewise, ECM 
degradation by B16 melanoma cells (Kramer et al., 1982) and transformed 
chicken fibroblasts (Chen et al., 1984) was not reproduced by their conditioned 
medium, suggesting that degradation was due to membrane-associated 
enzymes rather than secretory products. 
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Cell surface expression of proteinases by metastatic tumour cells has been 
described in many studies. In the case of serine proteinases, pro-uP A is 
activated while bound to a cell surface receptor and remains associated with it 
for a prolonged period (Section 1.6.1). Plasmin is thus generated in close 
proximity to the cell surface, and in turn activates several latent MMPs (Stetler-
Stevenson et al., 1993). The 72 kDa gelatinase is also activated at the cell 
surface, in the context of a poorly defined receptor/ activator system (Kleiner 
and Stetler-Stevenson, 1993). MMP activities able to degrade collagens, gelatin 
and fibronectin are highly enriched in plasma membrane fractions isolated 
from metastatic tumour cell lines of rat, murine and human origin (Chen and 
Chen, 1987; Chen et al., 1984; DiStefano et al., 1982; DiStefano et al., 1983; Zucker 
and Lysik, 1977; Zucker et al., 1985a; Zucker et al., 1985b; Zucker et al., 1987), 
and appear to be integral membrane proteins (Zucker et al., 1987). Active forms 
of cathepsins Band Lare also associated with the cell surface (Boyer and 
Tannock, 1993; Sloane et al., 1987). 
1.8 A role for the phosphomannosyl recognition system in cell 
surface expression of lysosomal hydrolases 
While it is recognised that cell surface expression of several classes of 
proteinase may be an important aspect of invasive behaviour, mechanisms for 
this have not been defined in many cases. In fact, in the case of cathepsin B, 
there are conflicting reports regarding its cell surface expression on invasive 
cells. Cysteine proteinase activity in human lung cancer cells appears to be 
only loosely associated with the plasma membrane (Zucker et al., 1987), 
however attempts to isolate cathepsin B from the plasma membrane fraction of 
B16 melanoma cells suggested it to be an integral membrane protein (Rozhin et 
al., 1987). Cytochemical staining of human breast carcinoma cells (Krepela et 
al., 1987) and B16 melanoma cells (Sloane et al., 1990) subsequently showed it to 
be associated with vesicles located at the periphery of the cells, and extending 
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out along cytoplasmic projections, and a later study located it on the outer 
surface of B16 melanoma cells (Sloane et al., 1991). These investigators 
suggested that cathepsins Band L might both be secreted from peripheral 
vesicles in response to an acidic microenvironment, but did not speculate 
further on means of attachment to the cell surface. 
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A mechanism for the cell surface expression of lysosomal hydrolases has been 
described in detail. Central to this mechanism are the mannose 6-phosphate 
receptors (MPRs), which mediate intracellular transport of lysosomal enzymes 
to the lysosomes (reviewed by Kornfeld, 1992). These receptors recognise a 
mannose 6-phosphate (M6P) marker common to all lysosomal enzymes, and 
transport newly synthesized enzymes from the Golgi apparatus to an acidified 
prelysosomal compartment, from which they are packaged into the lysosomes. 
MPRs are also expressed at the cell surface, where they function in the binding 
and endocytosis of exogenous lysosomal enzymes. Parish et al. (1990) have 
proposed that lysosomal enzymes secreted from the cell and bound by cell 
surface MPRs may contribute to the cell surface-associated degradative activity 
of cells with·invasive potential. 
This mechanism probably does not apply t? the cell surface expression of the 
lysosomal cathepsins on metastatic tumour cells, as cathepsin B associated with 
the plasma membrane fraction of B16 melanoma cells was not displaced by 
M6P, a competitive inhibitor of the MPR-lysosomal enzyme interaction (Rozhin 
et al., 1987), and cathepsin L secreted from transformed cells binds to MPR with 
low affinity, due to a defective M6P marker (Dong and Sahagian, 1990). 
However, while the cysteine proteases are the only class of lysosomal enzyme 
so far implicated in basement membrane degradation, the lysosomes are a rich 
source of enzymes with proteolytic and glycolytic activity, and many digest 
internalized ECM fragments in the context of the lysosomes (Kaiser, 1980). 
There may be other lysosomal enzymes that, like the cathepsins, are capable of 
acting in the extracellular environment, and may participate in the degradation 
of intact ECM. 
( vK 
In general support of this hypothesis, Wang and coworkers have demonstrated 
A 
that lysosomal hydrolases bound to cell surface MPRs degrade cell surface and 
substratum-attached proteoglycans. Addition of M6P to human fibroblast 
cultures inhibited degradation of extracellular 35S-labelled proteoglycans, but 
had no effect on proteoglycan turnover by fibroblasts from patients with I-cell 
disease, in which lysosomal enzymes lack the M6P marker. Furthermore, 
addition of "normal" lysosomal enzymes to I cells enhanced proteoglycan 
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degradation, an increase that was inhibitable with M6P. If lysosomal enzymes 
were active in solution, addition of M6P, which releases the enzymes from cell 
surface receptors, should have enhanced proteoglycan degradation by 
fibroblasts. Instead, these studies suggested that cell surface MPR anchored 
these enzymes in close proximity to pericellular and extracellular substrates 
(Brauker et al., 1986; Kornfeld, 1992; Roff et al., 1982). 
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Parish and coworkers initially tested their hypothesis using the animal disease 
model Experimental Autoimmune Encephalomyelitis (EAE). EAE is an 
inflammatory autoimmune disease of the central nervous system (CNS), 
produced in laboratory animals by immunization with neural tissue in 
adjuvant (Hashim et al., 1980; Raine, 1984). The host animal mounts a cell-
mediated attack on constituents of CNS myelin, the target antigen being a 
peptide found in the basic protein (BP) fraction (Hashim et al., 1978). The 
disease is characterised by leukocyte infiltration of the brain and spinal cord, 
oedema and fibrin deposition (Raine, 1984; Simmons et al., 1987). The influx of 
leukocytes, predominantly lymphocytes and macrophages, results in 
characteristic perivenular lesions. Inflammation in the CNS, predominantly in 
the lower spinal cord, leads to paresis and paralysis of the hind limbs. EAE can 
be induced passively by intravenous transfer of activated T cells, either from 
actively immunized donors, or MBP-specific T cell lines, to naive syngeneic 
recipients (Astrom and Waksman, 1962; Ben-Nun et al., 1981; Panitch and 
McFarlin, 1977; Paterson, 1960). Adoptively transferred EAE has been utilized 
in in vivo studies of lymphocyte extravasation, as development of disease is 
dependent on the passage of transferred T cells from the circulation into the 
CNS. 
Parish and coworkers demonstrated that several compounds which interfere 
with the lysosomal enzyme-MPR interaction inhibited the development of EAE 
in rats. M6P and its structural analogue fructose-1-phosphate (FlP), which 
competitively inhibit the binding of lysosomal enzymes to MPRs (Kaplan et al., 
1977a), reduced clinical signs of disease by over 80°/o. The number of spinal 
cord lesions was reduced dramatically, and in some animals completely 
(Willenborg et al., 1989b ). In contrast, D-mannose, which has low affinity for 
MPR (Kaplan et al., 1977a), failed to inhibit disease. The plant alkaloid 
castanospermine (CS), an inhibitor of glycoprotein processing which prevents 
the formation of the M6P recognition marker on lysosomal enzymes, also 
inhibited clinical signs of EAE (Willenborg et al., 1989a). CS did not reduce the 
number of inflammatory lesions in the CNS, however these were intense and 
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compact, with leukocytes tightly packed around the margins of vessels and 
little migration into the parenchyma compared to controls. The inhibitory 
effects of M6P and CS were not limited to T cell entry into the CNS, as these 
compounds also reduced joint inflammation in passively induced adjuvant 
arthritis (Willenborg et al., 1992). 
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These experiments support the hypothesis that MPRs provide a means of 
displaying lysosomal enzymes at the cell surface, and that these contribute to 
the degradation of the subendothelial basement membrane by extravasating 
leukocytes. The absence of lesions in the M6P-treated animals suggests that 
adoptively-transferred T lymphocytes were completely prevented from leaving 
the circulation. In the case of CS, cells were able to cross the vascular 
endothelium, indicating that the adhesion and transmigration processes were 
not affected, but then appeared to accumulate before some limiting structure, 
possibly the basement membrane (Willenborg et al., 1989a). The effect of CS on 
CNS lesions highlights the concept that lysosomal enzymes may be most 
effective when displayed on the cell surface via MPRs. Since CS prevents 
formation of the M6P marker, newly synthesized lysosomal enzymes are 
unable to bind . to MPRs in the Golgi, resulting in secretion of these enzymes via 
the secretory pathway (Hickman and Neufeld, 1972). If soluble lysosomal 
enzymes were effective in degrading basement membrane, CS should have 
enhanced leukocyte entry into the CNS. However, although the infiltrating 
lymphocytes in the EAE and arthritis models may have secreted lysosomal 
enzymes in unusually large amounts, their entry into the CNS parenchyma was 
reduced. 
These experiments support the proposal that MPR-mediated expression of 
lysosomal enzymes at the cell surface is an important feature of leukocyte 
migration. The aim of this thesis was to further examine the hypothesis that 
lysosomal enzymes in association with cell surface MPRs are involved in 
basement membrane degradation. The remainder of this review will focus on 
MPRs and the phosphomannosyl recognition system, as this forms the basis of 
the exp~rimental work described in this thesis. 
1.9 The phosphomannosyl recognition system: an overview 
Most lysosomal enzymes are soluble glycoproteins that are synthesized on the 
membrane-bound ribosomes of the rough endoplasmic reticulum (ER), 
together with secretory proteins, membrane proteins and proteins destined for 
the lumens of the ER and Golgi apparatus. The various classes of protein are 
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transported from the ER lumen to the Golgi, from which each is directed to it's 
correct destination. As soluble proteins are mixed together in the lumen of the 
Golgi, this requires their physical separation from one another. Segregation of 
lysosomal enzymes from other soluble proteins is effected via the 
phosphomannosyl recognition system. During their passage through the ER 
and Golgi apparatus, lysosomal enzymes selectively acquire asparagine-linked, 
high mannose-type oligosaccharides with terminal mannose 6-phosphate 
(M6P) residues. These bind with high affinity to M6P receptors (MPRs) in the 
Golgi membranes, effectively separating lysosomal enzymes from other soluble 
proteins which remain in the lumen. MPR-enzyme complexes are then 
gathered into clathrin-coated pits which bud off from the Golgi, forming coated 
vesicles which fuse with an acidified endosomal/prelysosomal compartment. 
The receptor-enzyme complex dissociates at low pH, and the freed enzymes are 
packaged into lysosomes, where acid phosphatase inactivates the M6P marker 
by removing the phosphate groups. The MPRs recycle back to the Golgi to 
repeat the process, or to the plasma membrane where they function in 
endocytosis of extracellular lysosomal enzymes. 
A significant percentage of most lysosomal enzymes escapes direct lysosomal 
delivery and is secreted; these enzymes may be recaptured by cell surface MPR. 
MPR-ligand complexes on the plasma membrane are also concentrated into 
coated pits where they are internalised and delivered to the same acidic 
prelysosomal compartment, which forms the intersection point between the 
biosynthetic and endocytic transport pathways (Fig. 1.9). The 
phosphomannosyl recognition system has been reviewed by Dahms et al. 
(1989), Kornfeld (1986), Kornfeld (1987), Kornfeld (1992), Kornfeld and 
Mellman (1989), Pfeffer (1991), Sly and Fischer (1982), and von Figura and 
Hasilik (1986). 
Three key processes contribute to lysosomal enzyme targeting via the 
phosphomannosyl recognition system: 
a) selective modification of lysosomal enzymes by Golgi enzymes which 
synthesize the M6P recognition marker 
b) recognition of this marker by MPRs 
c) recognition of MPRs by cellular components that mediate the selective 
transport of MPR-enzyme complexes to lysosomes (Kornfeld and Mellman, 
1989). 
Each of these processes will be considered in this review. 
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Fig. 1.9 Schematic pathway of lysosomal enzyme targeting to 
lysosomes. 
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Lysosomal enzymes and secretory proteins are synthesized in the rough 
endoplasmic reticulum (RER) and glycosylated by the transfer of a preformed 
oligosaccharide from dolichol-P-P-oligosaccharide (Dol). The newly synthesized 
proteins are translocated to the Golgi where the oligosaccharides of secretory 
proteins are processed to complex-type units and the oligosaccharides of 
lysosomal enzymes are phosphorylated on terminal mannose residues. Most of 
the lysosomal enzymes bind to mannose 6-phosphate receptors (MPRs) ( .... ) 
and are tranported to an acidified prelysosomal compartment where the receptor-
ligand complex dissociates. The MPRs recycle back to the Golgi or to the cell 
surface, while the enzymes are packaged into lysosomes. A small number of 
lysosomal enzymes fail to bind to the receptors in the Golgi, and are secreted via 
the secretory pathway (- - ~ ). These enzymes bind to cell surface MPR in 
coated pits ( ,~ 5 4), and are internalized to the prelysosomal compartment. 
f/ /1 I\\\ 
(•) N-acetylglucosamine; (O) mannose; (.6.) glucose; ( •) galactose; (+) sialic 
acid. 
From Kornfeld (1987). 
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1.10 The M6P recognition marker 
The importance of a recognition signal in lysosomal enzyme targeting was first 
demonstrated by Neufeld and coworkers, who showed that in the lysosomal 
storage disorder I-cell disease (mucolipidosis II), lysosomal enzymes lack this 
marker, and as a consequence are almost entirely secreted from the cell 
(Hickman and Neufeld, 1972; Neufeld and Cantz, 1971). The recognition 
marker was subsequently found to be sensitive to alkaline phosphatase (Brot et 
al., 1974; Glaser et al., 1975; Kaplan et al., 1977a; Kaplan et al., 1977b; Kaplan et 
al., 1977c; Lagunoff et al., 1973) and to include a carbohydrate component 
(Hickman et al., 1974), specifically a hexose phosphate (Kaplan et al., 1977a). 
Competitive inhibition studies with a range of monosaccharides suggested the 
hexose phosphate to be M6P or a structural analogue (Kaplan et al., 1977a; 
Kaplan et al., 1977c; Sando and Neufeld, 1977; Ullrich et al., 1978); in addition, 
endocytosis of lysosomal enzymes was inhibited by yeast mannans with 
exposed M6P groups (Kaplan et al., 1978) and BSA substituted with M6P 
(Sando, 197~). Several groups finally demonstrated the presence of M6P on 
lysosomal enzymes and its involvement in endocytosis (Hasilik and Neufeld, 
1980; Natowicz et al,, 1979; Sahagian et al., 1979; von Figura and Klein, 1979), 
providing direct evidence for M6P as a component of the recognition marker. 
1.10.1 Biosynthesis of the M6P marker 
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The structure and biosynthesis of the lysosomal enzyme recognition marker are 
now well characterized (reviewed by Kornfeld (1986), Kornfeld (1987), 
Kornfeld (1990), Kornfeld and Mellman (1989), Pfeffer (1991), and Sly and 
Fischer (1982)). Asparagine-linked oligosaccharides added to lysosomal 
enzymes in the ER are selectively modified in the Golgi apparatus, producing a 
high-mannose structure with one or two terminal M6P residues (Fig. 1.10). The 
early oligosaccharide processing steps are shared with secretory and membrane 
proteins, while the later ones are unique to lysosomal enzymes. 
Proteins within the ER are glycosylated by the co-translational transfer of a 
preformed oligosaccharide from a dolichol pyrophosphate carrier to the 
asparagine residue of an Asn-X-Ser /Thr sequence. The oligosaccharide 
consists of three glucose, nine mannose (man) and two N-acetylglucosamine 
(GNAc) residues. This undergoes a series of trimming and modification 
reactions, with the end result dependent on the protein moiety. The initial 
trimming reactions take place in the ER. The first glucose residue is rapidly 
removed by glucosidase I, and the remaining ones more slowly by glucosidase 
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Fig. 1.10 Synthesis of the M6P marker. 
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The main stages in processing of high mannose oligosaccharides on lysosomal enzymes. Three glucose and one mannose residue 
are trimmed from N-linked oligosaccharides in the endoplasmic reticulum (ER) (A). In the Golgi, the oligosaccharide is 
phosphorylated on either one or two mannose residues. Potential phosphorylation sites are marked i-v in (B). Of these five sites, 
three are preferred ( 0 ). Residues i and ii are phosphorylated most frequently, although never simultaneously, followed by 
residue iv. Residue vis the least common phosphorylation site. Phosphorylation occurs in a two step process: P-GNAc is 
transferred from UDP-GNAc to the mannose residue (C), and GNAc is removed (D). The enzymes involved are (1) UDP-N-
acetylglucosamine:lysosomal enzyme N-acetylglucosamine-phosphotransferase and (2) a-N-acetylglucosaminyl phosphodiester 
glycosidase. Outer non-phosphorylated mannose residues are also removed, exposing terminal M6P residues (Varki and 
Kornfeld, 1980; Varki and Kornfeld, 1983). 
Abbreviations: G (glucose), M (mannose), GNAc (N-acetylglucosamine), P (phosphate). 
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II. The terminal mannose residue is also removed from the middle branch by 
an a-mannosidase (Fig. 1.10 (a)) (Atkinson and Lee, 1984; Bischoff and 
Kornfeld, 1983; Hubbard and Robbins, 1979; Turco and Robbins, 1979). 
Proteins are then transported to the Golgi complex where the oligosaccharide 
chains are further trimmed and remodelled. 
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Functionally, the Golgi can be divided into three regions: cis, mid and trans. 
While not rigidly separated, these are involved in different carbohydrate 
modification reactions and proteins produced in the ER are subject to a 
vectorial, cis to trans, flow through the Golgi cisternae ( von Figura and Hasilik, 
1986). Oligosaccharides on secretory and membrane glycoproteins are 
processed to complex oligosaccharides, whereby they are trimmed to the 
innermost 5 residues, and a variable number of trisaccharide units (GNAc-
galactose-sialic acid) are attached to this core (Fig. 1.11). Most lysosomal 
enzymes undergo a different set of modifications, catalysed by two enzymes 
found in the membranes of the cis-Golgi cisternae (Waheed et al., 1982). The 
mans GNAc2 oligosaccharide is phosphorylated on one or two mannose 
residues, those available for phosphorylation being the three terminal residues, 
and the penult_imate residues on branches a and c (Fig. 1.10 (b )). Branches a 
and c are the most frequent substrates for the enzyme N-acetylglucosaminyl 
phosphotransferase, which catalyzes the transfer of N-GNAc-1-phosphate from 
UDP-GNAc to the C-6 position of the mannose residue, forming a 
phosphodiester intermediate (Fig. 1.10 (c)) (Hasilik et al., 1981; Reitman and 
Kornfeld, 1981; Varki and Kornfeld, 1980). The covering GNAc residue is then 
removed by a specific phosphodiesterase, along with any outer non-
phosphorylated mannose residues, exposing a terminal M6P residue (Fig. 1.10 
(d)) (Varki and Kornfeld, 1981; Waheed et al., 1981), reviewed by Kornfeld 
(1990) and von Figura and Hasilik (1986). The resulting M6P-bearing 
oligosaccharide acts as the recognition marker which mediates lysosomal 
enzyme binding to MPRs and their subsequent removal from the secretory 
pathway and translocation to lysosomes. 
1.10.2 Selective formation of the M6P marker on lysosomal enzymes 
Selective phosphorylation of mannose residues on lysosomal enzymes is crucial 
for their segregation from other soluble proteins in the Golgi lumen. This is 
achieved through the specificity of the phosphotransferase, which recognises a 
protein determinant common to lysosomal enzymes but absent from other 
glycoproteins (Lang et al., 1984; Reitman and Kornfeld, 1981; Waheed et al., 
1982). By using fragments of lysosomal cathepsin D to generate a 
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Fig. 1.11 General structure of complex oligosaccharides 
High mannose N-linked oligosaccharides are trimmed by ER and Golgi 
enzymes, leaving a core region of two N-GNAc and three mannose residues. 
The terminal region consists of GN Ac-galactose-sialic acid trisaccharides 
linked to a variable number of the core mannose residues. GNAc, galactose 
and sialic acid are added sequentially, in different regions of the Golgi. The 
terminal region may be truncated, consisting of disaccharides (GNAc-
galactose), or GNAc only (Alberts et al., 1986). 
Abbreviations: GNAc (N-acetylglucosamine), M (mannose), Gal (galactose), 
SA ( sialic acid). 
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phosphotransferase recognition site in the related secretory protein pepsinogen, 
Baranski et al. (1990) showed that two non-continuous sequences from the 
carboxyl lobe of cathepsin D (residues 188-230, particularly lysine 203, and 265-
292) are critical elements of this determinant. X-ray crystallography showed 
that the two sequences are located alongside one another on the surface of the 
protein, consistent with earlier studies showing the conformational dependence 
of the phosphotransferase recognition marker (Kornfeld, 1986). Additional 
elements of the phosphotransferase determinant were localised to the amino 
lobe of cathepsin D (Baranski et al., 1992), and chemical modification studies 
have shown lysine residues to be an essential component of the 
phosphorylation signal as a whole (Cuozzo and Sahagian, 1994). 
1.11 Mannose 6-phosphate receptors 
1.11.1 Receptors for lysosomal enzymes 
Receptors for lysosomal enzymes were initially detected at the cell surface, 
their existence inferred from the specificity and saturability of enzyme uptake 
by fibroblasts (Fischer et al., 1980a), and the demonstration of cell surface 
binding sites for a-L-iduronidase (Rome et al., 1979) and ~-glucuronidase 
(Gonzalez-Noriega et al., 1980). Evidence for intracellular receptors was 
provided by Fischer et al. (1980a), who found receptors for lysosomal enzymes 
on the internal membranes of fibroblasts. A lysosomal enzyme receptor was 
finally isolated from bovine liver on the basis of its affinity for ~-galactosidase 
(Sahagian et al., 1981), and was found to be an integral membrane glycoprotein 
with apparent Mr of 215 000 by SDS-P AGE, with high affinity for both 
lysosomal enzymes and M6P (Fischer et al., 1982; Sahagian et al., 1981; Steiner 
and Rome, 1982). 
While the 215, 000-Mr receptor was found to be widely distributed, it was 
absent from a number of rodent cell lines, such as P388D1 and J77 4 
macrophages, L cells (fibroblasts), MOPC315 (myeloma cells) (Gabel et al., 1983) 
and Morris hepatoma 7777 (Mainferme et al., 1985). These cells were still able 
to direct lysosomal enzymes to lysosomes, inferring the existence of an 
alternative pathway for lysosomal enzyme targeting (Gabel et al., 1983). 
Hoflack and Kornfeld (1985a) identified a second lysosomal enzyme receptor 
on P388D1 membranes, which required the presence of divalent cations for 
ligand binding in vitro. This receptor has since been purified from a variety of 
tissues (Distler and Jourdian, 1987; Hoflack and Kornfeld, 1985b; Stein et al., 
1987a; Stein et al., 1987c),and shown to be an integral membrane glycoprotein 
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with an apparent subunit Mr of approximately 46, 000. On the basis of their 
differential requirements for divalent cations, the larger receptor has frequently 
been referred to as the cation-independent M6P receptor (CI-MPR,) and the 
smaller receptor as the cation-dependent M6P receptor (CD-MPR). In this 
review, they will be referred to as MPR-300 and MPR-46 respectively, on the 
basis of their calculated Mr, 
1.11.2 The cation-independent MPR (MPR-300) 
1.11.2.1 Sequence and structure 
MPR-300 is a large, type I transmembrane glycoprotein (Sahagian and Steer, 
1985; von Figura et al., 1985), and a schematic diagram of its structure is shown 
in Fig. 1.12. Complete amino acid sequences have been deduced from cDNA 
clones for the human (Morgan et al., 1987; Oshima et al., 1988), bovine (Lobel et 
al., 1987; Lobel et al., 1988), murine (Ludwig et al., 1994) and rat receptors 
(MacDonald et al., 1988), and show 80-90°/o homology between species. The 
protein component has a calculated mass of 275 kDa, and is 2491/2499 amino 
acid residues long (human /bovine). The newly synthesized receptor _is guided 
into the lumen of_the rough ER by an N-terminal signal sequence of 40/ 44 
residues. A single hydrophobic stretch of 23 amino acid residues divides the 
receptor into cytoplasmic and extracytoplasmic domains of 164/163 and 
2265 /2269 residues, respectively (Lobel et al., 1988; Morgan et al., 1987; Oshima 
et al., 1988; von Figura et al., 1985). The M6P binding site is located on the N-
terminal extracytoplasmic domain (Sahagian and Steer, 1985), which is 
extensively cross-linked by disulfide bonds (Sahagian and Neufeld, 1983), and 
contains 19 potential asparagine-linked glycosylation sites, at least two of 
which are glycosylated with complex-type oligosaccharides (Lobel et al., 1987; 
Sahagian and Neufeld, 1983). The smaller cytoplasmic domain contains only 
two potential glycosylation sites (Lobel et al., 1988). Glycosylation yields a 
mature receptor of up to 300 kDa (Lobel et al., 1988). 
The extracytoplasmic domain has a highly repetitive structure, consisting of 15 
homologous repeat sequences of 134-167 amino acid residues, followed by a 23-
residue "stalk" adjacent to the transmembrane region (Lobel et al., 1987; Lobel et 
al., 1988). The repeating units share an overall 16-38°/o sequence identity, as 
well as regions of conservatively substituted amino acids (Dahms et al., 1989). 
Most notable is a distinctive pattern of 8 conserved cysteine residues, all of 
which participate in intrachain disulfide bonds. Each repeat also contains a 
highly conserved 13-amino acid stretch that matches the consensus sequence 
:·-:2:· · :3: \: 
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Fig. 1.12 Schematic representation of MPR-300. 
Segmentation of the extracellular portion of MPR-300 into domains is based on 
optimal alignment of repeating units. The number of amino acid residues in 
each domain is shown. The insertion in domain 13 represents the region that is 
similar to sequences found in fibronectin and factor XII. Closed circles represent 
N-linked glycosylation sites known to be used, while open circles represent 
potential glycosylation sites 
Modified from Kornfeld (1987). 
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Cys X)( X Phe X Trp X Thr XX Ala Cys. The homology between the repeat 
units suggests that they share similar tertiary structures and disulfide bonding 
patterns. Repeat 13 differs from the others in that it contains a 43 residue 
insertion which has 50°/o homology to sequences found in fibronectin, factor XII 
and a bovine seminal fluid protein. In fibronectin, this sequence forms part of a 
collagen binding domain (Lobel et al., 1987; Lobel et al., 1988), however it's 
functional significance in MPR-300 is unknown. 
The cytoplasmic domain is the least conserved between species, with an overall 
58°/o sequence identity between the human, bovine and rat receptors. Five 
regions, however, are highly conserved, with 91 °/o identity compared to 38°/o for 
the intervening regions, indicative of functional importance. The conserved 
regions include a highly charged stop-transfer sequence adjacent to the 
transmembrane region; an acidic region containing potential tyrosine and 
serine phosphorylation sites, and a possible casein kinase I substrate; and three 
other regions containing sequences known to be potential substrates for protein 
kinases, including protein kinase C, cAMP-dependent protein kinase, and 
casein kinases I and II (MacDonald et al ., 1988). 
1.11.2.2 Degradation of MPR-300 
MPR-300 from CHO cell monolayers and human fibroblasts have half-lives of 
16 hand 26 h respectively (Creek and Sly, 1983; Sahagian and Neufeld, 1983). 
The rate of degradation in fibroblasts is not greatly affected by agents that 
inhibit protein degradation in lysosomes, suggesting that this mechanism does 
not contribute to the turnover of MPR-300 (Creek and Sly, 1983). The presence 
of a soluble, truncated form of MPR-300 in serum and urine suggest that 
cleavage from the cell surface may contribute to MPR-300 turnover (Causin et 
al., 1988; MacDonald et al., 1989), and loss of cellular MPR-300 has since been 
shown to occur by a non-lysosomal mechanism involving proteolysis and 
release into the extracellular fluid (Clairmont and Czech, 1991). 
1.11.2.3 Binding to M6P-bearing ligands 
MPR-300 has two high affinity M6P binding sites per molecule (Tong et al. , 
1989). As each of the 15 repeat units of MPR-300 is homologous to the 
extracytoplasmic domain of MPR-46 (Dahms et al., 1987), which contains a 
single M6P binding site (Section 1.11.3.3), the two M6P binding sites on MPR-
300 were each proposed to occupy a single repeat unit (Tong et al., 1989). They 
have since been localized to repeats 1-3 and 7-9 (Westlund et al., 1991), and site-
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directed mutagenesis has shown that arginine 435 (repeat 3) and arginine 1334 
(repeat 9) are essential components of the binding sites (Dahms et al., 1993). 
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MPR-300 has maximum affinity for M6P-bearing ligands at pH 6.0-6.3. Binding 
decreases slowly with increasing pH, but very rapidly below pH 6.0, such that 
M6P binding at pH 5.5 is less than 25°/o of that at pH 6.0 (Tong et al., 1989). This 
pH range is well suited to allow ligand binding in the Golgi and at the cell 
surface, while favouring ligand release in the acidic prelysosomal/ endosomal 
compartment. 
1.11.2.4 Ligand characterization 
MPR-300 has high affinity for oligosaccharides bearing a terminal M6P residue, 
and lower affinity for phosphodiesters, such as found on lysosomal enzymes 
from the slime mold Dictyostelium discoideum (Kaplan et al., 1978; Tong et al., 
1989). While M6P makes the major contribution, other structural features of the 
high mannose oligosaccharide also contribute to the binding interaction, as 
oligosaccharides bearing a single phosphomonoester have higher affinity for 
MPR-300 than do either M6P or pentamannose phosphate (PMP). The major 
structural difference is that in the high mannose oligosaccharide, M6P is most 
commonly linked al,2 to the underlying mannose residue, whereas the linkage 
is al,3 in PMP, and there is no underlying mannose in M6P (Tong et al., 1989; 
Varki and Kornfeld, 1980). In this context, the disaccharide man-al,2-man 
inhibits lysosomal enzyme binding 17 times more potently than does mannose 
(Distler et al., 1979). Thus, MPR-300 may recognise an extended 
oligosaccharide structure which includes the M6P-al,2-mannose sequence, or 
alternatively, M6P linked al,2 to the underlying mannose may adopt a more 
favourable conformation for binding than M6P alone or with an al,3 linkage 
(Tong et al., 1989). 
The presence of two M6P binding sites on MPR-300 suggests that divalent 
interactions may occur between a single receptor molecule and ligands bearing 
more than one phosphomannosyl group. In support of this, lysosomal 
enzymes, and oligosaccharides carrying two terminal M6P residues, have 
greater affinity for MPR-300 than oligosaccharides with only one M6P (Tong et 
al., 1989; Varki and Kornfeld, 1983). The binding affinity of divalent ligands is 
lower than that predicted for binding to two non-interacting sites, however, 
possibly because the relative positioning of the two M6P residues on the 
oligosaccharide do not precisely match the positioning of the two binding sites, 
resulting in a sub-optimal interaction (Tong et al., 1989). This point raises the 
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question of whether or not M6P residues mediating divalent interactions 
between lysosomal enzymes and MPR-300 are located on the same 
oligosaccharide (Kornfeld, 1992). Of interest in this regard is cathepsin L, a 
lysosomal enzyme which is secreted in large amounts by virally-transformed 
mouse fibroblasts (Dong et al., 1989), seemingly due to an unusually low 
affinity for MPR-300. Significantly, it carries a single oligosaccharide with two 
terminal M6P residues, while cathepsin L produced by CHO cells bears two 
oligosaccharides, each with two M6P residues, and binds MPR-300 with high 
affinity (Dong and Sahagian, 1990). This suggests that M6P residues located on 
separate oligosaccharides may interact more favourably with MPR-300 than do 
two M6P residues on the same oligosaccharide (Kornfeld, 1992). 
1.11.2.5 Identity with the insulin-like growth factor II receptor 
The relationship between MPR-300 and the insulin-like growth factor II (IGF-II) 
receptor became apparent when Morgan et al. (1987) sequenced the human IGF-
II receptor from full length cDNA clones and found it 80°/o identical to a partial 
clone of bovine MPR-300 (Lobel et al., 1987). It was subsequently shown to be 
99°/o identical to human MPR-300 (Oshima et al., 1988). Expression of these 
essentially identical cDNAs resulted in the appearance of both cell surface IGF-
II receptors (Morgan et al., 1987) and a receptor able to mediate ~-glucuronidase 
uptake (Oshima et al., 1988). Furthermore, the purified IGF-II receptor was 
recognised by two different polyclonal antibodies specific for purified MPR-
300. 
Bovine, human and rat MPR-300 have a single high affinity binding site for 
IGF-II (Keiss et al., 1988; MacDonald et al., 1988; Nolan et al., 1990; Roth et al., 
1987; Tong et al., 1988), which also binds IGF-I with a much lower affinity (Tong 
et al., 1988). Chicken and Xenopus MPR-300 do not bind IGF-II, however, 
suggesting that the acquisition of this binding site occurred in evolution after 
the divergence of mammals from other vertebrates (Canfield and Kornfeld, 
1989; Clairmont and Czech, 1989). The IGF-II binding site is contained within 
repeats 5-11 of the extracytoplasmic domain, with residues in repeat 11 playing 
an important role (Dahms et al., 1994). The M6P and IGF-II binding sites are 
thought not to overlap as the two ligands bind MPR-300 simultaneously 
(Braulke et al., 1988; Waheed et al., 1988), but may be close as lysosomal enzyme 
binding appears to sterically hinder binding of IGF-II, such that M6P enhances 
IGF-II binding in the presence of endogenous lysosomal enzymes (Braulke et 
al., 1988; Keiss et al., 1988; Kiess et al., 1990; Polychronakos et al., 1988; Schardt et 
al., 1993; Tong et al., 1988). 
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Whether or not the two binding sites are independent is a matter of some 
disagreement. Several studies have shown that neither M6P or IGF-II binding 
to MPR-300 influences binding of the other (Braulke et al., 1988; Polychronakos 
and Piscina, 1988; Tong et al., 1988), however Kiess et al. (1989) demonstrated 
that IGF-II inhibited binding of ~-galactosidase to the surface of C6 and BRL-
3A2 cells and to purified MPR-300, suggesting that binding of M6P and IGF-II 
are not independent. 
1.11.2.6 The role of MPR-300 in IGF-II function 
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The insulin-like growth factors are peptides with structural homology to pro-
insulin, which stimulate proliferation and differentiation in a wide range of cell 
types (Lund et al., 1986). IGF-I is involved in metabolic processes, and has 
growth promoting effects on several tissues, while IGF-II is important in foetal 
and neonatal development (Froesch et al., 1985; Rechler and Nissley, 1985). The 
physiological role of IGF-II binding to MPR-300 is uncertain, since it also binds 
to the IGF-I and insulin receptors (Morgan et al., 1987), and many of its 
biological effects seem to be mediated by the IGF-I receptor (Roth, 1988). The 
major function of MPR-300 in growth regulation appears to be limiting 
embryonic growth by removal of extracelhJlar IGF-II, resulting in its 
degradation in the lysosomes (Haig and Graham, 1991). However, a number of 
reports suggest that binding of IGF-II to MPR-300 may have biological 
significance. IGF-II binding to MPR-300 has been reported to stimulate 
glycogen synthesis in human HepG2 cells (Hari et al., 1987); calcium influx and 
DNA synthesis in competent BALB/c 3T3 cells primed with EGF (Kojima et al., 
1988; Nishimoto et al., 1987a; Nishimoto et al., 1987b ); proliferation of K562 cells 
(Tally et al., 1987); motility in rhabdomyosarcoma cells (Minniti et al., 1992); and 
formation of inositol triphosphate in the basolateral membranes of proximal 
kidney tubular cells (Rogers and Hammerman, 1988). In the first two studies 
listed, antibodies to MPR-300 were able to reproduce the effects of IGF-II (Hari 
et al., 1987; Kojima et al., 1988), and in the last, its stimulatory effect was 
potentiated by M6P (Rogers and Hammerman, 1989). Sakano et al. (1991) took 
a different approach and prepared two IGF-II mutants, one binding only to 
MPR-300 and not to the IGF-I receptor, and a second with the reverse 
specificity. Using these mutants, they showed that stimulation of glycogen 
synthesis in HepG2 cells and DNA synthesis in BALBI c 3T3 cells was induced 
through the IGF-I receptor, in direct contrast to the studies mentioned above. 
Evidently the question of whether or not MPR-300 mediates any of the 
biological effects of IGF-II is yet to be resolved. 
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1.11.2.7 MPR-300 is involved in IGF-II-mediated signal transduction 
In spite of these uncertainties, MPR-300 has been shown to function in G 
protein activation (Figure 1.13), making a role in signal transduction very 
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likely. In phospholipid vesicles, IGF-II stimulates direct coupling of purified 
MPR-300 and Gi2, a G protein with a 40 kDa a subunit (Murayama et al., 1990; 
Nishimoto et al., 1989). A 14 amino acid sequence from the cytoplasmic domain 
of MPR-300 has been identified as mediating this interaction (reviewed by 
Nishimoto (1993)). Activation of Gi2 by MPR-300 can be reproduced by a 
synthetic peptide corresponding to this sequence, and is blocked by an 
antibody to this peptide, indicating a critical role for this small region of the 
cytoplasmic domain (Okamoto et al., 1990a). The nine residues to the C-
terminal end of this sequence appear to mediate binding to Gi2, while the N-
terminal end is involved in its activation (Nishimoto, 1993). As purified MPR-
300 only activates Gi2 in the presence of IGF-II, while the isolated sequence has 
no such constraint, this sequence must be masked or inactivated in some way 
in the intact receptor, and this suppression removed by the binding of IGF-II. 
How extracellular IGF-II regulates the activity of this peptide is still unknown 
(Nishimoto, 199.3). 
Unlike IGF-II, neither M6P nor the lysosomal enzyme P-glucuronidase 
stimulates coupling of MPR-300 and Gi proteins. Thus lysosomal enzyme 
sorting by MPR-300 probably does not involve Gi activation (Murayama et al., 
1990; Okamoto et al., 1990b ). Conversely, both M6P and P-glucuronidase 
suppress the stimulatory effect of IGF-II on MPR-300 (Murayama et al., 1990). 
This may account for conflicting reports concerning the signalling function of 
MPR-300. In several studies, .MPR-300 had no effect on cellular metabolism or 
proliferation, even when IGF-II bound to the receptor (Conover et al., 1987; 
Ewton et al., 1987; Kiess et al., 1987), while other experiments suggested that it 
did (Section 1.11.2.6). Such variation in receptor function may arise from the 
variable presence of endogenous M6P-containing proteins which counter the 
stimulatory effect of IGF-II (Murayama et al., 1990). These investigators also 
speculated that inhibition of a IGF-II-mediated growth signal by M6P may be 
relevant to the actions of several growth modulators which contain M6P and 
bind MPR-300, such as the transforming growth factor P1 precursor and 
proliferin. These may have the capacity to interfere with the IGF-II-mediated 
signalling function of MPR-300. 
Empty state 
Active state Inactive state 
a 
0 
Fig. 1.13 Activation of G proteins 
G proteins are a family of GTPases involved in transduction of sensory and 
hormonal stimuli across the plasma membrane. They mediate 
transmembrane signalling using a basic cycle of GTP binding and 
hydrolysis, whereby the GTP-bound form is "active" and the GDP-bound 
form "inactive" with respect to their ability to modulate the activity of 
effector proteins. Cell surface receptors, activated by binding of 
extracellular ligands (LR*), bind the GDP-bound G protein trimer and 
promote dissociation of GDP. GTP then binds to the a subunit, which 
triggers dissociation of the G protein from the receptor and separation of 
a.GTP from the BY complex. The "active" GTP-bound a chain then activates 
an effector enzyme or ion channel (E). Hydrolysis of bound GTP by the 
intrinsic GTPase activity of the a chain returns it to the "inactive" state, in 
which it dissociates from the effector molecule and binds BY once more. 
The resulting aBy.GDP complex is then available for activation by another 
receptor molecule (Bourne et al., 1990). 
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1.11.3 The cation-dependent MPR (MPR-46) 
1.11.3.1 Sequence and structure 
MPR-46 is a transmembrane glycoprotein, considerably smaller than MPR-300 
(Fig. 1.14). Amino acid sequences deduced from cDNA clones for the human 
(Pohlmann et al., 1987), bovine (Dahms et al., 1987) and murine (Koster et al., 
1991; Ma et al., 1991) receptors contain 277, 279 and 278 amino acid residues 
respectively. Cleavage of a signal sequence from the newly synthesized 
polypeptide yields a mature protein of 257 residues, divided by a 
transmembrane region (34 residues) into an N-terminal extracytoplasmic 
domain of 165 residues and a smaller cytoplasmic portion of 67 residues. 
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The human, bovine and murine amino acid sequences are 93-96°/o identical, 
with most of the non-conservative changes clustered near the N-terminus, in 
the extracytoplasmic domain. All potential glycosylation sites are conserved, as 
well as amino acids important for ligand binding and disulfide bonding. The 
cytoplasmic domains are completely identical (Koster et al., 1991; Pfeffer, 1991) 
and contain a single casein II site. The entire extracytoplasmic domain of MPR-
46 is similar to each of the 15 repeating units of MPR-300, with sequence 
identities ranging from 14 to 28°/o (Kornfeld, 1992). Greatest similarity is found 
in the highly conserved 13 amino acid sequence bordered by cysteine residues 
which is found in all the sequence repeats of MPR-300 (Dahms et al., 1987). 
Such sequence homology suggests a common ancestral gene for the 
extracytoplasmic domains of the two receptors, with MPR-300 arising through 
multiple duplications (Kornfeld, 1992). As the sequence encoding this domain 
spans four exons in the MPR-46 gene, duplication of the putative ancestral gene 
must have occurred before the introduction of the present intron sequences 
(Klier et al., 1991). There is no homology between the signal sequences and 
transmembrane regions of MPR-300 and MPR-46 (Kornfeld, 1992), and very 
little between the cytoplasmic domains, which is notable in view of the similar 
intracellular movement of these receptors. The only feature they share with 
one another, and with other endocytic receptors, is that all contain cysteine 
residues and clusters of acidic residues (Dahms et al., 1987). 
1.11.3.2 Glycosylation 
MPR-46 is heavily glycosylated, appearing as a diffuse band on SDS-P AGE 
gels. The deglycosylated form migrates with an apparent molecular mass of 
26.5-28 kDa by SDS-PAGE, corresponding to the calculated mass of 28-29 kDa 
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Fig. 1.14 Schematic representation of MPR-46: comparison with 
MPR-300. 
Segmentation of the extracellular portions into domains is based on optimal 
alignment of repeating units. The number of amino acid residues in each 
domain is shown. Closed circles represent N-linked glycosylation sites known 
to be used, while open circles represent potential glycosylation sites 
Modified from Kornfeld (1987). 
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(Dahms et al., 1987; Pohlmann et al., 1987). The glycosylated form varies in size 
depending on the tissue source, and has been reported as 42 kDa (bovine testes) 
(Distler and Jourdian, 1987), 43 kDa (human and rat liver, human fibroblasts) 
(Stein et al., 1987a; Stein et al., 1987c) and 46 kDa (P388Dl cells, bovine liver, 
HepG2 hepatoma cells and U937 monocytes) (Hoflack and Kornfeld, 1985b). 
Sequence data indicates five potential N-linked glycosylation sites clustered 
near the N-terminus (Dahms et al., 1987; Pohlmann et al., 1987). Of these, 
asparagines 57, 83, 107 and 113 are glycosylated. The two outer asparagines 
carry high-mannose type and the two inner sites carry complex-type 
oligosaccharides (Wendland et al., 1991b ). 
While early studies suggested N-glycosylation to be essential for ligand 
binding (Hille et al., 1989; Hoflack and Kornfeld, 1985b), MPR-46 acquires 
binding activity before N-linked oligosaccharides are fully processed (Hille et 
al., 1990), and non-glycosylated MPR-46 is capable of high affinity binding 
(Wendland et al., 1991b). Glycosylation does appear to contribute to the 
stability of a high-affinity conformation, however (Wendland et al., 1991b ). In 
some cases, glycosylation interferes with ligand binding. On a glycosylation 
isoform isolated from bovine testes, complex oligosaccharides containing 
polylactosamine sequences and terminal sialic acid residues impair ligand 
binding, possibly by steric or electrostatic interference with the M6P binding 
site, or by unfavourably altering the receptor conformation (Li and Jourdian, 
1991). 
1.11.3.3 Oligomeric forms 
Detergent-solubilized MPR-46 can exist as a monomer, dimer or tetramer 
depending on the experimental conditions (Dahms and Kornfeld, 1989; Hoflack 
and Kornfeld, 1985b; Kornfeld, 1992; Li et al., 1990; Stein et al., 1987b; Stein et al. , 
1987c; Waheed and von Figura, 1990; Wendland et al., 1989). Formation of the 
tetramer is favoured at low temperature ( <16°C), neutral pH, high receptor 
concentration and in the presence of M6P, whereas dissociation is favoured by 
higher temperatures, low pH and low receptor concentration. The three forms 
rapidly interconvert at 37°C (Waheed and von Figura, 1990; Waheed et al., 
1990), and the subunits interact by non-covalent bonds, as they can be 
dissociated by SDS under non-reducing conditions (Hoflack and Kornfeld, 
1985b). The transmembrane domain appears to be involved in oligomerization, 
as a series of truncated MPR-46 constructs showed that the extracytoplasmic 
domain alone is insufficient for aggregation, whereas the cytoplasmic domain 
is unnecessary (Dahms and Kornfeld, 1989). Oligomers may be partially 
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stabilized by interactions between extracytoplasmic domains, however, as a 
similar MPR-46 construct, containing the extracytoplasmic domain and the first 
amino acid of the transmembrane region, was able to form dimers (Wendland 
et al., 1989). 
Several cross-linking studies have shown that MPR-46 exists in membranes as 
non-covalently linked homodimers (Dahms and Kornfeld, 1989; Li et al., 1990; 
Stein et al., 1987 a; Stein et al., 1987b). However, monomeric, dimeric and 
tetrameric forms have all been observed in BHK cells overexpressing the 
receptor (Waheed et al., 1990). As the equilibrium between oligomeric forms is 
influenced by pH, and ligand and receptor concentrations in a manner that 
would favour MPR-46 association in the Golgi/TGN, where it binds ligand at 
near neutral pH, and dissociation in the acidic prelysosomal compartment 
where ligand is released, these authors have speculated that the quaternary 
structure of MPR-46 may change during its cycling between the different 
compartments, and may even contribute to the trafficking of the receptor 
(Waheed and von Figura, 1990). 
1.11.3.4 Binding of phosphomannosyl ligands 
MPR-46 is specific for oligosaccharides bearing terminal M6P residues (Pfeffer, 
1991). As with MPR-300, binding is enhanced when M6P is linked al,2 to a 
mannose residue, suggesting that the binding site may accomodate an 
extended oligosaccharide structure which includes the M6P a-1,2 man 
sequence (Tong and Kornfeld, 1989). Unlike MPR-300, MPR-46 does not bind 
the methylphosphomannosyl groups present on lysosomal enzymes from the 
slime mold Dictyostelium discoideum (Hoflack and Kornfeld, 1985a). MPR-46 
has a narrower pH optimum than MPR-300 (pH 6-6.3); ligand binding is 
reduced as the pH becomes neutral, and is non-existent below pH 5.3 (Hoflack 
et al., 1987; Tong and Kornfeld, 1989). 
Monomeric MPR-46 is capable of binding phosphomannosyl ligands (Dahms 
and Kornfeld, 1989; Wendland et al., 1989). Its affinity for M6P is low, however, 
and requires the presence of Mn2+ (Li et al., 1990), in fact Waheed and von 
Figura (1990) could not detect binding of the monomer to a phosphomannan-
Sepharose affinity column. Ligand binding is enhanced with increasing 
oligomerization (Li et al., 1990; Waheed et al., 1990), possibly due to changes in 
receptor conformation which make the binding site more accessible, or the 
ability of oligomers to bind multivalent ligands (Li et al., 1990). MPR-46 binds 
one mole of M6P, and 0.5 mole of a diphosphorylated high-mannose 
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oligosaccharide per monomeric subunit, thus each dimer has two binding sites, 
both of which can be occupied by a divalent ligand (Distler et al., 1991; Tong 
and Kornfeld, 1989). As a consequence, dimeric MPR-46 has a higher affinity 
for multivalent ligands such as lysosomal enzymes than for monovalent 
ligands (Hoflack et al., 1987; Ma et al., 1991; Tong and Kornfeld, 1989). 
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The M6P binding site resides on the extracytoplasmic domain of MPR-46, as 
lysosomal enzyme binding occurs on the luminal side of the membrane. His-
131 and Arg-137 are essential for ligand binding, as conservative replacement 
of these two residues by site-directed mutagenesis results in loss of binding 
activity without affecting other properties of the receptor. Chemical 
modification of arginine and histidine residues also destroys M6P binding 
(Wendland et al., 1991a). The presence of M6P during modification of arginine, 
but not histidine, protects against loss of binding activity, suggesting that arg-
137 is a component of the M6P binding site while his-131 may influence 
binding in a more indirect manner (Stein et al., 1987c). From the perspective of 
the ligand, the 6-phosphate and 2-hydroxyl groups of M6P both contribute to 
the binding interaction, probably through ionic or hydrogen bonding for the 
former, and hydrogen bonding for the latter (Tong and Kornfeld, 1989). The 
importance of ionic bonding suggests the presence of cationic amino acid 
residues in the binding pocket, consistent with the involvement of arg-137. 
Hydrogen bonding in protein-sugar interactions is mediated by the planar side 
chains of such amino acids as arginine, aspartic acid, glutamic acid and 
asparagine (Quiocho, 1986), which are abundant in the conserved membrane 
proximal region of the MPR-46 extracytoplasmic domain (Pfeffer, 1991). 
1.11.3.5 Requirement for divalent cations 
Although MPR-46 is frequently referred to as the cation-dependent MPR, the 
bovine and murine forms appear more reliant on divalent cations (Distler et al., 
1987; Hoflack et al., 1987; Hoflack and Kornfeld, 1985a; Hoflack and Kornfeld, 
1985b; Li et al., 1990; Ma et al., 1991) than are human or porcine MPR-46 (Baba et 
al., 1988; Junghans et al., 1988; Watanabe et al., 1990). However, although Mn2+ 
enhances binding to bovine MPR-46 at low ligand concentrations, it has little 
effect as the receptor approaches saturation, suggesting that divalent cations 
serve to increase the association constant (Ka) of the receptor-ligand complex 
rather than being an absolute requirement for binding (Distler et al., 1987). 
Divalent cations also have a greater effect on the dimeric and monomeric forms 
of MPR-46 than on the tetramer, which may explain the apparent species-
specific requirements for divalent cations, as the receptor preparations used in 
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the various studies may have contained differing proportions of the various 
oligomeric forms (Li et al., 1990). 
1.12 Intracellular transport of MPR-enzyme complexes 
1.12.1 Subcellular localization of MPR-300 and MPR-46 
MPR-300 and MPR-46 have a predominantly intracellular location. MPR-300 
was initially localized in subcellular fractions of rat liver by Fischer et al. 
(1980b), who reported 90°/o in the fraction containing ER, Golgi and lysosomal 
membranes, 9 .5°/o in the plasma membrane and less than 1 °/o in the 
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nuclear/ mitochondrial fraction. Subsequent immunocytochemical and 
biochemical studies have shown that at steady-state, most MPR-300 is present 
in one or more populations of endosomes, with smaller amounts in the Golgi 
apparatus, on the cell surface and in coated vesicles, and little or none in the 
lysosomes (Brown and Farquhar, 1984a; Brown and Farquhar, 1984b; Brown et 
al., 1986; Geuze et al., 1984a; Geuze et al., 1985; Geuze et al., 1984b; Geuze et al., 
1988; Goda and Pfeffer, 1988; Griffiths et al., 1988; Griffiths et al., 1990; Jin et al., 
1989; Messner et al., 1989; Willingham et al., 1983; Willingham et al., 1981). 
MPR-300 and MPR-46 are expressed simultaneously in most cells and have a 
similar subcellular distribution (Bleekemolen et al., 1988; Gabel et al., 1983). 
MPR-46 is localized primarily in the endosomes of U937 monocytes, mouse 
macrophages and proximal tubule cells (Bleekemolen et al., 1988), and cycles 
through trans Golgi elements containing sialyltransferase in CHO cells (Duncan 
and Kornfeld, 1988). Membrane preparations isolated by antibodies specific to 
each receptor are not identical, however, which may reflect small differences in 
their cellular distribution (Messner et al., 1989). 
1.12.2 Intracellular movement of MPR-300 and MPR-46 
As outlined in Section 1.9, MPRs mediate the targeting of lysosomal enzymes to 
lysosomes via both a biosynthetic and an endocytic pathway (Fig. 1.15). In the 
biosynthetic pathway, newly synthesized enzymes are bound by MPRs in the 
Golgi membranes and transported to an acidified prelysosomal organelle. 
Extracellular enzymes are captured by cell surface MPRs, and delivered by 
receptor-mediated endocytosis to the same acidic compartment, where the low 
pH causes M6P-containing ligands to dissociate. The enzymes later appear in 
mature lysosomes, while MPRs recycle back to the Golgi or the cell surface for 
another round of transport (reviewed by Duncan and Kornfeld (1988) and Jin et 
al. (1989)). 
Fig. 1.15 Schematic diagram of lysosomal enzyme targeting to 
lysosomes 
Lysosomal enzymes ( • ) and secretory proteins ( 0 ) are synthesized in 
the rough ER and transported to the Golgi, where lysososomal enzymes 
acquire M6P markers ( .. ). Most lysosomal enzymes bind MPRs ( Y ) 
in the trans Golgi network (TGN) and are transported in coated vesicles to 
an acidified prelysosomal/ endosomal compartment, where they are 
released. The enzymes are packaged into lysosomes where the M6P 
marker is inactivated by dephosphorylation. The receptors return to the 
Golgi or the plasma membrane for another round of lysosomal enzyme 
transport. 
Extracellular lysosomal enzymes may be delivered to the lysosomes via the 
endocytic pathway. A small portion of enzymes is typically secreted by 
cells, and these may bind to cell surface MPR and be internalized via 
clathrin-coated pits and vesicles. The enzymes are delivered to the 
acidifiedendosomal compartment, where they dissociate from MPRs and 
are delivered to the lysosomes. 
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There has been some disagreement concerning the region of the Golgi in which 
newly synthesized lysosomal enzymes encounter MPR and exit the secretory 
pathway. The results of MPR-300 immunolocalization studies are inconclusive. 
In some cell types, such as pancreatic, hepatic and epididymal cells, the 
receptor is concentrated in the cis-Golgi cisternae, suggesting that lysosomal 
enzymes exit the secretory pathway at this point, bypassing the trans-Golgi 
(Brown and Farquhar, 1984b). However, in normal rat kidney cells, MPR-300 
is found throughout the Golgi apparatus (Brown and Farquhar, 1988), and in 
many other cell types it is found primarily in the final Golgi compartment, 
known as the trans-Golgi network (TGN) (Brown et al. , 1986; Geuze et al., 1985; 
Griffiths et al., 1988; Willingham et al., 1983). Biochemical data suggest that 
MPR-ligand complexes do pass through to the trans-Golgi region and that the 
major site for lysosomal enzyme sorting is the TGN. The enzymes involved in 
processing of complex oligosaccharides are found in specific regions of the 
Golgi and the TGN: a-mannosidase in the cis and mid-Golgi cisternae, 
galactosyltransferase in the trans-Golgi cisternae, and sialyltransferase in the 
trans-Golgi and TGN, and so have the potential to tag enzymes and receptors 
which move through these compartments (Duncan and Kornfeld, 1988). 
Several lysosorrtal enzymes, including cathepsin D and ~-hexosaminidase, 
contain terminally-processed complex oligosaccharides in addition to 
phosphorylated high mannose-type oligosaccharides (Beem et al., 1987; Fedde 
and Sly, 1985; Gieselman et al., 1983; Hasilik and von Figura, 1981; Kozutsumi et 
al., 1986; Rosenfeld et al., 1982; Varki and Kornfeld, 1983; Vladutiu, 1983), and 
MPR-300 itself is terminally glycosylated (Sahagian and Neufeld, 1983). As the 
glycosyltransferases responsible for terminal glycosylation reside in the trans 
Golgi cisternae and TGN, these proteins must pass through the entire Golgi 
stack enroute to the lysosome. Kinetic studies of MPR trafficking in several cell 
types have also shown that both MPR-300 and MPR-46 on the plasma 
membrane routinely recycle to the TGN, but rarely return to the cis-Golgi 
cisternae and pass through the entire Golgi complex (Duncan and Kornfeld, 
1988; Goda and Pfeffer, 1988; Jin et al., 1989), implicating the TGN as the major 
site where lysosomal enzymes encounter MPRs. This is consistent with a 
model proposed by (Griffiths and Simons, 1986) in which the TGN is the site 
where newly synthesized proteins destined for the plasma membrane, 
secretory vesicles and lysosomes are sorted and packaged into the correct 
transport vesicles. 
MPRs on both Golgi and plasma membranes are transported to the acidified 
prelysosomal compartment in clathrin-coated vesicles (Pearse and Robinson, 
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1990). MPR-300 has been immunolocalized to coated vesicles near the Golgi 
stack in fibroblasts (Brown and Farquhar, 1984a), and lysosomal enzyme 
precursors transiently associate with coated membranes and coated vesicles in 
a M6P-dependent manner (Lemansky et al., 1987; Schulze-Lohoff et al., 1985). 
The transport process is best understood in the context of endocytosis. Cell 
surface receptors requiring internalization are found clustered in clathrin-
coated pits, which exclude other membrane proteins, thus separating proteins 
that are to be transported to another compartment from those that are to 
remain behind (Pearce and Bretscher, 1981). Coated pits bud off into the 
cytoplasm as coated vesicles, the coats disassemble, and the vesicles, with their 
cargo of receptors, fuse with a second compartment. This process allows 
specific receptors to bind soluble proteins on one membrane and deliver them 
efficiently to another compartment (reviewed by Pearse and Robinson (1990)) . 
Transport of MPRs in coated vesicles appears to be an energy-dependent 
process, as GTP hydrolysis is required for vesicular transport of MPR-300 from 
the the prelysosomal compartment to the TGN in semi-intact cell extracts 
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(Goda and Pfeffer, 1988). The rab family of ras-like GTPases may play a key 
role in regulating vesicular transport, for example, rab9 is essential for MPR-
300 recycling from the prelysosomal compartment to the TGN (Lombardi et al., 
1993; Riederer et al., 1994), rab5 regulates early endosome fusion, rab4 functions 
in receptor recycling between early endosomes and the plasma membrane, and 
rab 1 is involved in protein transport between the ER and the Golgi. These 
proteins are believed to function in ensuring the accuracy of vesicle targeting 
and fusion events (reviewed by Bourne et al. (1990), Lombardi et al. (1993), and 
Riederer et al. (1994)). 
MPR-enzyme complexes are delivered to an acidic reticular-vesicular structure 
close to the Golgi apparatus (Griffiths et al., 1988). Several studies suggest that 
this is identical to the endocytic CURL (Compartment of Uncoupling Receptors 
and Ligands) (Brown et al., 1986; Geuze et al., 1984a; Geuze et al., 1985; Geuze et 
al., 1984b; Pfeffer, 1987), an organelle intermediate between clathrin-coated 
endocytic vesicles and lysosomes, in which dissociation of receptor-ligand 
complexes appears to occur (Geuze et al., 1983). This prelysosomal/ endocytic 
compartment has been characterized in NRK cells and has a complex three-
dimensional structure, consisting of tubuol-reticular domains in continuity 
with vesicular parts. The latter contain internal membranes, either tubular or 
sheet-like, which are rich in MPR-300. Lysosomes may form from this 
compartment either by budding off or somehow "maturing" (Brown et al., 1986; 
Griffiths et al., 1990). 
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1.12.3 Intracellular and cell surface MPRs belong to a common pool 
Considerable evidence demonstrates that the cell surface and intracellular MPR 
pools are in equilibrium. Addition of MPR-300 antibody to the culture medium 
of fibroblasts inhibited both endocytosis of extracellular enzymes and sorting of 
newly synthesized ones, indicating that intracellular receptors were accessible 
to the antibody. Exposure of most of the MPR-300 pool to extracellular 
antibody implied a constant exchange between intracellular and cell surface 
receptors (Gartung et al., 1985; Nolan, 1987; Sahagian, 1984; von Figura et al., 
1984). One objection to this interpretation was raised by Kornfeld and Mellman 
(1989), who suggested that since these experiments were performed at 37°C, the 
antibody may have been internalized by fluid phase endocytosis and so 
contacted the intracellular receptor pool directly. 
More convincing evidence has been provided by biochemical studies showing 
that MPR-300 can be modified by Golgi-specific enzymes after expression on 
the cell surface. Cell surface MPR-300 and MPR-46 labelled with [3H] galactose 
at 4 °C were rapidly sialylated when the cells were warmed to 37°C. As 
sialyltransferase is located in the trans-Golgi and TGN, this demonstrated that 
cell surface MPRs routinely reach the Golgi apparatus after endocytosis 
(Duncan and Kornfeld, 1988). In a similar study, cell surface MPR-300 was 
desialylated by neuraminidase treatment. The receptors were rapidly 
resialylated at 37°C, indicating again that surface MPR-300 is transported to the 
trans- Golgi region. As only a fraction of the resialylated receptor returned to 
the cell surface, this also suggested that the cell surface and intracellular MPR 
pools were mixed after resialylation, and that a single pool of receptors cycles 
between all MPR-containing compartments Gin et al., 1989). 
1.12.4 Control of MPR movement 
1.12.4.1. Effects of ligand binding 
Several investigators have proposed that MPR movement is regulated by 
ligand occupancy. (Brown et al., 1984) showed that when Clone 9 hepatocytes 
were treated with tunicamycin, an inhibitor of N-linked glycosylation which 
prevents formation of the M6P marker on newly synthesized lysosomal 
enzymes, MPR-300 accumulated in the cis-Golgi at the expense of the 
prelysosomal compartment. Conversely, when ligand dissociation in the 
prelysosomal/ endosomal compartment was prevented by raising the pH with 
weak bases (chloroquine or ammonium chloride), MPR-300 accumulated in the 
CHAPTER 1 Literature Review 45 
endosomes and was depleted from the Golgi. Recycling to the Golgi was re-
established by allowing the cells to endocytose M6P, facilitating MPR-enzyme 
dissociation inspite of the high pH (Brown et al., 1986). These studies suggested 
that ligand binding triggers movement of MPR-300 to endosomes, and ligand 
dissociation triggers their return to the Golgi. Similarly, MPR-300 accumulated 
in the Golgi and in nearby coated vesicles, and was depleted from endosomes 
in I-cell fibroblasts, in which lysosomal enzymes lack the M6P recognition 
marker (Brown and Farquhar, 1984a). MPR-300 was thus enriched at the 
sorting site and reduced or absent at the delivery site. These investigators 
concluded that coated vesicles containing MPR-300 do not constitutively move 
along the normal delivery route from Golgi to lysosomes, but are triggered to 
do so by enzyme binding. 
In contrast, others have found that MPR-300 recycling through the biosynthetic 
pathway is constitutive. When HepG2 cells were treated with cycloheximide or 
tunicamycin, producing a deficiency of MPR ligands in the Golgi, endosomal 
MPR-300 was not reduced, suggesting that in this case it's movement along the 
intracellular route was independent of ligand binding (Pfeffer, 1987). 
Intracellular sorting of lysosomal enzymes.is also unaffected by overexpression 
of IGF-II, indicating that binding of this ligand does not influence the cellular 
distribution of MPR-300 (Braulke et al., 1991). 
The distribution of MPR-300 between the cell surface and the endosomal 
compartment appears to be influenced by receptor occupancy, however 
movement between these two compartments is not. Preventing ligand release 
in the acidified prelysosomal compartment with weak bases reduced cell 
surface MPR by 20-50°/o (Braulke et al., 1987; Braulke et al., 1992; Geuze et al., 
1985; Gonzalez-Noriega et al., 1980), but the rate of exchange between internal 
and cell surface MPR-300 was not affected. Free cell surface receptors were 
replaced with occupied ones, which continued to exchange with intracellular 
MPR-ligand complexes at the normal rate (Braulke et al., 1987). Extracellular 
M6P-containing ligands also had no effect on the internalization of cell surface 
MPR-300, as determined by resialylation of desialylated cell surface MPR-300 in 
the TGN Gin et al., 1989), nor did extracellular IGF-II (Oka and Czech, 1986). 
These studies suggest that receptor occupancy does not influence the exchange 
of MPR-300 between the cell surface and internal membranes, in either 
direction. This exchange was also unaffected by depletion of newly 
synthesized lysosomal enzymes from the Golgi by cycloheximide treatment, 
which indirectly implies that movement of receptors between internal 
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compartments is also constitutive (Braulke et al., 1987; Jin et al., 1989). These 
studies suggest that the MPRs move constantly between the Golgi or plasma 
membrane and the prelysosomal compartment, and transport lysosomal 
enzymes by virtue of.the pH difference between these two compartments. The 
approximately neutral pH in the Golgi or at the cell surface permits the binding 
of M6P-bearing ligands, while the acidic conditions in the prelysosomal 
compartment favour their release. 
1.12.4.2. The role of the cytoplasmic domain in MPR movement 
The cytoplasmic domains of both MPR-300 and MPR-46 regulate their 
movement between intracellular compartments. By transfecting MPR-300 
mutants with deletions in the cytoplasmic tail into receptor-deficient cells, 
Lobel et al. (1989) showed the C-terminal region to be important for 
intracellular trafficking, and the membrane-proximal portion essential for 
endocytosis (Lobel et al., 1989). The cytoplasmic tail of MPR-46, completely 
conserved between species (Koster et al., 1991), is also essential for 
internalizahon, as truncated receptors lacking this domain accumulate at the 
cell surface Oohnson et al., 1990; Peters et al., 1990; Weber et al., 1989). Signals 
required for MP~-46 cycling between the Golgi apparatus and prelysosomal 
compartment may also reside in the cytoplasmic tail (Nadimpalli et al., 1991). 
The cytoplasmic tails appear to include recognition sequences which target the 
receptors for inclusion in coated pits on the Golgi and plasma membranes, and 
hence for packaging into coated vesicles. Coated pits are associated with two 
distinct structural units: the clathrin triskelion and an adaptor protein. The 
adaptors interact with a recognition sequence in the cytoplasmic tail of 
appropriate receptors, gathering them into the coated pits while excluding 
other membrane proteins. Clathrin interacts with the adaptors, forming an 
outer polyhedral cage around the pit or vesicle (Fig. 1.16). Two adaptors, HA-I 
and HA-II, have been identified and are found in coated pits on the Golgi and 
plasma membranes respectively (Pearse and Robinson, 1990). They appear to 
recognise distinct amino acid sequences, such that the LDL and transferrin 
receptors associate with HA-II at the plasma membrane and are constitutively 
endocytosed, while newly synthesized receptors fail to interact with HA-I in 
the Golgi (Pearse and Robinson, 1990). 
Both adaptors bind to distinct regions of the MPR cytoplasmic tail, thus MPRs 
associate with HA-II adaptors in plasma membrane coated pits, and with HA-I 
adaptors in the Golgi (Glickman et al., 1989; Pearse and Robinson, 1990). The 
l 
clathrin triskelion receptor + ligand 0 adaptor clathrin 
Fig. 1.16 General scheme of a cycle of coated pit formation 
Soluble clathrin triskelions and adaptors interact at the membrane with the 
cytoplasmic tails of receptors. Coated pits form by assembly of further 
receptors and coat components, and pinch off to form coated vesicles. These 
rapidly uncoat, releasing the vesicle and allowing the soluble coat components 
to form another coated pit. 
Adapted from Pearse and Robinson (1990) 
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specific sequence recognised by HA-I adaptors has not been characterized, but 
probably involves the C-terminal region of the MPR-300 cytoplasmic tail, as 
this is required for intracellular sorting (Lobel et al., 1989). HA-II binds to the 
membrane-proximal portion of the MPR-300 cytoplasmic tail (Glickman et al., 
1989; Keen, 1990), consistent with the requirement for this region in receptor 
endocytosis, and the sequence Tyr-Lys-Tyr-Ser-Lys-Val (residues 24-29 from 
the membrane) has been identified as the internalization signal (Canfield et al., 
1991). Tyrosine 26 and valine 29 are the most important residues, though 
tyrosine 24 and lysine 28 also contribute; lysine 25 and serine 27 are not critical. 
The tyrosines can be replaced by phenylalanine, indicating a requirement for 
an aromatic residue in these positions rather than for tyrosine specifically. The 
contribution of lysine 28 may be due to its positive charge, as it can be replaced 
by other charged residues, and valine 29 can be replaced by phenylalanine, 
leucine, isoleucine or methionine, suggesting a requirement for a large 
hydrophobic residue in this position (Jadot et al., 1992). The determinants for 
MPR-46 endocytosis have been localized to two distinct regions of it's 
cytoplasmic tail. One region includes phenylalanine 18 as the key residue with 
phenylalanine 1_3 as a secondary component, while the other involves tyrosine 
45. The former is more potent than the latter, but both are required for 
maximal internalization (Johnson et al., 1990). 
The crucial elements of these sequences are found in the internalization signals 
of a number of other cell surface receptors which undergo rapid 
internalization: common features are a 4 or 6 amino acid motif, with an 
aromatic residue (usually tyrosine) in the N-terminal position and a large 
hydrophobic residue (valine, phenylalanine or isoleucine) in the C-terminal 
position. The 6-residue internalization signal of MPR-300 has been successfully 
replaced by the 4-residue sequences of seven other receptors known to undergo 
rapid internalization. The signal for receptor internalization is thus a general 
motif, interchangeable between receptors, rather than a specific sequence (Jadot 
et al., 1992). 
1.12.4.3 Other factors influencing MPR movement 
While the cytoplasmic tails of MPR-300 and MPR-46 are clearly involved in 
regulating intracellular movement, the extracytoplasmic and transmembrane 
domains may also have some influence. A chimeric protein comprising the 
extracellular and transmembrane domains of the human EGF receptor, joined 
to the MPR-300 cytoplasmic domain, was found predominantly at the cell 
surface, whereas most MPR-300 is intracellular. However, chimeric receptors 
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comprised of MPR-300 extracellular and transmembrane sequences joined to 
the cytoplasmic domains of the EGF or LDL receptors were efficiently 
endocytosed, and colocalized with native MPR-300 in intracellular 
compartments. These experiments suggest that the extracytoplasmic or 
transmembrane domains of MPR-300 contain an "endosome-retention" signal 
which keeps the native receptor in the endosomal compartment (Dintzis and 
Pfeffer, 1990; Dintzis et al., 1994). 
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The quaternary structure of MPR-46 may also regulate receptor trafficking. The 
equilibrium between the monomeric, dimeric and tetrameric forms of the 
receptor is controlled by pH, ligand binding and receptor concentration, all of 
which are subject to variation between the sites where MPR-46 binds and 
releases lysosomal enzymes (Waheed and von Figura, 1990; Waheed et al., 1990) 
(Section 1.11.3.3). This has led to speculation that the quaternary structure of 
MPR-46 not only varies in different cellular compartments, but actively 
contributes to receptor trafficking. As the conformation of the cytoplasmic tail 
is affected by the qua ternary structure of the receptor, changes in qua ternary 
structure may expose signals required for intracellular movement (Nadimpalli 
et al., 1991). 
1.13 Comparison of the roles of MPR-300 and MPR-46 in 
lysosomal enzyme targeting 
1.13.1 Both MPR-300 and MPR-46 transport newly synthesized 
Iysosomal enzymes 
Both MPR-300 and MPR-46 have been implicated in the binding and targeting 
of newly synthesized M6P-bearing proteins to lysosomes. MPR-300 is 
predominantly involved in the intracellular retention of lysosomal enzymes, in 
that it transports newly synthesized enzymes to the prelysosomal 
compartment, and internalizes extracellular enzymes. Thus, cells which lack 
MPR-300 (Gabel et al., 1983), or are depleted of it by specific antibodies (von 
Figura et al., 1984), secrete newly synthesized enzymes in large amounts and 
are unable to endocytose extracellular ligands. Transfection of MPR-300 cDNA 
into MPR-300-deficient cell lines almost completely corrects the hypersecretion 
defect and allows endocytosis of exogenous ligands (Kyle et al., 1988; Lobel et 
al., 1989). 
MPR-46 also participates in targeting of newly synthesized enzymes to the 
lysosomes. Although cells deficient in MPR-300 hypersecrete acid hydrolases, 
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30-40°/o of newly synthesized enzymes are still directed to lysosomes (Gabel et 
al., 1983), and immunodepletion of MPR-46 increases enzyme secretion further 
(Stein et al., 1987d). Transgenic mice in which the MPR-46 gene is deleted, but 
MPR-300 is retained, exhibit defects in lysosomal enzyme targeting: elevated 
levels of phosphorylated lysosomal enzymes are present in the body fluids, and 
are secreted from cultured cells (Koster et al., 1993; Ludwig et al., 1993). 
Both receptors appear to be required for optimal intracellular sorting of 
lysosomal enzymes. In vitro studies have suggested this not to be the case, as 
immunodepletion of MPR-300 in cells expressing both receptors increases 
lysosomal enzyme secretion, while depletion of MPR-46 does not, suggesting 
that both receptors can participate in sorting, but MPR-300 dominates when 
both are present (Braulke et al., 1989; Nolan, 1987; Stein et al., 1987d). In 
contrast, the studies using MPR-46-deficient transgenic mice clearly show that a 
complete loss of MPR-46 is associated with misrouting of up to 50°/o of M6P-
containing polypeptides. MPR-300 thus cannot compensate for the complete 
absence of MPR-46, which appears to be responsible for half of the lysosomal 
enzyme targeting (Ludwig et al., 1993). 
1.13.2 MPR-46 is not involved in endocytosis of lysosomal enzymes 
Although MPR-46 contributes to sorting of newly synthesized lysosomal 
enzymes, it does not internalize extracellular enzymes. At very high levels of 
overexpression, MPR-46 can mediate endocytosis (Watanabe et al., 1990), 
however MPR-300-deficient cell lines such as M.H. 7777 neither bind nor 
internalise extracellular ligand. Lysosomal enzyme uptake by U937 cells, 
which express both types of MPR, is inhibited by antibodies specific for MPR-
300, but not MPR-46. Internalization of anti-MPR-46 antibodies indicates that 
the failure of this receptor to mediate endocytosis is due not to its absence from 
the cell surface or an inability to be internalized, but rather to an inability of the 
cell surface receptor to bind ligand. The reason for this is unknown (Stein et al., 
1987d). 
1.13.3 MPR-46 is involved in secretion of lysosomal enzymes 
In addition to its role in transporting newly synthesized enzymes to lysosomes, 
MPR-46 is directly involved in their secretion (Chao, 1990). When cells 
expressing both receptors were transfected with MPR-46 cDNA, they secreted 
excessive amounts of M6P-containing proteins. Secretion was reduced by 
antibodies which blocked the MPR-46 binding site, indicating that these 
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proteins bound to MPR-46 prior to their secretion. Since co-transfection with 
MPR-300 negated the increase in secretion, these investigators concluded that 
MPR-46 was directly involved in secretion, and that enhanced secretion 
resulted from an imbalance of the two receptors in favour of MPR-46. 
A model was proposed whereby the two receptors compete for binding of 
newly synthesized lysosomal enzymes in the Golgi: those bound by MPR-300 
are transported to lysosomes, while MPR-46 transports its ligands either to the 
lysosomes or to a site from vvhich they can exit the cell. As secreted enzymes 
are in precursor form, this site must be situated prior to the prelysosomal 
compartment and lysosomes, in which proteolytic processing of many 
lysosomal enzymes occurs. MPR-46 may release it's ligand directly at the cell 
surface, for the same reasons that prevent extracellular ligands from binding to 
cell surface MPR-46, or in early endosomes, where the free ligand would reach 
the cell surface as part of the fluid phase. 
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Table 1.1 Comparison of MPR-300 and MPR-46 
Characteristic MPR-300 MPR-46 
Relative molecular -polypeptide 275,000 26, 500 - 28, 000 
weight 
- glycosylated 300,000 46, 000 (varies with tissue 
source) 
Structural Some sequence homology between extracytoplasmic 
comparison domains. 
No homology between transmembrane and 
cytoplasmic domains. 
Extracytoplasmic 15 cysteine-rich repeat 1 cysteine-rich domain; 
domain sequences with 16-38% shares 14-28% homology 
sequence identity. with MPR-300 repeat 
sequences. 
Oligomeric structure Probably a monomer. Monomer, dimer, or 
tetramer, depending 
onpH, and receptor or 
ligand concentration. 
Ligand specificity Both bind M6P phosphomonoesters, preferably linked 
al,2 to an underlying mannose residue. 
• some affinity for • does not bind phospho-
phosphodiesters diesters 
• has greater· affinity for 
divalent ligands than does 
MPR-46 
•binds IGF-II 
Number of M6P 
binding sites per 2 1 
monomer 
Number of IGF-II 
binding sites per 1 0 
monomer 
pH dependence of low pH optimal at pH 6.0-6.3, decreases sharply below 6.0 
M6Pbinding 
neutral pH slight decrease between rapid decline between 
6.0-7.4 6.0-7.4 
Intracellular location Co-expressed in most cells. 
About 90% expressed in intracellular membranes 
(Golgi, TGN, endosomes, coated vesicles). 
Approximately 10% on the olasma membrane. 
Role in lysosomal • Intracellular transport • Intracellular transport 
enzyme targeting • Endocytosis of extra- • Secretion of enzymes 
cellular enzymes 
Role in signal IGF-11 binding stimulates a No known role in signal 
transduction Gi protein-mediated signal transduction. 
transduction pathway. 
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1.14 Aims of this study 
The aim of this study was to test the hypothesis proposed by Parish et al. (1990) 
that extracellular lysosomal enzymes, expressed on the cell surface of 
extravasating leukocytes by means of MPRs, contribute to their ability to 
degrade the subendothelial basement membrane. Under normal 
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circumstances, a small percentage of lysosomal enzymes are secreted instead of 
being delivered to the lysosomes. This may occur directly, by means of MPR-
46 (Chao, 1990), or by failure to bind either MPR in the trans-Golgi/TGN, such 
that the enzyme continues along the secretory pathway. Secreted enzymes may 
be recaptured and endocytosed by MPR-300 expressed at the cell surface. 
MPR-300 has a half-life of 3-5 minutes at the plasma membrane (Braulke et al., 
1987; Gonzalez-Noriega et al., 1980), which is not affected by ligand binding Gin 
et al., 1989), thus bound lysosomal enzymes can remain at the cell surface for up 
to several minutes. This may provide sufficient time for any one enzyme to 
degrade surrounding basement membrane components. It is important to note 
that in this scenario, enzymes must be secreted prior to their delivery to the 
lysosomes, so that their M6P marker remains intact. Some inflammatory cells, 
such as macrophages, secrete bulk amounts of lysosomal enzymes by fusion of 
lysosomes with the plasma membrane (Henson, 1971; Movat et al., 1964; Parish, 
1969; Tew et al., 1969; Weissman et al., 1971). As these enzymes no longer carry 
the M6P marker, they cannot be displayed on the cell surface in the manner 
proposed here, and instead, must exert their effects in a soluble form. 
The inhibition of T cell-mediated, passively induced EAE and adjuvant arthritis 
by CS and M6P, described in Section 1.8, provides indirect support for this 
hypothesis. This study sought to extend this work and provide more direct 
evidence that MPR-mediated expression of lysosomal enzymes on the cell 
surface of T lymphocytes could contribute to their degradation of the 
subendothelial basement membrane and subsequent entry into tissues. Two 
approaches were taken. 
1. Is MPR required for cell surface expression of degradative enzymes? 
Firstly, if MPR-300 is involved in the cell surface expression of degradative 
enzymes, then disrupting ligand binding should reduce the ability of 
extravasating cells to degrade the subendothelial basement membrane, by 
analogy with the proposed mechanism of action of M6P. The first part of this 
study aimed to specifically prevent lysosomal enzyme binding to cell surface 
MPR-300 using monoclonal antibodies specific for this receptor, and to evaluate 
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the effect on the degradative ability of T lymphocytes, both in terms of their 
ability to induce EAE in vivo and to degrade ECM laid down by cultured 
endothelial cells. 
2. Does T lymphocyte activation affect MPR expression? 
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Adoptive transfer of EAE is effected by activated, MBP-specific T cells. In 
recent years, it has become apparent that the CNS is randomly surveyed by T 
cells, and can be entered by activated T cell blasts, regardless of their antigen 
specificity. Wekerle et al. (1986) obtained preliminary evidence that activated T 
cells specific for non-CNS antigens could enter the CNS, and proposed that 
emigration of lymphocytes into the CNS depends only on the activation state of 
the cell. Subsequent experiments have confirmed that activated, but not 
resting, T cells enter the CNS (Hickey et al., 1991; Ludowyk et al., 1992). In vitro 
studies have also shown that activated T cells are more adhesive for 
endothelium, and that secretion of matrix-degrading proteases and 
heparanases is enhanced in comparison with resting cells (Ebnet et al., 1991; 
Naparstek et al., 1984; Savion et al., 1984; Simon et al., 1991), providing some 
insight into the mechanisms behind their invasive behaviour. Parish and 
coworkers have proposed that T cell activation also increases their invasive 
potential by increasing cell surface expression of lysosomal enzymes. If 
lysosomal enzymes are expressed on the cell surface by means of MPR-300, 
activation could bring about an increase in their cell surface expression by 
either or both of the following. 
a) Increasing the expression of MPR-300 at the cell surface, thus increasing the 
number of lysosomal enzyme binding sites available. 
b) Increasing the availability of ligand by an increased secretion of lysosomal 
enzymes, assuming that cell surface MPR-300 on the resting cell is not saturated 
with ligand. An increase in lysosomal enzyme secretion could be accomplished 
by several mechanisms: 
i) Increased synthesis of a specific lysosomal enzyme 
Expression of sufficiently large amounts of any enzyme saturates the 
available M6P binding sites in the trans-Golgi and TGN, and excess 
enzyme is secreted via the secretory pathway. Other lysosomal enzymes 
are also secreted, as they compete for the same binding sites. This is 
illustrated in hormone-dependent breast cancer cells, in which estrogen 
stimulates overexpression of cathepsin D and down-regulates MPR-300. 
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The depleted levels of intracellular MPR-300 are saturated by their 
estrogen-induced ligand, and consequently the secretion of both cathepsin 
D and other lysosomal enzymes, produced in lesser amounts, is increased 
(Capony et al., 1990; Mathieu et al., 1991). 
Secretion of lysosomal enzymes can also arise from incorrect synthesis of 
the M6P recognition marker. This is seen in I cell disease, where most 
lysosomal enzymes are affected (Hickman and Neufeld, 1972; Neufeld 
and Cantz, 1971), and in transformed murine fibroblasts, where cathepsin 
L has an unusually low affinity for MPR, and is selectively secreted (Dong 
et al., 1989; Dong and Sahagian, 1990; Sahagian and Gottesman, 1982). As 
the secreted enzymes in these examples bind inefficiently to MPR, this 
means of increasing the concentration of extracellular lysosomal enzymes 
is inappropriate in the context of our model, as they bind equally poorly 
to cell surface MPR-300 as to the intracellular receptor. 
ii) Changes in the distribution of either or both of MPR-300 and MPR-46 
MPR-300 and MPR-46 are expressed simultaneously in most cells, have a 
similar intracellular distribution (Bleekmolen et al., 1988; Gabel et al., 
1983), and compete for binding of newly synthesized lysosomal enzymes 
in the trans-Golgi and TGN. While both are involved in intracellular 
transport to lysosomes, MPR-46 has also been reported to transport 
enzymes directly to the cell surface (Chao, 1990). Secretion of lysosomal 
enzymes could thus be enhanced by increasing the proportion of MPR-46 
in the Golgi region. Fewer lysosomal enzymes would then be directed to 
lysosomes by MPR-300, and more to the cell surface by MPR-46. 
To summarize, T cell activation could increase cell surface binding of lysosomal 
enzymes by increasing the expression of MPR-300 at the cell surface, and/ or 
the expression of MPR-46 in the Golgi. This could be achieved by a 
redistribution of the existing MPR pool, with or without an increase in receptor 
synthesis. The second part of this study aimed to use mAbs specific for MPR-
300 and MPR-46 to compare the expression of the two receptors in resting and 
activated T lymphocytes. 
CHAPTER 2 
DEVELOPMENT OF AN ASSAY TO 
DETECT MPR-300 EXPRESSION 
·ON THE CELL SURFACE 
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2.1 INTRODUCTION 
Parish et al. (1990) have proposed that lysosomal enzymes, displayed on the 
surface of extravasating T cells by MPRs, participate in the degradation of the 
subendothelial basement membrane. The aim of the first part of this study was 
to examine the consequences of preventing lysosomal enzyme binding to the T 
cell surface, using monoclonal antibodies (mAbs) specific for rat MPR-300. This 
chapter describes a simple assay for detecting MPR-300 on the surface of intact 
cells, based on the binding and endocytosis of a fluorescent, M6P-rich ligand. 
This assay was developed to provide a means of (a) identifying a rat cell line 
with sufficiently high expression of MPR-300 on the cell surface for screening 
hybridoma supernants for binding to the extracellular domain of the receptor; 
and (b) screening antibodies for their ability to interfere with ligand binding to 
cell surface MPR-300. 
In previous studies, cell surface and intracellular MPR in intact cells and tissue 
sections have been detected by immunofluorescence, immuno-
electronmicroscopy and immunocytochemistry at the light microscopic level, 
using antisera specific for MPR-300 and MPR-46 (Brown et al., 1984; Brown and 
Farquhar, 1984b; Geuze et al., 1984a; Geuze et al., 1988; Griffiths et al., 1988; 
Matovcik et al., 1990; Prydz et al., 1990; Willingham et al., 1983). While antibody 
binding is a sensitive assay for the presence of receptors, and is used in later 
chapters to detect cell surface MPR-300 on leukocytes, it could not be used to 
screen mAbs for their ability to interfere with ligand binding. For this purpose, 
a functional assay dependent on ligand binding was required. 
Other studies concerned with ligand characterization, and the kinetics of ligand 
binding and MPR-300 internalization, have utilized assays involving either 
ligand binding to membranes or whole cells at 4°C, or uptake by cells at 37°C. 
Ligands include lysosomal enzymes, such as mammalian ~-glucuronidase 
(Fischer et al., 1980a; Kaplan et al., 1977a; Kaplan et al., 1977c; Kaplan et al., 1978; 
O'Brien et al., 1989), ~-galactosidase (Distler et al., 1979; Sahagian et al., 1979), ~-
hexosaminidase B (Fischer et al., 1980b) and L-iduronidase (Rome et al., 1979; 
Sando, 1978; Sando and Neufeld, 1977), and a-mannosidase from the slime 
mold Dictyostelium discoideum (Shepherd et al., 1984). These lysosomal enzymes 
were purified from cellular secretions rather than whole cells, as an intact M6P 
marker is required for binding to MPR. Alternative ligands include 
phosphorylated oligosaccharides, such as high mannose-type oligosaccharides 
derived from lysosomal enzymes (Natowicz et al., 1983), and pentamannose 
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phosphate (PMP) conjugated to BSA (Braulke et al., 1987). Detection of these 
ligands has relied on radioactive labelling, or assaying for cell-associated 
enzymatic activity. 
While these methods fulfilled the requirement for an assay dependent on 
ligand binding, detection of the bound or endocytosed ligand were technically 
laborious. For use in antibody screening, a rapid and simple assay was 
required. This chapter describes an assay based on those described above, in 
which binding and uptake of a highly fluorescent, M6P-rich polysaccharide 
was measured by flow cytometry. 
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The MPR ligand was isolated from the exopolysaccharide secreted by the yeast 
Pichia holstii. Acid hydrolysis of yeast exopolysaccharides yields a 
phosphomannan monoester core polysaccharide (PPME), containing many 
exposed M6P residues, and smaller pentamannose phosphate (PMP) fragments 
(Fischer et al., 1980c). Phosphomannans and their partial hydrolysis products 
competitively inhibit lysosomal enzyme uptake by fibroblasts (Fischer et al., 
1980c; Kaplan et al., 1977a; Kaplan et al., 1978), and biosynthetically-labelled 
PPME and PMP bind saturably to the cell s:urface of fibroblasts. The 
multivalent PPME has a high affinity for cell surface MPR, is a potent inhibitor 
of lysosomal enzyme uptake, and is endocytosed efficiently (Fischer et al., 
1980c). This chapter describes the binding and uptake of fluorescein-labelled 
PPME by the U937 cell line. 
2.2. EXPERIMENT AL PROCEDURES 
2.2.1 Materials 
Rabbit antiserum raised against bovine MPR-300, and cross-reactive with 
human MPR-300, was a generous gift from Dr G. Gary Sahagian (Tufts 
University, Boston, MA). Fluorescein-labelled PPME (fl-PPME), purified from 
Pishia holstii, and fluorescein-labelled mannan (fl-mannan) were a gift from Dr 
Susan Weston (Manchester University, Manchester, UK). Phosphosugars and 
D-mannose were obtained from Sigma Chemical Co. (St. Louis, MO). 
2.2.2 Cell culture 
The cell lines U937, Clone 9, BRL-3A and McA RH7777 were obtained from the 
American Type Culture Collection (Rockville, MD), and the P388Dl cell line 
from Dr Carolyn Geczy (Heart Research Institute, Sydney, Australia). U937, 
P388D1 and Clone 9 cells were maintained at 37°C (5°/o CO2) in RPMI 1640 
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medium (Gibco, Gaithersburg, MD), supplemented with 10°/o foetal calf serum 
(FCS; Commonwealth Serum Laboratories, Melbourne, Australia), 2 mg/ml 
sodium bicarbonate, 0.2 mM glutamine, 30 µg/ ml penicillin, 50 µg/ ml 
streptamycin sulfate and 50 µg/ ml neomycin sulfate. BRL-3A were cultured in 
RPMI 1640 medium as above, supplemented with 5°/o FCS. McA RH7777 cells 
were maintained at 37°C (10°/o CO2) in Dulbecco's modified Eagle's medium 
(DMEM; #430-1600, Gibco, Gaithersburg, MD) supplemented with 20°/o FCS, 
3.7 mg/ml sodium bicarbonate, 4 mM glutamine, 3.5 mg/ml glucose, 120 
µg/ml penicillin, 200 µg/ml streptomycin sulfate and 200 µg/ml neomycin 
sulfate. 
U937 cells were subcultured by inoculation into fresh medium at a density 
between 5 x 104 and 1 x 10s cells/ml, and were grown to a maximum density of 
1 x 106 cells/ml. Adherent cells (P388Dl, Clone 9, BRL-3A and McA-RH7777) 
were released for subculturing with 0.25°/o trypsin (Cytosystems, Sydney, 
Australia) and 0.1 °/o EDTA in PBS when monolayers were confluent. The 
subcultivation ratio was between 1:6 and 1:30 for Clone 9 cells, 1:4 for BRL-3A 
and P388D1 cells, and between 1:2 and 1:6 for McA RH7777 cells. 
2.2.3 Immunofluoresent flow cytometry 
U937 cells were treated with rabbit antiserum, washed and incubated with a 
fluorescein-Protein A conjugate (Pharmacia, Uppsala, Sweden) at 100 µg/ml. 
Incubations were in 96-well V-bottomed plastic plates (Nunc, Roskilde, 
Denmark) using 1 x 10s cells/ml in 40 µl volumes. All incubations were for 30 
min on ice, and cells were washed three times with 10°/o FCS/RPMI between 
the two incubations. The final incubation was followed by two washes with 
10°/o FCS/RPMI and one with PBS. Cells were fixed with 1 °/o 
paraformaldehyde in PBS (pH 7.4) and analysed for fluorescence by flow 
cytometry (Section 2.2.5). 
2.2.4 Assays for binding and uptake of fl-PPME 
2.2.4.1 Binding and uptake of fl-PP ME by cells in suspension 
Where appropriate, adherent cells were released using 0.1 °/o EDTA in PBS. 
Cells were resuspended in 10°/o FCS/RPMI medium and incubated with fl-
PPME (up to 100 µg/ml) or fl-mannan, with or without inhibitors, for 60 min at 
4°C (binding assays) or 3 hat 37°C (uptake assays), except where otherwise 
stated. Incubations were in 96 well V-bottomed plastic microtitre plates, using 
1 x 10s cells in 40 µl volumes. Cells were washed twice with 10°/o FCS/RPMI 
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and once with PBS, then fixed with 1 °/o paraformaldehyde in PBS and analysed 
for fluorescence by flow cytometry. Background autofluorescence of cells 
incubated with medium alone was subtracted from all samples. 
2.2.4.2 Binding and uptake of fl-PP ME by adherent cells 
Adherent cells were released from flasks using 0.25 °/o trypsin and 0.1 °/o EDTA 
in PBS, and resuspended in the appropriate medium at the same density used 
for subculturing. Monolayers were prepared in 24-well tissue culture plates 
(Linbro, ICN Biomedicals, Costa Mesa, CA) by adding 2 ml of the cell 
suspension per well, and incubating at 37°C until confluent. Monolayers were 
washed twice with 10°/o FCS/RPMI and incubated with 200 µl of fl-PPME or fl-
mannan, with or without 2.5 mM M6P, for 3 hat 37°C. Cells were washed 
twice with 10°/o FCS/RPMI and released from the wells with 0.25°/o trypsin. 
The cells were washed again with RPMI medium, then with PBS and fixed in 
1 °/o paraformaldehyde in PBS. Cells were analysed for fluorescence by flow 
cytometry. 
2.2.5 Flow cytometry 
Cells were analysed for fluorescence using a F ACScan (Becton Dickinson, 
Mountain View, CA) and Lysys II software. Cell populations were gated on 
the basis of forward and side scatter to exclude dead and aggregated cells, and 
results expressed as median fluorescence intensity units (FIU). 
2.2.6 Confocal microscopy 
The intracellular location of fl-PPME taken up by U937 cells was analysed by 
confocal microscopy, using an MRC-500 Confocal Imaging System (Biorad, 
Abingdon, Oxfordshire, UK) controlled by a dedicated computer system and 
equipped with a 25 mW multiline argon ion laser and Nikon Optiphot 
fluoresence microscope (Nikon, Tokyo, Japan). 
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2.3 RESULTS 
2.3.1 Cell surf ace expression of MPR-300 on U937 cells 
The human monocyte cell line U937 was used to develop an assay for detecting 
cell surface expression of MPR, as it has a relatively high content of both MPR-
300 and MPR-46, with about 12°10 of each receptor found at the cell surface 
(Bleekmolen et al., 1988). Initially, a rabbit antiserum specific for bovine MPR-
300, and cross reactive with the human receptor, was used to confirm the 
presence of MPR-300 on the cell surface of U937 cells. Antibody binding was 
detected by immunofluorescent flow cytometry and is illustrated in Fig. 2.1. 
Antibody binding was maximal at 1/100 - 1/200 dilution and was substantially 
greater than binding of a control rabbit antiserum, consistent with cell surface 
expression of MPR-300 on these cells. 
PPME binding was examined by incubating U937 cells with fl-PPME for 60 min 
at 4°C. The .dependence of binding on ligand concentration is shown in Fig. 2.2. 
Non-specific binding was determined as binding of fl-PPME in the pr~sence of 
5 mM M6P. The ~6P-specific component of binding appeared saturable, 
consistent with binding to a cell surface receptor (Warlow, 1989). 
The extent of fl-PPME binding varied considerably between experiments, with 
cell-associated fluorescence varying by as much as 100°10 (data not shown). The 
M6P-inhibitable component of the fluorescence was quantitatively low (6-11 
FIU at 50 µg/ml PPME), and was not increased by preincubating the cells with 
M6P in order to remove endogenous lysosomal enzymes (data not shown). 
Thus, endocytosis of PPME was examined so as to increase the sensitivity of the 
assay. 
2.3.2 Uptake of fl-PPME by U937 cells 
A more sensitive variant of the PPME binding assay was developed by 
exploiting the ability of cell surface MPR to bind and internalize ligand. Fig. 2.3 
illustrates uptake of fluorescent PPME as a function of ligand concentration. 
The degree of uptake varied between experiments, as was the case for fl-PPME 
binding, but results were qualitatively similar each time. Non-specific uptake 
was determined by including 5 mM M6P in the assay. As fl-PPME uptake in 
the presence of M6P was very low over the entire concentration range, it is 
likely to be mediated entirely by a receptor for M6P. However, since PPME 
contains a high proportion of mannose residues, with a mannose: phosphate 
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Fig. 2.1 
Binding of a polyclonal rabbit anti-MPR-300 antiserum to U937 cells. 
Cells (1 x 10 5 ) were incubated with anti-MPR-300 antiserum ( • ) for 30 
min at 4 °C, and antibody binding measured by immunofluorescent flow 
cytometry. All values are corrected for background autofluorescence. 
Fluorescence is compared with that due to binding of a rabbit antiserum 
(1/100 dilution) specific for chicken histidine-rich glycoprotein ( 0 ). 
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Fig. 2.2 
Binding of fl-PPME to U937 cells (1 x 10 5 ) incubated with increasing 
concentrations of ligand for 60 min at 4 °C. Cell-associated fluorescence 
was determined by flow cytometry. Non-specific binding was determined 
by adding 5 mM M6P to companion assays. All values are corrected for 
background autofluorescence. Single data points are shown, however 
similar results were obtained in 9 separate experiments. 
80 
fl-PPME 
>- 60 
-~ 
en 
C 
Q) 
.... 
C 
Q) 
() 
C 
Q) 
() 40 en 
Q) 
lo.. 
0 
::::J 
;;::: 
C 
C'O 
-c Q) 
E 20 
fl-PPME + M6P 
0l'llf---__,,ji.-------'-----'--------1-----'--------1 
0 25 50 75 100 125 150 
FI-PPME concentration (µg/ml) 
Fig. 2.3 
Uptake of fl-PPME by U937 cells (1 x 10 5 ) incubated with increasing 
concentrations of ligand for 3 hat 37°C. Cell-associated fluorescence was 
determined by flow cytometry. Non-specific binding was determined by 
adding 5 mM M6P to companion assays. All values are corrected for 
background autofluorescence. Single data points are shown, however 
similar results were obtained in 10 separate experiments. 
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ratio of 20:1 (Weston, 1991)), mannose-specific uptake was also determined. 
Mannose itself is a poor inhibitor of mannose-specific uptake (Lennartz et al., 
1987; Stephenson and Shepherd, 1987), so uptake of fl-PPME and fl-mannan (a 
yeast polysaccharide consisting only on mannose residues) were compared. Fl-
mannan uptake was neglible (Fig. 2.4), indicating that mannose recognition 
does not contribute to endocytosis of fl-PPME by U937 cells. 
Uptake of fl-PPME was saturable at the higher ligand concentrations (Fig. 2.3), 
however the concentration required to saturate uptake varied between 
experiments. Cell-associated fluorescence under saturating conditions also 
varied, ranging from 100 to over 500 FIU after 3 hat 37°C. As binding of fl-
PPME to U937 cells also varied on separate occasions, these were attributed to 
variation in the level of MPR expression, and possibly also in the rate of 
endocytosis. When fl-PPME uptake was saturating at low concentrations, MPR 
expression/endocytosis was presumably low, and when high PPME 
concentrations were required to achieve saturation, MPR levels were 
presumably higher. Saturating levels of fl-PPME produced a fluorescent signal 
considerably higher than that due to cell surface binding, thus FL-PPME uptake 
provided a more sensitive indicator of MPR activity at the cell surface. 
Although uptake of fl-PPME was dose-saturable at any given incubation time, 
increasing the incubation time permitted endocytosis of seemingly indefinite 
quantities of PPME, with no evidence of time-limited saturation. Fig. 2.5 
illustrates that at 3 µg/ml fl-PPME, cell-associated fluorescence was maximal 
by 2 h, presumably due to depletion of fl-PPME from the medium, while at 50 
µg/ml, PPME was endocytosed almost linearly over a 5 h period. Despite the 
availability of 20 times as much fl-PPME in the latter assay, cell-associated 
fluorescence after 5 h was only 5 fold higher than in the cells incubated with 3 
µg/ml PPME, suggesting that they could continue to endocytose PPME for 
much longer. This is consistent with the continuous recycling of MPRs 
between sites of ligand binding and release (Section 1.9). 
Confocal micrographs of cells incubated with PPME at 37°C showed that the 
internalized ligand is compartmentalized (Fig. 2.6), consistent with release of fl-
PPME in the prelysosomal compartment, and subsequent delivery to lysosomes 
(Section 1.12.2). Fl-PPME uptake was also inhibited in the presence of 
chloroquine, a lysosomotropic amine which reduces cell surface expression of 
MPR-300 (Braulke et al., 1987; Gonzalez-Noriega et al., 1980), and also raises the 
pH of acidic organelles (Shoji and Poole, 1978), preventing ligand-MPR 
dissociation within the prelysosomal compartment (Brown et al., 1984). After a 
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Comparison of uptake of fl-PPME and fl-mannan by U937 cells. Cells 
(1 x 105 ) were incubated with fl-PPME or fl-mannan (50 µg/ml) for 3 h 
at 37°C. Non-specific uptake of fl-PPME was determined by including 
5 mM M6P in a companion assay. Cell-associated fluorescence was 
determined by flow cytometry. All values are corrected for background 
autofluorescence. Values represent mean+ SEM (n=3). 
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Time course of fl-PPME uptake by U937 cells (1 x 105 ) incubated at 37°C 
with fl-PPME at concentrations of 3 µg/ml and 50 µg/ml. Cell-associated 
fluorescence was determined by flow cytometry. All values are corrected 
for background autofluorescence. Single data points are shown, but 
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Fig. 2.6 
Intracellular destination of endocytosed fl-PPME. U937 cells (1 x 105) were 
incubated with fl-PPME (50 µg/ml) for 6 hat 37°C. Washed cells were fixed 
with 1 °/o paraformaldehyde and examined by confocal fluorescence 
. 
microscopy. 
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5 h incubation in the presence of 25 mM chloroquine, cell-associated 
fluorescence was only 15 °/o of the control level (Fig. 2.7). This is consistent with 
the effect of chloroquine on MPRs; by preventing ligand release in the acidified 
prelysosomal/ endosomal compartment, chloroquine depletes the cell of 
unoccupied receptors, thus preventing endocytosis of exogenous ligand 
(Gonzalez-Noriega et al., 1980). 
The sugar specificity of fl-PPME uptake was tested using several 
phosphosugars as inhibitors (Fig. 2.8). Fl-PPME uptake by U937 cells was 
strongly inhibited by M6P and fructose 1-phosphate (FlP). Fructose 6-
phosphate (F6P) and glucose 6-phosphate (G6P) weakly inhibited PPME 
uptake, while the effects of galactose 6-phosphate (Gal6P) and mannose 1-
phosphate (MlP; data not shown) were little better than mannose. 
2.3.4 The contribution of MPR-300 to fl-PPME uptake 
Although both MPR-300 and MPR-46 are found on the plasma membrane of 
U937 cells, <?nly MPR-300 binds extracellular M6P-bearing ligands (Stein et al., 
1987d). It is probable then that fl-PPME uptake is mediated by MPR-300 alone. 
To confirm this, two cell lines which do not'express MPR-300 were incubated 
with fl-PPME at 4 °C and 37°C. M6P-specific binding and uptake of fl-PPME by 
the murine P388Dl macrophage cell line (Gabel et al., 1983; Hoflack and 
Kornfeld, 1985a) was very low, and negligible compared to that observed for 
U937 cells (Fig. 2.9 (a, b )). The McA RH7777 cell line is derived from the rat 
M.H. 7777 hepatoma line, which has also been reported not to express MPR-300 
(Mainferme et al., 1985). McA RH7777 cells also showed no M6P-specific 
binding or uptake of PPME (data not shown). This suggests that fl-PPME 
uptake is specific for MPR-300. 
2.3.4 Detection of cell surface MPR-300 on rat cell lines 
A rat cell line was required for screening hybridoma supematants for binding 
to cell surface MPR. Two rat hepatocyte cell lines, Clone 9 and BRL-3A, were 
obtained and tested for M6P-specific uptake of fl-PPME. Adherent cells of both 
types endocytosed fl-PPME in a M6P-dependent manner, however M6P-
specific uptake by Clone 9 cells was 35-fold higher than by BRL-3A cells (Fig. 
2.10). As non-adherent cells were required for the antibody screening assay, 
Clone 9 cells were detached using EDTA and examined for uptake of fl-PPME. 
The detached cells bound and endocytosed fl-PPME in an M6P-inhibitable 
manner, although less efficiently than did the adherent cells (Fig. 2.11). The 
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Fig. 2.7 
Effect of chloroquine on uptake of fl-PPME by U937 cells. Cells (1 x 105 ) 
were incubated with 50 µg/ml fl-PPME for varying times at 37°C in the 
presence and absence of 25 mM chloroquine. Cell-associated fluorescence 
was determined by flow cytometry. All values are corrected for background 
autofluorescence. Single data points are shown. 
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Fig. 2.8 
Inhibition of fl-PPME uptake by a range of phosphosugars and 
mannose. U937 cells (1x10 5 ) were incubated with fl-PPME (25 µg/ml) 
for 4 h at 37°C in the presence of varying concentrations of mannose 
6-phosphate ( • ), fructose 1-phosphate ( O ), fructose 6-phosphate ( • ), 
glucose 6-phosphate ( D) and mannose ( • ). Cell-associated 
fluorescence was determined by flow cytometry. All values are 
corrected for background autofluorescence. Single data points are 
shown, however similar results were obtained in two separate 
experiments. 
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Fig. 2.9 
Binding (a) and uptake (b) of fl-PPME by P388Dl murine macrophages. 
Adherent cells were detached with 0.1 °/o EDTA and incubated with 
fl-PPME (50 µg/ml) for 1 hat 4°C (a), or 3 hat 37°C (b). Non-specific 
binding/uptake was determined by including 5 mM M6P in companion 
assays. Cell-associated fluorescence was determined by flow cytometry. 
All values are corrected for background autofluorescence. Single data 
points are shown, but similar results were obtained in two separate 
experiments. 
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Fig. 2.10 
Uptake of fl-PPME and fl-mannan by Clone 9 ( • ) and BRL-3A ( t?J) rat 
hepatocytes. Adherent cells grown in 24-well plates were incubated with 
fl-PPME or fl-mannan (25 µg/ml) for 3 hat 37°C. Non-specific uptake of 
fl-PPME was determined by including 2.5 mM M6P in a companion assay. 
Adherent cells were released with trypsin and cell-associated fluorescence 
was determined by flow cytometry. All values are corrected for background 
autofluorescence. Values represent mean+ SEM (n=3). 
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Fig. 2.11 
Uptake (•)and binding(~) of fl-PPME by non-adherent Clone 9 
hepatocytes. Adherent cells were released with 0.1 °/o EDTA and incubated 
with fl-PPME (50 µg/ml) for 3 hat 37°C Non-specific uptake/binding 
was determined by including 5 mM M6P in companion assays. 
Cell-associated fluorescence was determined by flow cytometry. All values 
are corrected for background autofluorescence. Values represent mean+ 
SEM (n=3). 
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concentration of fl-PPME used (50 µg/ml) was assumed sufficient to saturate 
binding and uptake by Clone 9 hepatocytes, as U937 cells incubated with FL-
PPME at 50 µg/ml gave much higher fluorescence signals (up to 500-600 FIU). 
2.4 DISCUSSION 
This chapter describes an assay for the detection of M6P-binding proteins on 
the surface of intact cells. It involves a simple procedure, in which cells are 
incubated with fluorescent-labelled PPME at 4 °C or 37°C, and cell-associated 
fluorescence is measured by flow cytometry. 
2.4.1 Specificity of PPME binding and uptake 
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Since this assay was developed for the detection of MPR-300 at the cell surface, 
it is important to consider the specificity of fl-PPME binding. Although PPME 
has been shown to bind strongly to MPRs on the cell surface of fibroblasts 
(Fischer et al., 1980c), it is less specific for these receptors than are lysosomal 
enzymes, or phosphorylated oligosaccharides derived from them, as it also 
binds other M6P and mannose-binding proteins. For example, PPME is 
endocytosed by-splenic sinusoidal cells via -a mannose receptor (Weston and 
Parish, 1991), and also binds to L-selectin on leukocytes in a M6P-dependent 
manner (Yednock et al., 1987b). Most mammalian macrophages express a cell 
surface mannose receptor, however it has not been found on macrophage-
derived cell lines, freshly isolated monocytes or monocyte-like cell lines such as 
U937 and HL-60 (Diment et al., 1987; Kataoka and Tavassoli, 1985; Pimpaneau 
et al., 1991; Roche et al., 1990; Shepherd et al., 1982). Thus, mannose binding is 
unlikely to contribute to the binding and uptake of fl-PPME described in this 
chapter, and in fact fl-mannan was not endocytosed by U937 cells, or by BRL-
3A and Clone 9 hepatocytes. 
M6P inhibited both binding and uptake of fl-PPME, confirming that binding 
was mediated by a M6P receptor. Three known cell surface proteins bind M6P, 
namely MPR-300, MPR-46 and L-selectin. It is unlikely that fl-PPME binds to 
cell surface MPR-46, as this receptor appears unable to bind or endocytose 
extracellular ligand (Stein et al., 1987d). This was reinforced by the inability of 
both the McA 7777 hepatoma cell line and the P388D1 macrophage cell line to 
bind and endocytose fl-PPME. 
L-selectin is a lectin-like adhesion molecule which binds anionic sugar-bearing 
ligands such as PPME (Imai et al., 1990; Yednock et al., 1987b), and is 
constitutively expressed on the cell surface of unstimulated lymphocytes, 
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monocytes, neutrophils and other myeloid cells (Lewinsohn et al., 1987; Rosen 
and Yednock, 1986). It is involved in adhesion of leukocytes to activated 
endothelium at inflammatory sites Gutila et al., 1991; Jutila et al., 1989; 
Lewinsohn et al., 1987; Watson et al., 1991), and of lymphocytes to peripheral 
lymph node HEVs (reviewed by (Picker and Butcher, 1992)), and is rapidly 
down-regulated on activated cells (Jutila et al., 1990; Jutila et al., 1989; Kishimoto 
et al., 1989a). Fl-PPME has been used extensively as a soluble model of it's 
natural ligand at a similar concentration range to that used in this study 
(Brandley et al., 1987; Jutila et al., 1990; Kansas et al., 1991; Spertini et al., 1991a; 
Spertini et al., 1991b; Watanabe et al., 1992; Yednock et al., 1987a). It is possible 
that the fl-PPME binding assay described in this chapter could detect cell 
surface L-selectin, as well as MPR-300, on leukocytes expressing both 
molecules. While L-selectin has not been reported on U937 cells, this is a 
monocyte-like cell line and it may well be expressed and contribute to binding 
of fl-PPME. 
Measurement of fl-PPME uptake, rather than binding, biases the assay in 
favour of MPR-300, as L-selectin has not been implicated in endocytic uptake of 
carbohydrate ligands. In the presence of cell surface MPR-300, any binding of 
fl-PPME to L-selectin would be masked by fluorescence due to MPR-mediated 
endocytosis. Other characteristics of fl-PPME uptake were also consistent with 
the known behaviour of MPR-300. Linear uptake of fl-PPME over a prolonged 
period, indicating an undiminished supply of unoccupied receptors, is 
consistent with recycling of MPR-300. Inhibition of uptake by chloroquine is 
compatible with the demonstration by (Gonzalez-Noriega et al., 1980) that 
preventing ligand release in the prelysosomal compartment depletes the cell of 
unoccupied MPR-300, and prevents further endocytosis of exogenous ligands. 
Inhibition of fl-PPME uptake by various phosphosugars was also consistent 
with the known specificity of MPR-300. Uptake by U937 cells was strongly 
inhibited by M6P and FlP, both potent inhibitors of ligand binding to MPR-300 
and MPR-46 (Kaplan et al., 1977a; Tong and Kornfeld, 1989). The concentration 
of M6P required to produce a 50°/o inhibition of uptake was approximately 0.4 
mM, compatible with the binding specificity of MPR-300 (0.95 mM) (Distler et 
al., 1991). Low inhibition by F6P, G6P, Gal6P and MlP were also consistent 
with binding to MPR-300 (Kaplan et al., 1977a). In summary, uptake of fl-
PPME by U937 cells appears to be mediated by MPR-300. This assay may, 
however, be unsuitable for detecting small amounts of MPR-300 on cells which 
also express high levels of L-selectin. 
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2.4.2 Detection of MPR-300 on the surface of U937 cells by 
binding and uptake of fl-PPME 
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Fl-PPME binding to the surface of cells at 4°C was saturable and M6P-specific, 
providing a direct, although insensitive, measure of MPR-300 at the cell surface. 
Receptor-mediated endocytosis of fl-PPME at 37°C was far more sensitive, as it 
exploited the continuous recycling of MPR-300. As ligand internalized by 
MPR-300 is delivered to lysosomes while empty receptors recycle back to the 
cell surface, large amounts of fl-PPME accumulated within the cell over time, 
producing a very high fluorescence intensity, limited only by the incubation 
time and the amount of fl-PPME supplied. As PPME must initially bind to 
receptors at the cell surface, this assay is totally dependent on the presence of 
cell surface MPR-300, and is, in effect, a cumulative measure of total cell surface 
expression over the time of the assay. 
Endocytosis of fl-PPME by cells thus provides a useful and sensitive assay for 
the presence of MPR-300 at the cell surface. It should be noted that the rate of 
endocytosis contributes to the extent of fl-PPME accumulation also, so PPME 
uptake does not-provide a quantitative meqsure of cell surface MPR-300. 
Instead, it indicates the presence of MPR-300 on the plasma membrane of a 
given cell type, with greater sensitivity than PPME binding. This assay does 
not lend itself easily to mathematical analysis of binding and uptake (Spertini et 
al., 1991a), as PPME is multivalent. However, it should be useful for 
comparisons between different cell types or treatments. 
2.4.3 Selection of a suitable rat cell line for antibody screening 
A rat cell line expressing MPR-300 and MPR-46 on the cell surface was required 
for screening hybridoma supematants for their ability to bind to cell-associated 
MPRs. As liver tissue and cell lines have been used in many studies of MPR 
expression, two rat hepatocyte cell lines were examined using the PPME uptake 
assay. Clone 9 and BRL-3A cells are both reported to express MPR-300 on the 
cell surface (Brown et al., 1984; Clairmont and Czech, 1991). MPR-46 
distribution has been studied in Clone 9 cells, however cell surface expression 
was not noted (Matovcik et al., 1990). As the two receptors have been reported 
to have similar subcellular distributions in other cell types (Bleekmolen et al., 
1988), MPR-46 may also be present on the Clone 9 cell surface. Expression of 
MPR-46 has not been examined in BRL-3A cells. 
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Comparison of MPR-300 cell surface expression on these two cell lines, using 
the fl-PPME uptake assay, showed that Clone 9 cells expressed far more MPR-
300 on the cell surface than did the BRL-3A cell line. The Clone 9 cell line was 
thus selected for screening of hybridoma supernatants. 
2.4.4 PPME binding and uptake as a measure of MPR function 
One aim of this study was to develop a screening assay to identify antibodies 
able to interfere with ligand binding to cell surface MPR-300. The fl-PPME 
binding and uptake assays both detect MPR-300 on the basis of its ability to 
bind and endocytose M6P-bearing ligands, thus both assays should be sensitive 
to inhibition of ligand binding. The assay procedure is suitable for use as a 
screening assay, as it is very simple, and the incubation of cells with fl-PPME 
can be done in a microtitre plate, a format which facilitates the handling of 
large numbers of samples. Fl-PPME binding to the cell surface may limited in 
this application by its low sensitivity. Fl-PPME uptake by cells is more 
sensitive than binding, and so provides a larger window for detecting 
inhibition of ligand binding, with the disadvantage that exogenous antibody 
will be rapidly i_nternalized and depleted from the medium. A high initial 
concentration of antibody will therefore be required to ensure that there is 
sufficient to bind fresh MPR-300 as it arrives at the cell surface over the 
duration of the incubation period. 
2.5 SUMMARY 
Lysosomal enzymes expressed at the cell surface in association with MPR-300 
are proposed to contribute to the invasive capacity of activated T lymphocytes 
by participating in basement membrane degradation. In order to examine the 
consequences of specifically inhibiting the enzyme-MPR interaction on the 
ability of T cells to degrade basement membrane components in vitro and 
initiate an inflammatory response in the rat model EAE, monoclonal antibodies 
were raised against MPR-300. This chapter describes a simple ligand binding 
assay for MPR-300, developed to (a) identify a suitable rat cell line for screening 
hybridoma supernatants for antibodies specific for the extracellular portion of 
MPR-300; and (b) facilitate screening of antibodies for their ability to inhibit the 
binding of M6P-bearing ligands to MPR-300. 
The human monocytic cell line U937, known to express both MPR-300 and 
MPR-46 on the plasma membrane, was used to determine the characteristics of 
PPME binding and endocytosis. Fluorescein-labelled PPME bound saturably to 
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the cell surface at 4 °C, in a M6P-inhibitable manner. Cell-associated 
fluorescence was quanti ta ti vel y low, however, a·nd endocytosis of PPME 
provided a more sensitive indicator of cell surface binding sites. PPME uptake 
at 37°C was dose saturable at any given incubation time, and inhibitable by 
M6P. 
Several characteristics of PPME uptake correlate with the known behaviour of 
MPR-300, suggesting that endocytosis is mediated by this receptor: (a) two cell 
lines which express MPR-46 but are deficient in MPR-300 did not bind or 
endocytose PPME; (b) PPME uptake by cells was limited only by the amount 
supplied, consistent with recycling of MPR-300; (c) internalized PPME is 
compartmentalized, consistent with ligand release in the prelysosomal 
compartment, and subsequent delivery to lysosomes; (d) PPME uptake was 
inhibited by chloroquine treatment, which prevents dissociation of the MPR-
300-ligand complex in intracellular acidified compartments, depleting the cell 
of unoccupied receptors; and (e) PPME uptake was inhibited by M6P and 
fructose-I-phosphate, but not by galactose-1-phosphate, mannose-1-phosphate 
or mannose. Uptake of PPME generated a far greater fluorescent signal than 
produced by cell surface binding, thus endocytosis of fluorescein-labelled 
PPME provides a sensitive assay for the presence of MPR-300 at the cell 
surface. 
Two rat cell lines, Clone 9 and BRL-3A hepatocytes, were shown to endocytose 
PPME in a M6P-inhibitable manner. As uptake by Clone 9 cells was 35-fold 
greater than by BRL-3A cells, this cell line was selected for screening 
hybridoma supernatants for antibodies specific for the extracellular domain of 
MPR-300. As McA RH7777 cells did not internalize PPME, they were selected 
as a negative control for MPR-300, and for detecting antibodies with specificity 
for MPR-46. 
Both PPME binding and uptake were suitable assays for screening antibodies 
for their ability to inhibit M6P-mediated ligand binding. Both detect cell 
surface MPR-300 on the basis of its ability to bind a M6P-bearing ligand, and in 
addition, the assay procedure is simple and conducive to handling large 
numbers of samples. 
l 
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PREPARATION OF 
MONOCLONAL ANTIBODIES 
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3.1 INTRODUCTION 
Parish and coworkers have proposed that lysosomal enzymes, attached to the 
cell surface of extravasating leukocytes by MPRs, participate in degrading the 
subendothelial basement membrane. As activated T lymphocytes are required 
for the passive transfer of EAE, they further proposed that cell surface 
expression of lysosomal enzymes may be enhanced by cellular activation, thus 
contributing to an increased invasive capacity. As described in Section 1.14, 
such as increase could be mediated by an activation-induced redistribution of 
the existing MPR pool, such that MPR-300 expression is increased at the cell 
surface, thus increasing the number of binding sites for extracellular lysosomal 
enzymes. An increase in intracellular expression of MPR-46 could also 
contribute, as this receptor is directly involved in the secretion of lysosomal 
enzymes, and so could increase their concentration in the extracellular space. 
The aim of the experiments described in this chapter was to produce 
monoclonal antibodies (mAbs) specific for MPR-300 and MPR-46, to enable the 
examination of (a) the cellular distribution of MPR-300 and MPR-46 in resting 
and activated T _cells; and (b) the consequences of neutralizing the binding of 
lysosomal enzymes to cell surface MPR-300. 
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The effect of inhibiting lysosomal enzyme binding to cell surface MPR-300 has 
been partially explored using M6P as a competitive inhibitor. M6P binds to 
both purified MPR-300 (Tong et al., 1989) and MPR-46 (Tong and Kornfeld, 
1989), and is a potent inhibitor of lysosomal enzyme uptake by intact cells 
(Kaplan et al., 1977a; Kaplan et al., 1977c; Sando and Neufeld, 1977; Ullrich et al., 
1978). M6P also inhibited the heparanase activity of PMA-stimulated human 
peripheral blood lymphocytes in an in vitro ECM degradation assay (Bartlett et 
al., 1995a), and diminished lesion formation in adoptively transferred EAE and 
adjuvant arthritis in rats (which are initiated by entry of activated T cells into 
the CNS and joints respectively) (Willenborg et al., 1989b; Willenborg et al., 
1992). These three studies demonstrate a positive correlation between 
inhibition of lysosomal enzyme binding to MPRs and loss of T cell degradative 
activity. However, M6P could conceivably act by some means other than 
disrupting the MPR-lysosomal enzyme complex. Thus, as well as providing 
reagents which could be used to compare the cellular distribution of MPRs in 
resting and activated cells, an aim of generating mAbs to these receptors was to 
provide a means of specifically inhibiting the interaction between cell surface 
MPR-300 and extracellular lysosomal enzymes, the effect of which could then 
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be examined on the ability of T cells to degrade basement membrane in vitro 
and induce EAE in vivo. 
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Several groups have prepared polyclonal antibodies which block ligand 
binding to human MPR-300, and prevent binding and endocytosis of 
extracellular lysosomal enzymes by fibroblasts (Creek and Sly, 1983; von Figura 
et al., 1984; Gartung et al., 1985; Kiess et al., 1989). Antibodies prepared by 
another group did not strongly inhibit ligand binding to MPR-300, but instead 
depleted the receptor from the cell surface. Internalized MPR-300 normally 
recycles to the Golgi/TGN or back to the plasma membrane, however cross 
linking of cell surface receptors by polyclonal antibodies, or by Fab fragments 
linked by a secondary antibody, caused their accumulation in an unidentified 
compartment from which they did not recycle but were ultimately degraded 
(Nolan et al., 1987). Antibodies capable of preventing the binding of 
extracellular lysosomal enzymes to cell surface MPR-300 have thus been 
described for the human receptor. This study aimed to produce similarly 
effective antibodies to rat MPR-300, so that their effect on passively-induced 
EAE could be examined. MAbs were produced in preference to polyclonal 
antisera due to their greater specificity and .reproducibility. This chapter 
describes the preparation of mAbs specific for rat MPR-300, and an assessment 
of their potential for neutralizing the binding of lysosomal enzymes to this 
receptor. 
3.2 EXPERIMENT AL PROCEDURES 
3.2.1 Purification of MPR from rat liver 
3.2.1.1 Preparation of rat liver extract 
A mixture of MPR-300 and MPR-46 was purified from rat liver using a 
modification of the method of (Li et al., 1989), who purified the two MPRs from 
bovine testes. Rats were killed by CO2 asphyxiation and the livers removed, 
rinsed in cold PBS, weighed and stored at -20°C. A tissue mass of 130-150 g per 
batch was found most convenient. Frozen livers were thawed and blended 
thoroughly , adding sufficient 1 mM PMSF /PBS to liquify the tissue. This and 
all following steps was done at 4 °C. The homogenate was centrifuged for 15 
min at 21, OOOxg, and the pellet washed in distilled water containing 1 mM 
PMSF. The pellet was resuspended in Solubilizing Buffer (50 mM imidazole 
(pH 6.5), 150 mM sodium chloride, 1 °/o Triton X-100, 0.5 mM PMSF) and 
agitated overnight. The suspension was centrifuged for 60 min at 100, OOOxg 
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and the supernatant passed through a single thickness of Whatman No. 1 filter 
paper. 1 M MnCl2 stock solution was added to give a final concentration of 10 
mM MnCl2, and the supernatant immediately subjected to affinity 
chromatography on PMP-Sepharose 4B, as described in Section 3.2.1.3. 
3.2.1.2 Preparation of PMP-Sepharose 
The affinity matrix was prepared by coupling an arylamino derivative of 
pentamannose phosphate (PMP) to cyanogen bromide-activated Sepharose 4B. 
PMP was isolated from the exopolysaccharide secreted by the yeast Pichia 
holstii (strain ATCC 13689), and was provided by Dr Susan Weston 
(Manchester University, UK). It was coupled to 2-( 4-aminophenyl) ethylamine 
using a modification of the method of Oeffery et al., 1975). PMP (600 mg) was 
added to 2-( 4-aminophenyl) ethylamine (3 ml) in a 20 ml round-bottomed flask 
with a drying tube (half soda lime, half calcium chloride) attached,and stirred 
at 37°C until the PMP dissolved to form a viscous solution (5 days). Absolute 
ethanol (3 ml) was added, followed immediately with sodium borohydride (72 
mg) in ethanol (6 ml), and stirred at 4°C for 48 h, with a drying tube attached. 
The mixture was diluted with cold distilled water (24 ml) and the pH adjusted 
to 5.6 with glacial acetic acid. Ethanol and water were evaporated under 
reduced pressure and the PMP derivative precipitated from the residue with 4 
volumes of ethanol. The precipitate was isolated by centrifugation, 
resuspended in 0.5 M sodium chloride in PBS and reprecipitated with four 
volumes of ethanol. This step was repeated a further three times. The 
precipitate was then dissolved in PBS, reprecipitated with four volumes of 
ethanol, and dissolved in distilled water and lyophilised, yielding 490 mg. 
Amine determination (A2ss) indicated that 42°/o of the PMP was derivatized. 
The product was stored in 50 mg portions under nitrogen in a dessicator at 
-20°C. 
The arylamino PMP derivative (52 mg; 21.6 µmol) was coupled to 7 ml of 
swollen cyanogen bromide-activated Sepharose 4B beads (Pharmacia, Uppsala, 
Sweden) following the manufacturer's instructions. Coupling efficiency was 
96°/o. 
3.2.1.3 Purification of MP Rs by affinity chromatography 
The rat liver extract (Section 3.2.1.1) was pre-adsorbed on a Sepharose 4B 
column (2.5 x 4 cm), equilibrated with Binding Buffer I (50 mM imidazole (pH 
6.5), 0.5 M sodium chloride, 10 mM MnCl2, 0.5 mM PMSF, 0.05°/o Triton X-100). 
CHAPTER 3 Experimental procedures 69 
The eluate was then applied to a PMP-Sepharose column (1.5 x 5.5 cm), also 
equilibrated with Binding Buffer I, and allowed to flow by gravity feed. 
Unbound protein was removed by washing with 500 ml of Binding Buffer I. 
Triton X-100 was exchanged for octylglucoside by washing with Binding Buffer 
II (50 mM imidazole (pH 6.5), 0.5 M sodium chloride, 10 mM MnCl2, 0.5 mM 
PMSF, 25 mM octylglucoside). MPR-300 and MPR-46 were eluted with 40 ml 
of either Eluting Buffer I (100 mM sodium acetate, pH 4.5, 0.5 M sodium 
chloride, 10 mM MnCl2, 25 mM octylglucoside, 0.5 mM PMSF) or Eluting 
Buffer II (20 mM M6P, 0.5 M sodium chloride, 10 mM MnCl2, 25 mM 
octylglucoside, 0.5 mM PMSF), and 1 ml fractions collected. Fractions eluted 
with Eluting Buffer I were immediately neutralized with 0.5 M imidazole (pH 
6.5). Fractions were analysed by SDS-PAGE and the protein bands visualized 
by silver staining (Section 3.2.1.4). MPR-containing fractions were pooled and 
concentrated by centrifugation in Centricon-10 microconcentrators (Am.icon) at 
3000xg until the volume was below 200 µl. The solution was diluted with 25 
mM octylglucoside in PBS and reconcentrated. This step was repeated, and the 
concentrated MPR solution stored at -20°C. 
The PMP-Sepharose column was regenerated after use by washing with 100 
mM glycine-HCl; pH 2.5, then three alternating washes with 0.1 M boric acid, 
0.5 M sodium chloride (pH 8) and 0.1 M acetic acid, 0.5 M sodium chloride (pH 
4.0). 
3.2.1.4 SDS-PAGE 
Column fractions were analysed by one dimensional 10°/o SDS-PAGE 
according to the method of Laemmli (1970). Samples (30 µl) were mixed with 
an equal volume of 2x sample buffer (125.mM Tris, 100 mM dithiothreitol, 160 
mM SDS, 60°/o v /v glycerol, pH 6.8) and boiled for 5 min before loading onto 
the gel. Proteins were electrophoresed at a constant current of 20 mA for 3 h. 
Gels were silver stained using the method of Blum et al. (1987) and dried onto 
blotting paper under vacuum in a gel dryer at 80°C for 1 h. Molecular weight 
markers used were rabbit skeletal muscle myosin MW 200,000; E.coli~-
galactosidase MW 116, 250; rabbit muscle phosphorylase b MW 97, 400; bovine 
serum albumin MW 66, 200; hen egg white ovalbumin MW 45, 000; bovine 
carbonic anhydrase MW 31, 000; soybean trypsin inhibitor MW 21, 500; and hen 
egg white lysosyme MW 14,400 (Biorad Laboratories, Richmond, CA). 
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3.2.2 Immunization of mice 
The MPR preparation (5-100 µg diluted in 200 µl of saline) was mixed with an 
equal volume of Freund's complete adjuvant under sterile conditions and 
injected subcutaneously into four sites on the flanks of 8 week old female 
BALBI c mice (50 µl per site). Preimmune serum was obtain~d .before th~ first 
~ :> u b c u {L"' e-c, '::, • -1 be +-• c:i '"' 
injection. After 4 weeks, mice were boosted with/\5-100 µg of the MPR 
preparation in 200 µl of saline, mixed with an equal volume of Freund's 
incomplete adjuvant. Ten days later, blood was collected from a lateral tail 
vein and assayed for the presence of antibodies specific for MPR (Section 
50 \?~ t\ eo S ~ 
3.2.8.1). A second boost was given_}hree days before fusion. 
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Antigen was prepared by placing the adjuvant in a small glass bottle, held at an 
angle with plasticine. The MPR stock solution (in 25 mM octylglucoside/PBS) 
was diluted with saline and added dropwise to the adjuvant, mixing well with 
a glass syringe until an emulsion formed. 
3.2.3 Production of antibody-secreting hybridomas 
3.2.3.1 Preparation of a single cell suspension from mouse spleen 
Three days after the final immunization, mice were killed by cervical 
dislocation and the spleen removed and washed in serum-free DMEM. This 
and all following steps were performed under sterile conditions. A cell 
suspension was prepared by finely mincing the spleen with curved surgical 
scissors and gently pressing the tissue through a fine wire mesh into serum-free 
DMEM. The cell suspension was transferred to a 50 ml centrifuge tube, leaving 
behind any large pieces of tissue. Lymphocytes were counted by removing a 10 
µl sample of the spleen cell suspension and lysing red blood cells with 4~ µl of 
0.83°/o ammonium chloride for 3 min at 37°C. The unlysed cells were counted 
using a haemocytometer and viability assessed by trypan blue exclusion. 
Spleens contained approximately 2.5xl08 cells. 5xl06 cells were reserved as 
tissue culture controls to moniter death of unfused spleen cells. 
3.2.3.2 Preparation of myeloma cells 
The fusion partner was the murine myeloma cell line P3-NS1/l-Ag4-l, which 
does not secrete immunoglobulin, but does synthesize light chains, which can 
be incorporated into immunoglobulins in hybrid cells. On average, one 
immunoglobulin molecule in four produced by a hybrid cell will be completely 
derived from the spleen cell partner (Galfre and Milstein, 1981; Kohler and 
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Milstein, 1976). Myeloma cells were harvested from a logarithmic phase 
culture, and viability determined by trypan blue exclusion. 5xl06 cells were 
reserved as tissue culture controls to moniter death of unfused myeloma cells. 
3.2.3.3 Fusion of spleen and myeloma cells 
The myeloma and spleen cell suspensions were mixed such that the ratio of 
spleen to myeloma cells was 5:1, and centrifuged in a 50 ml plastic tube at 
200xg for 5 min. The supernatant was discarded and the cell pellet 
resuspended in serum-free DMEM and recentrifuged, to ensure even 
distribution of the fusion partners. The supernatant was again discarded, and 
the pellet loosened. Fusion of spleen and myeloma cells was mediated by 
polyethylene glycol (PEG). A 40°/o PEG solution (2 ml) was warmed to 37°C 
and added to the cell pellet dropwise over exactly 30 s, while constantly 
agitating the tube. When PEG addition was complete, the cells were 
resuspended over 30 s by gently bubbling air through a 5 ml pipette. The cell 
suspension was then allowed to stand for 30 s, before being gently diluted by 
dropwise addition of 5 ml of serum-free DMEM over 2 min, followed by 
another 5 ml added all at once. The cells were allowed to stand for 3 min, then 
centrifuged at 500xg for 5 min. The cell pellet was resuspended gently in 190 
ml of medium containing HAT (Table 3.1). Aliquots (100 µl) of the cell 
suspension were placed in the wells of flat-bottomed 96-well tissue culture 
plates (Linbro, ICN Biomedicals, Costa Mesa, CA), using a multichannel pipette 
with wide bore tips. Feeder cells were not required as conditioned medium 
from human umbilical vein endothelial (HUVE) cells was included in the 
medium (Astaldi, 1980). Reserved spleen and myeloma cells were resuspended 
at lxl06 cells/ml in HAT medium, and similarly aliquoted into a 96-well plate. 
These were observed after 7 days to ensure the deaths of both parent cell types. 
3.2.4 Maintenance of hybridomas 
3.2.4.1 Initial cell culture 
Cultures were incubated in a humidified (90°/o) atmosphere of 10°/o CO2 in air at 
37°C. Plates were left undisturbed until the 7th day post fusion, when 100 µl of 
HT medium (Table 3.1) was added to each well. Between 7 and 14 days after 
fusion, all wells were examined for colony growth using an inverted 
microscope (Olympus Optical Co. Ltd., Tokyo, Japan). On day 14, 150 µl of 
medium was transferred from wells with colony growth into sterile 96 well 
plates and stored at 4°C for use in screening assays. Medium from wells with 
Table 3.1 
Constituents of hybridoma culture media. 
HATmediuma 
15°/o v / v hybriserum 
10°/o v /v endothelial cell conditioned mediumb 
0.1 °/o v /v 2-mercaptoethanol 
2.5 mg/L amphotericin 
13.6 mg/L hypoxanthine 
3.9 mg/L thymidine 
72 µg/L aminopterin (omitted from HT medium) 
Freezing mediuma 
20°/o v / v hybriserurn 
0.1 °/o v /v 2-mercaptoethanol 
2.5 mg/L amphotericin 
6°/o v /v dimethylsulfoxide (DMSO) 
a All media were based on Dulbecco's Modified Eagle Medium (DMEM; #430-
1600, Gibco, Gaithersburg, MD). Medium was supplemented with 3.7 g/L 
sodium bicarbonate, 200 mg/L neomycin sulfate, 200 mg/L streptomycin 
sulfate, and 120 mg/L penicillin were added to all media. 
b Provides growth-promotion activity for hybridoma cells, and substitutes for 
feeder cells (Astaldi, 1980) 
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no colony growth was discarded. Wells with large amounts of cell growth 
were subcultured: cells were resuspended in 150 µl of HT medium and 100 µl 
was transferred to a new well in a flat-bottomed 96-well tissue culture plate 
(Linbro, ICN Biomedicals, Costa Mesa, CA). Fresh HT medium (150 µl) was 
added to all colony-containing wells. 
3.2.4.2 Expansion of cultures into 24-well plates 
Culture supernatants collected between 2 and 4 weeks post fusion were tested 
for the presence of MFR-specific antibodies using the DELFIA screening assay 
(Section 3.2.8.1). Cultures which gave a strong positive response were 
expanded into 24-well plates, so as to prepare a reserve of frozen cells in case 
cloning was unsuccessful. Spent medium was removed from wells and cells 
were resuspended in fresh HT medium (100 µl). The cell suspension was 
transferred to one well of a 24-well plate, and diluted to 1 ml with fresh 
medium. HT medium (150 µl) was added to the original well to allow 
regrowth of any remaining cells. 
3.2.4.3 Freezing hybridoma cultures 
96-well plates containing subcultured cells were eventually frozen. Spent 
medium was removed from all wells and replaced with 50 µl of ice-cold 
freezing medium (Table 3.1). Each plate was wrapped first with plastic wrap, 
then with bubble-wrap and placed immediately at -70°C. 
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Cells transferred to 24 well plates were frozen when the culture was expanded 
into at least 4 wells. Healthy cells were harvested by centrifugation at 4 °C, 
resuspended in chilled freezing medium, and transferred in 1 ml aliquots to 
plastic 2 ml cryotubes (Nunc, Denmark). Cryotubes were frozen at -20°C for 2 
h, then at -70°C overnight. Frozen tubes were placed in liquid nitrogen for long 
term storage. 
3.2.4.4 Thawing frozen cells 
Frozen cells were thawed into 10 ml HT medium, washed once and counted. 
Cells were resuspended at a density of 2-4 x 106 cells/ml and aliquots (100 µl) 
were placed in the wells of a U-bottomed 96-well tissue culture plate (Linbro, 
ICN Biomedicals, Costa Mesa, CA). After 7 days, the cells were screened for 
antibody production (Section 3.2.8.1) and expanded into 24-well plates. 
CHAPTER3 Experimental procedures 73 
3.2.4.5 Collection of hybridoma culture supernatants 
Hybridomas were grown in either 24-well tissue culture plates or tissue culture 
flasks of varying sizes. Cultures were grown until the cells died, and the 
supernatant was collected. Debris was removed by centrifugation at lOOOxg for 
10 min. Small volumes were passed through sterile Acrodisc PF syringe filters 
(Gelman Sciences, Ann Arbor, MI) and larger volumes through 0.2 µm bottle 
filters (Costar, Cambridge, MA). Filtered supematants were stored in sterile 
plastic containers at 4 °C. 
3.2.5 Cloning by limiting dilution 
A suspension of viable hybridoma cells (10 cells/ ml) was prepared by serial 
dilution in 48 ml of HT medium. Aliquots (100 µl) were placed in the wells of 
96-well round-bottomed tissue culture plates (Linbro, ICN Biomedicals, Costa 
Mesa, CA), giving an average of 1 cell/well. As previously, feeder cells were 
replaced by the inclusion of conditioned medium from HUVE cells in the 
culture medium. The plates were incubated at 37°C (90°/o humidity, 10°/o CO2 
in air) and left undisturbed for 5 days. All.plates were then examined for signs 
of colony growth, and wells with a single small colony were noted. Wells with 
two or more colonies were disregarded, as were wells containing large single 
colonies which could have resulted from the merging of several rapidly 
growing smaller ones. When growth of single colonies covered about 1/3 to 
1/2 of the well, cells were subcultured 1:2 into flat-bottomed 96 well plates 
(Linbro, ICN Biomedicals, Costa Mesa, CA). When both wells reattained this 
level of growth, cells were expanded into 24-well plates. 
3.2.6 Production of ascites fluid containing monoclonal 
antibodies 
The hybridoma 1G7 /9H4 was grown in HT medium in 175 cm2 tissue culture 
flasks. Cells were harvested by centrifugation, washed with sterile PBS and 
resuspended at a concentration of 2.5 x 106 cells/ml. Outbred Swiss nude mice, 
injected five to ten days earlier with 1 ml of pristine (2,6,10,14-
tetramethylpentadecane), were injected i.p. with 2 ml of cells. Two to three 
weeks later, mice were killed and peritoneal fluid harvested. Ascites from 
twenty mice were pooled and delipidated by passing through glass wool. 
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3.2.7 Purification of IgG1 from ascites fluid 
Antibodies (IgG1) were purified from 1G7 /9H4 ascites by affinity 
chromatography using the Affi-Prep Protein A MAPS II Kit (Bio-Rad 
Laboratories, North Ryde, Australia), following the procedure recommended in 
the manufacturers instructions. 
3.2.8 Screening hybridoma culture supemantants: antibody 
detection assays 
3.2.8.1 Antibody detection by Dissociation Enhanced Lanthanide 
Fluoroimmunoassay (DELFIA) 
The MPR preparation (in 25 mM octylglucoside/PBS) was diluted to 2.5 µg/ml 
with coating buffer (2.86 g/1 Na2C03, 7.56 g/1 NaHC03). Round-bottomed, 
polyvinylchoride (PVC) microtitre plates (Dynatech Laboratories Inc., 
Alexandria, VA) were coated overnight at 4°C with dilute MPR (100 µ1/well). 
Control wells were incubated with coating buffer alone. Plates were blocked 
with 3°/o BSA in PBS for 2 hat 37°C (200 µ1/well) and were washed three times 
with 0.05°/o Tween 20 in PBS (PBST) after this and all subsequent steps. All 
subsequent dilutions were in 1 °/o BSA/PBST, except where otherwise stated, 
and all incubations were at room temperature. Test antibody (either undiluted 
culture supernatant, supernatant diluted in HT medium, or antiserum diluted 
in 1 °/o BSA/PBST) was added (50 µ1/well) and incubated for 2 h, followed by a 
1:1000 dilution of biotinylated rabbit- antimouse lg F(ab')2 fragment 
(Dakopatts, Denmark) for 1 h (50 µI/well), and a 1:1000 dilution of DELFIA 
Europium-Labelled Streptavidin (Wallac Oy, Turku, Finland) for 1 h (75 
µI/well). DELFIA Enhancement Solution (Wallac Oy, Turku, Finland) was 
added and incubated for 5 min (200 µI/well). Fluorescence was measured 
using a 1234 DELFIA Research Fluorometer (Pharmacia, Uppsala, Sweden) and 
data analysed using Multicalc software. Specific antibody binding was 
calculated by subtracting fluorescence due to antibody binding to an uncoated 
well from fluorescence due to binding to a MPR-coated well. 
3.2.8.2 Antibody detection by immunofiuorescent flow cytometry 
3.2.8.2.1 Antibody binding to Clone 9 hepatocytes 
Adherent Clone 9 hepatocytes were detached with 0.1 °/o EDTA in PBS, and 
resuspended in 10°/o FCS/RPMI medium at a density of lxl07 cells/ml. Cells 
were treated with hybridoma supernatant, washed and incubated with a 
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saturating concentration of an affinity-isolated sheep anti-mouse lg F(ab')2 
fragment, directly conjugated to fluorescein (Silenus, Hawthorne, Australia). 
Incubations were in 96-well V-bottomed plastic plates, using 2xl05 cells/well in 
40 µl volumes. All incubations were for 30 min on ice, and cells were washed 
three times with 10°/o FCS/RPMI medium between the two incubations. The 
final incubation was followed by washing twice with 10°/o FCS/RPMI and once 
with PBS. Cells were fixed with 1 °/o paraformaldehyde/PBS, pH 7.4 and 
analysed for fluorescence by flow cytometry (Section 2.2.3). Samples treated 
with hybridoma supernatants were compared with control samples incubated 
with an irrelevant hybridoma culture supernatant, specific for human 
endothelial cell surface antigens. 
3.2.8.2.2 Antibody binding to U937 cells 
U937 cells were harvested by centrifugation and resuspended in 10°/o 
FCS/RPMI medium at a density of 5xl06 cells/ml. Cells were treated with 
hybridoma supernatant, washed and incubated with a saturating concentration 
of a Protein A-fluorescein conjugate (100 µg/ml) (Pharmacia, Uppsala, 
Sweden). Incubations were in 96-well V-b~ttomed plastic plates using 1 x 10s 
cells/well in 40 µl volumes. All incubations were for 30 min on ice, and cells 
were washed three times with 10°/o FCS/RPMI medium between the two 
incubations. The final incubation was followed by washing twice with 10°/o 
FCS /RPMI and once with PBS. Cells were fixed with 1 °/o 
paraformaldehyde/PBS, pH 7.4 and analysed for fluorescence by 
immunofluorescent flow cytometry (Section 2.2.3). Samples treated with 
hybridoma supernatants were compared with control samples incubated with 
an irrelevant hybridoma culture supernatant, specific for human endothelial 
cell surf ace antigens. 
3.2.9 Immunoprecipitation by hybridoma culture supematants 
3.2.9.1 Biotinylation of the affinity purified MPR preparation 
MPR stock solution was diluted to 200 µg/ml with 100 mM NaHC03 buffer, 
pH 8.5, containing 25 mM octylglucoside. A 20 mM stock solution of sulfo-S-
biotin (Pierce, Rockford, IL) was prepared in the same buffer, and sufficient 
added to the MPR solution to give a final concentration of 2 mM. The reaction 
mixture was incubated at 4°C for 2 hours. Free biotin was removed by 
concentrating in a Centricon-10 microconcentrator and rediluting with 25 mM 
octylglucoside/PBS. This procedure was repeated twice more. The 
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biotinylated protein was diluted to a concentration of 100 µg/ ml and stored in 
100 µl aliquots at -20°C. 
3.2.9.2 Immunoprecipitation ofbiotinylated MPR 
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Protein G-Sepharose (20 µl packed volume) (Pharmacia, Uppsala, Sweden) was 
washed with 0.5°/o Triton X-100 /PBS (TPBS) and incubated with 300 µl of 
hybridoma culture supernatant containing 0.5 °/o Triton X-100, for 2 hours at 
4°C. The beads were centrifuged and washed four times with TPBS. 
Biotinylated MPR was diluted to 3.3 µg/ml with 0.1 °/o BSA/TPBS and 
preadsorbed to washed protein G-Sepharose overnight at 4 °C. The preadsorbed 
MPR (300 µl) was incubated with the antibody-coated protein G-Sepharose for 
4.5 h at 4 °C. The beads were centrifuged, and washed six times with TPBS. 
Reduced Sample Buffer (30 µl) (Section 3.2.1.4) was added to each sample and 
boiled for 1 minute. The beads were pelleted by centrifugation and the 
supernatants analysed by SDS-PAGE (Section 3.2.1.4). Protein was 
electroblotted onto a Hybond-C Super transfer membrane (Amersham, 
Buckinghamshire, England) at a constant current of 120 mA for 90 min. The 
buffer for both anode and cathode contain~d 39 mM glycine, 48 mM Tris, 
0.0375°/o w /v SDS and 20°/o methanol. The membrane was air-dried, then 
blocked with 3°/o BSA/0.05°/o Tween-20/PBS (PBST) for 1 h, washed with PBST 
(2 rinses, 2x5 minutes) and probed with streptavidin-horseradish peroxidase 
conjugate (1/1000 dilution in 0.1 °/o BSA/PBST) (Amersham, Buckinghamshire, 
England) for 1 hour at RT. The membrane was washed with PBST (2 rinses, 
lx15 minutes, 4x5 minutes). Biotinylated protein was detected using the ECL 
detection reagent (Amersham, Buckinghamshire, England). 
3.2.10 Determination of antibody isotype by ELISA 
Four PVC microtitre plates (Dynatech Laboratories Inc., Alexandria, VA) were 
coated with affinity-purified goat anti-mouse lg antibodies (Southern 
Biotechnology, Birmingham, AL) overnight at 4 °C. Antibodies were specific 
for either mouse IgM, IgG1, IgG2a or IgG2b. They were diluted in coating 
buffer (2.86 g/L Na2C03, 7.56 g/L NaHC03) to concentrations of 0.5 µg/ml 
(anti-IgM) and 0.2 µg/ml (anti-IgG1, IgG2a and IgG2b), and used at 100 µ1/well. 
Plates were blocked with 3°/o BSA/PBS for 2 hat 37°C (200 µ1/well) and 
washed three times with 0.05°/o Tween 20 in PBS (PBST) after this and all 
subsequent steps. All subsequent dilutions were in 1 °/o BSA/PBST, except 
where otherwise stated, and all incubations were at room temperature. 
Hybridoma culture supernatant was added (50 µ1/well) and incubated for 2 h, 
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followed by 50 µ1/well of a biotinylated isotype-specific goat anti-mouse lg 
antibody for 1 h (1 µg/ml for anti-IgM and IgG2a, 0.25 µg/ml for anti-IgGl, 2 
µg/ml for anti-IgG2b) (Southern Biotechnology, Birmingham, AL). Wells were 
incubated with 75 µl streptavidin-horseradish peroxidase conjugate 
(Amersham, Buckinghamshire, England) for 1 h. Substrate solution (1 mg/ml 
2, 2'-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid; 0.03°/o hydrogen peroxide 
in 0.1 M sodium citrate buffer, pH 4.5) was added (100 µ1/well) and incubated 
until colour developed. The reaction was stopped with 0.2 M citric acid (100 
µ1/well) and absorbance at 405 nm (reference 490 nm) measured immediately 
using a microplate reader (Molecular Devices). Data was analysed using 
Softmax software. 
3.2.11 Effect of antibodies on ligand binding to MPR 
3.2.11.1 Lysosomal enzyme binding to purified MPR 
3.2.11.1.1 Secretion of newly synthesized lysosomal enzymes by Clone 9 
hepatocytes 
Clone 9 hepatocytes were subcultured at a ratio of 1:2, and lM ammonium 
chloride added to the medium to give a final concentration of 10 mM. Cells 
were cultured for 60 h, and the 1 ysosomal enzyme-enriched culture medium 
collected and frozen in 1 ml aliquots. 
3.2.11.1.2 Lysosomal enzyme binding to purified MPR 
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PVC microtitre plates were coated overnight at 4°C with 100 µ1/well of sheep 
anti-mouse lg antibody (Silenus, Hawthorne, Australia), diluted to 10 µg/ ml in 
coating buffer (2.86 g/L Na2C03, 7.56 g/L NaHC03). Wells were blocked with 
3°/o BSA/PBS for 1.5 hat 37°C (200 µ1/well), and washed three times with 
0.05°/o Tween 20 in PBS (PBST) after this and all subsequent steps. All dilutions 
were in 1 °/o BSA/PBST, except where otherwise stated, and all incubations were 
at room temperature. Culture supernatant from the hybridoma 5G5/17B5 (50 
µ1/well) was added and incubated for 1 h, followed by 50 µl of dilute MPR 
preparation (2.5 µg/ml) for 2 h. Lysosomal enzyme-enriched Clone 9 culture 
medium was added (50 µ1/well) and incubated for 2 h. 10 mM mannose or 10 
mM M6P was included in control wells. Wells were incubated overnight at 
37°C with 200 µl of ~-glucuronidase substrate solution (10 µl of 100 µM 4-
methylumbelliferyl-~-D-glucuronide, 190 µl of 20 mM sodium acetate, pH 5.0). 
The contents of each well was transferred to a 96-well MicroFluor microtitre 
plate (Dynatech Laboratories Inc., Alexandria, VA). ~-Glucuronidase activity 
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was estimated in fluorescence intensity units (FIU) using an automated 
fluorescence plate reader (MicroFluor Reader, Dynatech Laboratories Inc., 
Alexandria, VA). 
3.2.11.1.3 The effect of antibodies on binding of lysosomal enzymes to 
purified MPR 
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The ability of hybridoma culture supernatants to influence lysosomal enzyme 
binding to purified MPR was assessed by a modification to the above 
procedure. After binding 5G5/17B5 antibodies to the wells, excess sheep anti-
mouse lg was blocked with 50 µl of an irrelevant mouse antibody (lgG1) for 1 h. 
Wells were then incubated with 50 µl of the MPR preparation (2.5 µg/ml) for 2 
h, followed by 50 µl of the test hybridoma supernatant for 30 min. Without 
removing the supernatant, 50 µl of lysosomal enzyme-enriched medium was 
added, and the plate incubated overnight at 4°C. Wells were washed, then 
incubated with P-glucuronidase substrate solution for 8 h at 37°C. P-
glucuronidase activity was measured as before and the ability of the antibodies 
to influence _lysosomal enzyme binding was compared with the effects of M6P 
and mannose. · 
3.2.11.2 The effect of antibodies on binding of fluorescent PPME to Clone 
9 hepatocytes 
Adherent Clone 9 hepatocytes were detached using 0.1 °/o EDTA in PBS and 
resuspended in 10°/o FCS/RPMI medium at a density of lxl07 cells/ml. 
Aliquots (20 µl) were placed in the wells of a V-bottomed 96-well plate (2xl05 
cells/well), and incubated with 20 µl of hybridoma culture supernatant for 30 
min at 4°C. 40 µl of fl-PPME, diluted to 0.1 mg/ml in 10°/o FCS/RPMI medium 
(pH 7.0), was incubated with the cells for 30 min at 4°C. The cells were washed 
twice with cold 10°/o FCS/RPMI and once with cold PBS, and were fixed with 
1 °/o paraformaldehyde/PBS, pH 7.4. Fluorescence was measured by flow 
cytometry either immediately or the following day (Section 2.2.5). Median FIU 
values of mAb-treated samples were compared with those of cells allowed to 
bind PPME-FITC (i) in the absence of antibody and (ii) in the presence of 5 mM 
M6P. All samples were done in duplicate. 
Results were corrected for autofluorescence, and the M6P- and antibody-
treated samples expressed as a percentage of fl-PPME binding in the absence of 
antibody. Replicates from all experiments were averaged and SEM values 
calculated. Means of antibody-treated samples were compared with control fl-
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PPME binding by Student's t test (Swinscow, 1978). p values less than 0.05 
were considered to be statistically significant. 
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3.2.11.3 The effect of antibodies on uptake of fluorescent PPME by Clone 9 
hepatocytes 
Clone 9 hepatocytes were aliquoted into V-bottomed 96-well plates as 
described in Section 3.2.11.2, and incubated with 60 µl of hybridoma culture 
supernatant for 30 min at 4°C. 20 µl of fl-PPME diluted in 10°/o FCS/RPMI, pH 
7.0 (0.25 mg/ml) was added and the cells incubated for a further 3 hat 37°C. 
Cells were washed twice with ice cold 10°/o FCS/RPMI medium and once with 
cold PBS, and fixed with 1 °/o paraformaldehyde/PBS, pH 7.4. Fluorescence was 
measured either immediately or the following day by flow cytometry (Section 
2.2.5) and median FIU values analysed as in Section 3.2.11.2. 
3.2.11.4 The effects of PMP and PPME on binding of antibodies to Clone 
9 hepatocytes 
Clone 9 cells were aliquoted into V-bottomed microtitre plates as described in 
Section 3.2.11.2. 20 µl of PMP or PPME, diluted to 0.1 mg/ml in 10°/o 
FCS /RPMI (pH 7.0) was added to half the wells, and medium alone to the 
remaining wells, and the cells incubated for 1 hat 4°C. Each hybridoma 
supernatant (20 µl) was then added to (i) PMP /PPME-treated cells and (ii) 
control cells, and incubated for 30 min at 4°C. Cells were washed 3 times with 
cold 10°/o FCS /RPMI, then incubated for 30 min at 4 °C with a saturating 
concentration of sheep anti-mouse lg F(ab')2 fragment, directly conjugated with 
fluorescein (Silenus, Hawthorne, Australia). Cells were washed twice in cold 
10°/o FCS/RPMI medium and once in cold PBS, and fixed with 1 °/o 
paraformaldehyde/PBS, pH 7.4. Fluorescence was measured either 
immediately or the following day by flow cytometry (Section 2.2.5). Median 
FIU values were corrected by subtracting the fluorescence due to binding of an 
irrelevant mouse IgG1, specific for human endothelial cell antigens. 
Antibody binding to PMP /PPME-treated samples were expressed as a 
percentage of binding to control cells. Replicates from all experiments were 
averaged and SEM values calculated. For each antibody, the mean binding to 
polysaccharide-treated cells was compared with the control value of 100°/o 
using Student's t test (Swinscow, 1978). p values <0.05 were considered 
statistically significant. 
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3.2.11.5 Ability of antibodies to deplete MPR-300 from the cell surface 
U937 or Clone 9 cells were aliquoted (20 µl) into V-bottomed microtitre plates 
as described in Section 3.2.11.2. U937 cells were incubated for 2 hat 37°C with 
20 µl of a rabbit antiserum specific for human MPR-300, with an irrelevant 
control antibody (specific for chicken histidine-rich glycoprotein), or with 
medium. Clone 9 cells were incubated with 80 µl of a mAb specific for rat 
MPR-300 (purified mAb 1G7 /9H4 at 10 µg/ml, or one of several hybridoma 
culture supernatants), with isotype control antibodies (purified mAb specific 
for a murine erythrocyte enzyme at 10 µg/ ml, or irrelevant hybridoma 
supernatant), or with medium. After incubation with antibody at 37°C, 
expression of cell surface MPR-300 on antibody-treated cells was measured by 
(a) immunofluorescent flow cytometry, or (b) uptake of fl-PPME, and 
compared with antibody binding or PPME uptake by untreated cells. 
(a) Cell surface MPR-300 was measured by antibody binding at 4°C. Cells were 
washed once in cold 10°/o FCS/RPMI medium, then incubated for 30 min at 4°C 
with the same anti-MPR-300 antibody as in the previous incubation; cells 
treated with isotype control antibodies were also incubated with an anti-MPR-
300 antibody. Each antibody was also used to stain MPR-300 on untreated 
control cells. Cells were washed three times with 10°/o FCS/RPMI, then 
incubated for 30 min at 4 °C with a saturating concentration of a fluorescein-
Protein A conjugate (Pharmacia, Uppsala, Sweden) in the case of U937 cells, or 
a fluoresceinated sheep anti-mouse lg F(ab')2 fragment (Silenus, Hawthorne, 
Australia) in the case of Clone 9 cells. Cells were then washed twice with 10°/o 
FCS/RPMI and once with PBS, fixed with 1 °/o paraformaldehyde/PBS, pH 7.4, 
and analysed the following day by flow cytometry (Section 2.2.5). Fluorescence 
histograms of cells treated with anti-MPR-300 or isotype control antibodies 
were compared to those of the untreated control cells. 
(b) MFR-mediated internalization of fl-PPME was also measured following 
incubation of cells with anti-MPR-300 or isotype control antibodies at 37°C. 
Cells were washed once with 10°/o FCS/RPMI medium, and 20 µl of fl-PPME 
(150 µg/ml in 10°/o FCS/RPMI, pH 7.0) added. Cells were incubated for 2 hat 
37°C, washed and analysed by flow cytometry. 
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3.2.11.6 Effect of antibodies on IGF-II binding to MPR 
3.2.11.6.1 IGF-II binding to purified MPR 
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Round-bottomed PVC microtitre plates (Dynatech Laboratories, Alexandria, 
VA) were coated overnight at 4°C with 100 µl of the MPR preparation diluted 
in coating buffer (2.5 µg/ml). Control wells were incubated with coating buffer 
only. Plates were blocked with 3°/o BSA/PBST for 2 hat 37°C, and washed with 
PBST. Serial dilutions of iodinated IGF-II (0-1 nM; specific activity= 2000 
Ci/ mol) were prepared in 1 °/o BSA/PBST, and incubated with both MPR-
coated and control wells (50 ml/well) for 3h at RT. Unbound 125I-IGF-II was 
removed and the plate washed 5 times with PBST. Wells were removed from 
the plate with a hot wire and counted by an Auto-gamma 5650 counter 
(Packard Instrument International, Meriden, CT). Specific binding was 
determined by subtracting the binding of J125-IGF-II to uncoated control wells 
from binding to MPR-coated wells. 
3.2.11.6.2 Effect of antibodies on IGF-II binding to MPR 
Round-bottomed PVC microtitre plates were coated overnight at 4°C with 100 
µl of MPR preparation (2.5 µg/ml) diluted in coating buffer, or with coating 
buffer alone. Duplicate MPR-coated wells were included. All wells were 
blocked with 3°/o BSA/PBST for 2 h at 37°C, then incubated with 100 µl of 
hybridoma supernatant at a saturating concentration for 2 h at RT. Control 
wells were incubated with HT medium. Iodinated IGF-II (2 nM stock) was 
diluted to 1 nM with 1 °/o BSA/PBST and 50 µl incubated with each well for 3 h 
at RT. Unbound 125J-IGF-II was removed and the plate washed 5 times with 
PBST. Wells were removed from the plate with a hot wire and counted by an 
Auto-gamma 5650 counter. Specific binding was determined by subtracting the 
binding of Jl25-IGF-II to uncoated wells from the mean binding to MPR coated 
wells. Binding to each :tvfPR-antibody complex was expressed as a percentage 
of binding to MFR-coated wells in the absence of antibody. 
3.2.12 The effect of a purified mAb specific for MPR-300 on 
passively-induced EAE 
Single cell suspensions were prepared from the spleens of Lewis (JC) rats 
sensitized ten days previously with 25 µg MBP emulsified in Freund's 
Complete Adjuvant. Cells were cultured at a density of 2xl06 cells/ml in 10°/o 
FCS/RPMI 1640 medium, and stimulated with 2 µg/ml Con A for 72 hat 37°C. 
Cells were harvested by centrifugation, washed three times in Hank's Balanced 
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Salt Solution and resuspended in serum-free RPMI 1640 at a density of 107 
cells/ml. One third of the cells were incubated with purified 1G7 /9H4 
antibody (100 µg/ ml) for 45 min at 37°C, and the remaining cells with an 
isotype control antibody (specific for a murine erythrocyte enzyme). Cells were 
washed twice with serum-free RPMI, resuspended in RPMI at a concentration 
of 3xl07 cells/ml and injected i.v. into three groups of 4-6 healthy recipients (1 
ml/ rat). Groups A and C received cells preincubated with the isotype control 
mAb, while group B received cells preincubated with 1G7 /9H4 mAb. Rats 
were injected i.p. with antibody at the time of cell transfer, and on days 1, 2, 3, 4 
and 6 at a dosage of 6 mg/kg. Group A received the isotype control mAb, 
while groups B and C received the 1G7 /9H4 mAb. 
Rats were examined daily for clinical signs of EAE and scored on an arbitrary 
scale of severity from O to 5 where: 0 = asymptomatic, 1 = distal half of tail 
flaccid, 2 = entire tail flaccid, 3 = ataxia, difficulty in righting reflex, 4 = 
hindlimb weakness, 5 = hindlimb paralysis. Mean clinical scores were 
calculated for each day of treatment, and groups B and C compared with group 
A using Student's t test (Swinscow, 1978) and Spearman's Rank test (Moroney, 
1951). 
3.3 RESULTS 
3.3.1. MPR purification 
Rat liver was selected as the source of MPR as earlier experiments, 
demonstrating the inhibitory effect of M6P on inflammation in EAE and 
adjuvant arthritis, were performed in rats, and it was anticipated that any 
biologically active mAbs would be tested in the EAE model. A mixture of 
MPR-300 and MPR-46 was purified from rat liver by affinity chromatography 
on PMP-Sepharose 4B. A typical elution pattern, as assessed by SDS-P AGE, is 
shown in Fig. 3.1. The two MPRs were eluted either competitively with M6P or 
with a low pH buffer, the latter taking advantage of the decrease in binding 
affinity for M6P-bearing ligands below pH 6 (Hoflack et al., 1987; Tong and 
Kornfeld, 1989). Both the low pH sodium acetate buffer and M6P were able to 
elute all M6P-binding proteins from the column. MPR-46 eluted more readily 
than MPR-300, usually being released over a 4-5 ml volume. The elution 
volume for MPR-46 was similar regardless of the buffer used, thus both were 
equally suitable for MPR-46 elution. The bulk of MPR-300 eluted with MPR-46, 
although small amounts continued to elute slowly from the column with 
additional washing. This "tail" of MPR-300 was released more rapidly by low 
Fig. 3.1 
Analysis of M6P-binding proteins purified from rat liver by affinity 
chromatography on PMP-Sepharose 4B. Bound protein was eluted with 
sodium acetate buffer (pH 4.5) . Samples (30 µl) from the column fractions 
indicated were electrophoresed on a 10°/o SDS-polyacrylamide gel under 
reducing conditions. Protein was stained with silver nitrate. Molecular 
weight standards ar~ indicated in kDa. 
200 -
116 -
97 -
66 -
45 -
31 -
22 -
Fraction number 
4 5 6 7 8 9 10 11 12 
MPR-300 
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pH than by M6P. Sodium acetate buffer was therefore a more efficient elution 
buffer for MPR-300, and was used more frequently. Two additional proteins, 
with apparent Mr of approximately 27 kDa, were consistently eluted by both 
M6P and sodium acetate elution buffers (Fig. 3.1), but not by mannose (data not 
shown), suggesting that these proteins were also specific for M6P. 
Although MPR-300 and MPR-46 can be separated from one another by size-
exclusion chromatography (Li et al., 1989), mice were immunized with the 
mixed MPR preparation. Multiple batches of the MPR preparation were 
pooled and concentrated, and used to immunize a group of seven BALB / c 
mice. 
3.3.2. MAb production and characterization 
3.3.2.1. Screening hybridoma supernatants by antibody capture on 
purified MPR 
Two fusions were performed in an attempt to produce mAbs against both 
MPR-300 and MPR-46. Tissue culture plates from fusion 1 were scored for the 
presence of colonies on day 12 post fusion. Supernatants from colony-
containing wells were collected at either day 13 or day 21 post-fusion and 
screened for antibody binding to components of the purified MPR preparation. 
In order to maximise the sensitivity of antibody detection, a time-resolved 
fluorescence assay (DELFIA) was used in preference to an ELISA. A negative 
control (preimmune mouse serum), and a positive control (immune mouse 
serum) was included in each assay. Hybridomas were considered to be 
producing specific antibody if the fluorescence, corrected for non-specific 
binding, exceeded 30 000 fluorescence intensity units (FIU). Fig 3.2 illustrates 
the results for 48 supernatants from a representative plate, collected on day 13. 
Of 1776 supernatants screened, 549 were positive, and the 305 giving the 
strongest signals were expanded into 24-well plates. These hybridomas were 
grown until the cultures filled between 2 and 12 wells, then were harvested by 
centrifugation and frozen. The spent medium from these hybridomas was 
stored in sterile containers at 4°C for further characterization. 
Supernatants from expanded cultures were retested using the same assay. On 
comparison with controls (negative = 25, 000 FIU; positive = 700, 000 FIU), forty 
were considered to be weakly positive (40,000 - 100,000 FIU) and nine strongly 
positive (over 100 000 FIU). These nine hybridomas, designated 1G2, 4F5, 7B3, 
9H4, 11G3, 13B7, 13Cll, 21F10 and 22D3 on the basis of their position in the 
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Fig. 3.2 
Binding of fusion-1 hybridoma supernatants to an immobilized MPR 
preparation. Binding was assessed using the DELFIA assay described in 
Section 3.2.8.1. Non-specific binding was subtracted from all samples. A 
positive control (immune mouse serum) gave a value of 40,000 FIU, and a 
negative control (preimmune mouse serum) was below zero. Supernatants 
giving> 30,000 FIU (indicated by the dotted line) were considered to show 
significant specific binding. 
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original microtitre plates, were retained for further investigations. The 
remaining 256 supernatants were negative. This loss of reactivity after 
prolonged culture was probably due to detection of carry-over antibody 
produced by unfused spleen cells in the original screening assay, and/ or to 
overgrowing of cultures by non-producing hybridomas. 
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The nine strongly positive supernatants were titrated using the DELFIA assay. 
Hybridomas 4F5, 7B3 and 2203 performed poorly, and were discarded. 
Hybridomas 9H4 and 13B7 titrated out to a dilution of 1:15, 625; 1G2 and 13Cll 
to 1:3, 125; and 11G3 and 21F10 to only 1:25. These six hybridomas were 
retained for further characterisation. 
In the second fusion, plates were scored for colony growth at 11 days post 
fusion, yielding 424 colony-containing wells. Supematants were screened by 
the DELFIA assay in the fourth week post fusion to avoid excessive positive 
results due to carry-over antibody from dead spleen cells. Negative 
(preimmune mouse serum and HT medium) and positive (immune mouse 
serum and 1G2 supernatant from fusion 1) controls were included on each 
plate and yielded Fills of around 0-7, 000 and 500, 000 respectively. Forty-eight 
supernatants exceeded 100,000 counts, and are shown in Table 3.2, grouped 
according to reactivity. Ten hybridomas with a range of reactivities were 
selected for further characterization. 
3.3.2.2 Screening hybridoma supernatants for binding to cell surface 
MPR 
The sixteen hybridomas selected from the two fusions were screened for 
antibody binding to the cell surface of the rat Clone 9 hepatocytes by 
immunofluorecent flow cytometry. This identified antibodies able to bind to 
the extracellular portion of the MPRs in their native conformation. Clone 9 cells 
express both MPR-300 and MPR-46 on intracellular membranes (Matovcik et al., 
1990), and MPR-300 has been detected at the cell surface (Brown et al., 1984). 
As MPR-300 and MPR-46 have a similar subcellular distribution in other cell 
types (Bleekemolen et al., 1988), MPR-46 was assumed also to be present at the 
cell surface. Representative fluorescence histograms are shown in Fig. 3.3. Fig 
3.4 illustrates that the supematants from hybridomas 21F10, 2E3 and 6C4 
bound weakly to Clone 9 cells, with fluorescence comparable to that of the 
negative control. These were omitted from further investigations, as was 
18Cl0, whose binding was also low. The remaining supematants showed 
Table 3.2 
Binding of hybridoma supernatants from fusion-2 to purified MPR 
preparation. 
100 - 199 
lGlb 
1B4 
1C4 
1A7 
6C7 
7E6 
8E9 
9E5 
9A8 
10E6 
10E8 
12E10 
15H3 
16G7 
17E9 
18C2 
18D5 
1sc1oc 
19A10 
20F4 
2Qf7C 
20D10 
20Ell 
Fluorescence intensity units (x 10-3) a 
200 - 299 300 - 399 400 - 499 500 - 599 
2E3C lCll SGSC 15C8 
13C6C 5C7 10D5 16B9 
13C8 5G10 12Fl 
14C4 6C4C 
15E4C 7C2 
8C5 
12F12 
16A3 
18f4C 
> 600 
5f3C 
5F10 
15Fl0 
17BSC 
17B6 
a Antibody binding to purified MPR, immobilized on PVC, was assessed 
using the DELFIA assay (Section 3.2.8.1). Background fluorescence (due to 
binding of an irrelevant mAb) was in the range O - 8000 FIU. 
b Well number, based on position in original 96-well plates 
c Hybridomas retained for further characterization 
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Fig. 3.4 
Binding of hybridoma supematants to Clone 9 hepatocyte cell surface MPR, 
as assessed by immunofluorescent flow cytometry. Values shown are the 
means of duplicate samples. Non-specific staining, due to binding of the 
fluoresceinated anti-mouse lg reagent, was subtracted from all samples. 
Antibody binding was compared with that of a control mAb specific for 
human endothelial cell surface antigens. 
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variation in binding with the strongest being 1G2, 9H4, 13B7, 5F3, SGS, 17B5 
and 20F7. 
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The twelve positive supematants were screened for binding to the rat 
hepatoma cell line McA RH7777, which is derived from a cell line lacking MPR-
300 (Mainferme et al., 1985), and does not endocytose PPME in a M6P-
inhibitable manner (Section 2.3.4). All gave negative results (data not shown), 
indicating that the antibodies were not binding non-specifically to other cell 
surface components, and probably do not recognise MPR-46. 
The human cell line U937 has been shown to express cell surface MPR-300, by 
both antibody staining and PPME uptake (Sections 2.3.1 and 2.3.2), and is also 
reported to express a relatively large amount of MPR-46 on the cell surface 
(Bleekemolen et al., 1988). Hybridoma supematants were screened for antibody 
binding to the surface of U937 cells by immunofluorescent flow cytometry. All 
yielded negative results, indicating that none cross-react with human MPR-300 
or MPR-46. 
3.3.2.3 Immunoprecipitation 
Antibody specificity was determined by immunoprecipitation, using the MPR 
preparation as the source of antigen. Results for a group of six hybridomas are 
shown in Fig. 3.5. MPR-300 either did not biotinylate well, or was transferred 
poorly to the nitrocellulose membrane, as the band corresponding to this 
receptor appears less intense than by SDS-P AGE. It was visibly precipitated by 
all six antibodies, however. None of the antibodies immunoprecipitated MPR-
46. The 27 kDa protein(s) described earlier bound non-specifically to control 
beads (preincubated with HT medium); antibodies were regarded as binding 
specifically to these proteins if the band was more intense than that of the 
control. Several contaminating bands, with molecular weights intermediate 
between MPR-300 and MPR-46, were evident in the biotinylated MPR 
preparation. These may be degradation products, as they were more apparent 
in older MPR preparations than in a freshly prepared one (data not shown). 
They bound non-specifically to control beads, and in greater amounts to some 
of the antibodies. 
Results for all hybridomas are summarised in Table 3.3. All antibodies except 
20G7 bound MPR-300; the reactivity of 20G7 was unclear. Antibodies 
produced by the hybridomas 9H4, 13Cl 1, 5F3, SGS, 13C6, 17B5 and 20F7 also 
bound the 27 kDa protein(s). None of the antibodies bound to MPR-46. 
MPR-46 
27 kDa 
protein 
Fig. 3.5 
' 
• 
Analysis of hybridoma supernatants by immunoprecipitation. i\ntibodies 
were adsorbed onto Protein G-Sepharose, and the beads incubated with a 
biotinylated MPR preparation. Bound protein was released by boiling in 
SDS sample buffer, separated by SDS-PAGE, and electroblotted onto a 
nitrocellulose membrane. Biotinylated proteins were detected by probing 
the membrane with streptavidin-HRP complex, and visualized using an 
ECL Western blot detection reagent (Amersham ). 
Table 3.3 
Ability of antibodies to immunoprecipitate biotinylated MPR-300, 
MPR-46 and an associated 27 kDa protein. 
Fusion no. Hybridoma Reactivity with MPR preparation 
MPR-300 MPR-46 27kDa 
protein 
1 1G2 + 
1 9H4 + + 
1 11G3 + 
1 13B7 + ? 
1 13Cll + + 
2 5F3 + + 
2 5GB + + 
2 13C6 + + 
2 15E4 
2 17B5 + + 
2 18F4 + 
2 20F7 ? + 
+ antibody reacts with MPR component 
- antibody does not react with MPR component 
? reactivity unclear 
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Supernatant from 15E4 failed to bind any of the bands of interest; this 
hybridoma was subsequently shown to secrete IgM antibodies, hence this mAb 
was unable to bind to the Protein G beads. 
3.3.3 Cloning of hybridomas 
3.3.3.1 Selection of hybridomas for cloning 
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Hybridoma supernatants were allocated to one of four groups binding different 
epitopes on MPR-300 on the basis of additive binding to Clone 9 cells. The 
hybridoma 17B5 was cloned by limiting dilution, and one clone (5G5/17B5) 
chosen as the initial reference antibody. A saturating amount of 5G5/17B5 
(determined by titration) and a second, uncloned, hybridoma supernatant were 
incubated simultaneously with Clone 9 hepatocytes, and the bound antibodies 
detected by immunofluorescent flow cytometry. Fluorescence was compared 
with that resulting from binding of the two antibodies individually. Where the 
second antibody bound to the same epitope as 5G5/17B5, its presence did not 
increase the fluorescence over that produced by the first antibody alone. If, 
however, the second antibody bound to a different epitope, then the resulting 
fluorescence was close to the sum of that produced by the two antibodies 
individually. E_leven supernatants were sorted into two groups on this basis, 
those that bound to the same epitope as 5G5/17B5 (non-additive), and those 
that did not (additive) (Fig. 3.6). The process was then repeated on the additive 
group, selecting a new reference antibody, until all supematants were allocated 
to one of four groups. The results are summarized in Table 3.4. 
Representatives from each group were then selected for cloning. 
3.3.3.2 Cloning of hybridomas 
The seven hybridomas 5G8 and 17B5 (group 1), 9H4 (group 2), 13Cll and 13C6 
(group 3), and 15E4 and 20F7 (group 4) were cloned by limiting dilution. 5G8, 
17B5 and 15E4 were cloned from growing cultures, while 9H4, 13Cl l, 13C6 and 
20F7 were thawed from frozen stocks and cultured for 14 days before cloning. 
Supernatants from wells identified as containing single colonies were assayed 
for binding to the purified MPR preparation by the DELFIA assay. Positive 
supernatants were assayed for binding to cell surface MPR on Clone 9 
hepatocytes. All seven hybridomas produced between 17 and 67 colonies that 
gave positive results in both assays. Results are summarised in Table 3.5. All 
positive clones were expanded to fill at least 2 wells of a 24-well tissue culture 
plate, and were frozen for storage. From each hybridoma, six clones which 
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Fig. 3.6 
Additive binding of hybridoma supematants to Clone 9 hepatocytes. A 
saturating amount of mAb 5G5/17B5 was incubated with cells at 4°C, together 
with a second, uncloned hybridoma supernatant. Bound antibodies were 
detected by immunofluorescent flow cytometry. Each value is the mean+ 
SEM where n=3 (one experiment in triplicate). The dotted line represents 
fluorescence due to mAb 5G5/17B5. Data is expressed as fluorescence due to 
hybridoma supernatant alone (~),or in combination with mAb 5G5/17B5 
(•),with the theoretical maximum fluorescence if the two antibodies have 
completely different binding sites depicted as II. A statistically significant 
increase over 5G5/17B5 binding is indicated by* (p<0.05) and** (p<0.02). 
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Table 3.4 
Subdivision of hybridomas into epitope groupings based on 
additive binding to MPRa. 
Reference antibody: 5G5/17B5 
Non-Additive Additive Group 1 
5G5/17B5 9H4 1G2 
1G2 13Cll 5F3 
5F3 13C6 5GB 
5GB 15E4 13B7 
13B7 20F7 5G5/17B5 
18F4 18F4 
Reference antibody: 9H4 
Non-Additive Additive Group 2 
9H4 13Cll 9H4 
13C6 
15E4 
20F7 
Reference antibody: 13C11 
Non-Additive Additive Group 3 
13Cll 15E4 13C6 
13C6 20F7 13Cll 
Group 4 
15E4 
20F7 
a Hybridomas were allocated to one of four groups on the basis of their ability 
to bind to MPR on Clone 9 hepatocytes simultaneously with mAbs 
5G5/17B5, 9H4 or 13Cll, as assessed by immunofluorescent flow cytometry. 
I 
i 
--
Table 3.5 
Cloning of hybridomas 
Hybridoma Epitope Frequency of Binding of mAbs Binding of mAbs 
group clones to purified MPR to Clone 9 
preparation cell surf ace 
5G8 1 77 I 470 = 16°/o 50/51 50/50 
17B5 1 89/432 = 21°/o 67 /71 67/67 
9H4 2 40/384 = 10°/o 40/40 40/40 
13C6 3 58/384 = 15°/o 46/49 46/46 
13Cll 3 64/384 = 17°/o 27/48 27/27 
15E4 4 63/ 476 = 13°/o 17/30 17/17 
20F7 4 63/384 = 16°/o 52/57 52/52 
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bound strongly to Clone 9 cells were expanded to fill a 24-well plate, the cells 
frozen and the medium stored in sterile containers at 4°C for future use. 
3.3.3.3 Immunoglobulin subclass of monoclonal antibodies 
The antibody isotype of six to twelve clones of each of hybridoma was 
determined by ELISA. All 15E4 clones produced IgM antibodies, while all 
clones of the remaining six hybridomas produced IgG1. 
3.3.4 Functional activity of antibodies 
3.3.4.1 The effect of antibodies on ligand binding to the M6P binding site 
3.3.4.1.1 Lysosomal enzyme binding to purified MPR 
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All twelve antibodies (both cloned and uncloned) were tested for their ability to 
inhibit the MPR-ligand interaction. This required a sensitive assay for ligand 
binding, using a suitable ligand. As lysosomal enzymes are the most 
biologically relevant ligand, an assay was developed to measure binding of 
lysosomal enzymes to purified MPR. Spent medium from Clone 9 hepatocytes 
cultured in the presence of 10 mM ammonium chloride was used as the source 
of lysosomal enzymes. Weak bases such as. ammonium chloride raise the pH of 
acidic organelles and so prevent release of lysosomal enzymes into the 
prelysosomal compartment. Thus, the cell becomes depleted of unoccupied 
receptors, and newly synthesized lysosomal enzymes are secreted via the 
secretory pathway with M6P markers intact (von Figura and Hasilik, 1986). 
The lysosomal enzyme-enriched medium was incubated with purified MPR 
immobilised on PVC plates, and binding of P-glucuronidase detected using the 
derivatised substrate 4-methylumbelliferyl-P-D-glucuronide, which the enzyme 
cleaves to yield the fluorescent product 4-methylumbelliferone. Fig. 3.7 shows 
that production of the fluorescent product was dependent on the presence of 
both MPR and lysosomal enzymes, and was inhibited by M6P but not by 
mannose. 
When antibodies were allowed to bind to immobilised MPR before adding the 
lysosomal enzyme-enriched medium, lysosomal enzyme binding was 
enhanced rather than inhibited, in some cases by 10-fold (data not shown). 
Such strong enhancement seemed an unlikely result, especially in view of the 
effects of the antibodies on PPME binding to cell surf ace MPR ( described 
below). A more likely explanation is that the antibodies cross-linked and 
stabilized the immobilized MPR on the plate, so that ligand binding was 
MPR LE Inhibitor 
+ + 
+ 
+ 
+ + M6P 
+ + mannose 
0 5 10 15 20 
Fluorescence intensity units (1 o-2 ) 
Fig. 3.7 
Binding of lysosomal enzymes (LE) to purified MPR immobilized on a PVC 
plate via anti-MPR mAb (5G5/17B5). Enzyme binding was assessed by 
measuring bound ~-glucuronidase activity. Inhibitors included in the assay 
were M6P and mannose, both at 10 mM. 
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greater than when the test antibody was not included. This technique, while 
suitable for measuring lysosomal enzyme binding to MPR, was clearly not 
suitable for detecting the inhibition of such binding by mAbs. 
3.3.4.1.2 Binding and uptake of fl-PP ME by Clone 9 hepatocytes 
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An alternative assay for MPR-ligand binding was the binding and uptake of 
fluorescent PPME by cell surface MPR, described in Chapter 2. M6P inhibited 
PPME binding by 25°/o, a small but statistically significant effect. Fig. 3.8 shows 
that the antibodies had little effect on PPME binding; only clones 1C2/13Cll, 
1B6/15E4 and 2G6/20F7 had a statistically significant effect, and inhibition by 
these antibodies was less than 10°/o. Uptake of fl-PPME at 37°C provides a 
much stronger fluorescent signal than fl-PPME binding, and hence a greater 
window in which to observe an inhibitory effect. Fig. 3.8 shows that, again, 
most antibodies had no significant effect on PPME uptake. Inhibition by clones 
1G7 /9H4, 13B7 and 1B6/15E4 was statistically significant, at about 80°/o of 
control PPME uptake. However, only clone 1B6/15E4 inhibited both PPME 
binding and uptake at a statistically significant level, and the degree of 
inhibition was low in both cases. The low levels of inhibition and lack of 
reproducibility between the two sets of experiments suggests that any effects of 
these antibodies· on PPME binding to cell surface MPR-300 are minor. 
3.3.4.2 The effect of PMP and PPME on antibody binding to cell surface 
MPR 
The effects of PMP and PPME on binding of antibodies to cell surface MPR 
were assessed, since antibody binding to a site that includes the M6P binding 
site might be blocked by prior binding of ligand. PPME was expected to be 
more effective, as it is larger than PMP (approximately 2000 kDa compared to 1 
kDa) and so should obscure a greater area around the ligand binding site. 
PMP, on the other hand, would only interfere with antibodies that bind very 
close to the M6P binding site. Fig. 3.9 shows that again, only a few antibodies 
were significantly affected by the presence of either ligand. PMP inhibited the 
binding of clones 1G7 /9H4, 13B7, 1C2/13Cll and 5El/SG8 by 20-40°/o. PPME 
inhibited binding of clones 1C2/13Cll, SF3, SG8, SGS/17BS and 2G6/20F7 by 
30-50°/o. Binding of only two antibodies, clone 1C2/13Cll and SG8, was 
inhibited by both PMP and PPME, suggestive of antibody binding in the 
vicinity of the binding site, but these antibodies did not themselves inhibit 
ligand binding by more than 10°/o (Fig. 3.8). In general, the lack of 
reproducibility between experiments, and the relatively small effects observed, 
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Inhibition of anti-MPR mAb binding to Clone 9 hepatocytes by PMP (~)and 
PPME ( II ), as measured by immunofluorescent flow cytometry. Each value 
is the mean + SEM where n=4 for PMP inhibition and n=6 or 9 for PPME 
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* (p<0.05), ** (p< 0.01) and*** (p<0.001). 
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again suggest that neither PMP or PPME binding interferes with the antibody 
binding sites. 
3.3.4.3 Inhibition of IGF-II binding to MPR-300 
As IGF-II is a known ligand of MPR-300, and has a binding site distinct from 
that of M6P (Kiess et al. , 1988; MacDonald et al. , 1988; Waheed et al., 1988), 
binding of iodinated IGF-II to purified MPR-300 immobilized on PVC was 
assessed. 125J-IGF-II binding of to MPR-300 increased linearly with increasing 
IGF-II concentration, over the range 0-1 nM (Fig. 3.10a). Binding was specific, 
as it was greatly decreased by the addition of a 100-fold excess of unlabelled 
IGF-II, and was minimal in control wells that were not coated with MPR (Fig. 
3.10b ). 
The ability of hybridoma supernatants to inhibit IGF-II binding was assessed 
by binding antibodies to immobilized MPR before adding 125J-IGF-II. Effects 
ranged from a 57°/o decrease in binding by clone 1C2/13Cll to a 20°/o increase 
in binding by 18F4 (Fig. 3.11). Since the error of the assay was approximately 
+10°/o, the only mAb which clearly inhibited IGF-II binding was 1C2/13Cll. 
3.3.4.4 Ability of mAbs to deplete cell surface MPR-300 
Cross-linking of cell surface MPR-300 with certain antibodies at 37°C has been 
shown to deplete MPR from the plasma membrane (Nolan et al., 1987). The 
mAbs were tested for a similar ability, with the view that if individual 
antibodies were ineffective, being unable to cross-link the receptors, 
combinations of two or more mAbs might work. Cells were incubated with 
hybridoma culture supernatants at 37°C, then MPR-300 remaining on the cell 
surface was detected by both immunofluorescent flow cytometry, using the 
same mAb as a probe, and by the ability of cells to endocytose fluorescent 
PPME. Cell surface MPR-300 was compared with MPR-300 expression by 
untreated, control cells. 
Initially, the rabbit antiserum specific for human MPR-300 was tested on U937 
cells, but did not noticably affect cell surface expression (data not shown). 
Twelve mAbs specific for rat MPR-300 (both cloned and uncloned) were then 
assessed using the Clone 9 hepatocyte cell line. All appeared to cause loss of 
MPR-300 from a subpopulation of the cells (data not shown), however this 
ability was shared by an isotype control antibody. Since the purified mAb 
1G7 /9H4 had no such effect, this was evidently due to some other component 
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Ability of different anti-MPR mAbs to inhibit binding of 1 nM 1251-IGF-II 
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of spent hybridoma medium. Testing combinations of mAbs would thus have 
required purification of each one. This was not done. 
3.3.5 The effect of mAb 1G7/9H4 on clinical signs of EAE 
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Although none of the mAbs had a substantial effect on the binding of M6P-
bearing ligands to MPR-300, one mAb, chosen for its high affinity for MPR-300, 
was tested for its effect on EAE. EAE was induced by passive transfer of Con 
A-stimulated spleen cells from a rat with actively-induced disease into 
susceptible animals. Rats were treated in three groups: rats in group A were 
inoculated with cells preincubated with an isotype control mAb, and treated 
i.p. with the same mAb at the time of cell transfer and on subsequent days; rats 
in group B were inoculated with cells pre-incubated with mAb 1G7 /9H4, and 
further treated with the same mAb; rats in group C were inoculated with cells 
preincubated with the control mAb, and then treated with mAb 1G7 /9H4. The 
results are summarized in Fig. 3.12. Of the 4 rats in group B, only two 
developed EAE during the 8 day period for which they were monitered. 
Control rats (group A) all developed disease. Group C, inoculated with cells 
preincubated with control mAb, but then treated with mAb 1G7 /9H4, also all 
developed disease. The data shown in Fig. 3.12 suggests that the treatment 
given to animals in group B reduced the severity of disease compared with 
animals in groups A and C, implying that pre-incubation of effector T cells with 
mAb 1G7 /9H4 was necessary to achieve a protective effect. However, both 
Student's t test and Spearman's Rank test indicate that group B was not 
significantly different to groups A or Cat the 5°/o level. 
3.4 DISCUSSION 
3.4.1 Purification of MPR-300 and MPR-46 
MPR-300 and MPR-46 were purified by affinity chromatography on the basis of 
their ability to bind M6P at pH 6.5, and release it at an acidic pH. Three protein 
bands were apparent by SDS-P AGE. The two bands of high and intermediate 
Mr were assumed to be MPR-300 and MPR-46, respectively. MPR-46 appeared 
as a diffuse, broad band, reflecting the high oligosaccharide content of this 
protein. Although it's apparent Mr was below 46, 000, the glycosylated form of 
MPR-46 has been observed to vary in size depending on the tissue source, with 
43, 000 previously reported for the rat liver receptor (Section 1.11.3.2). 
The affinity purified preparation contained two additional proteins, both with 
Mr of approximately 27, 000 by SDS-P AGE. These bands may represent: 
Fig. 3.12 
Effect of mAb 1G7 /9H4 on passively-transferred EAE. Female Lewis rats 
were injected i.v. with Con A stimulated cells prepared from the spleen of 
a rat immunized ten days previously with 25 µg MBP in FCA. Prior to 
inoculation, cells were incubated with mAb 1G7 /9H4 (group B) or an 
isotype control mAb (groups A and C). Rats were then injected i.p. with 6 
mg/kg of mAb 1G7 /9H4 (groups B and C) or isotype control mAb (group 
A) at the time of cell transfer and on days 1, 2, 3, 4 and 6 post inoculation. 
Clinical profiles of individual rats are shown, where severity of EAE was 
scored on an arbitary scale from O to 5. 
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i) MPR degradation products which either have retained the ability to bind 
M6P, indicating that they contain at least one M6P binding site, or were formed 
after MPR elution from the affinity column 
ii) MPR-associated proteins, or proteins which bind to MPR during the 
purification process, which are released during either the elution step or SDS-
P AGE 
iii) additional M6P-binding proteins, with similar binding properties to MPR-
300 and MPR-46, in that they bind and are released from PMP-Sepharose under 
the same conditions. 
Most studies involving MPR purification have reported the presence of MPR-
300 and MPR-46 only. Several studies, however, suggested that MPR-300 is 
either an aggregate of low molecular weight components, or that low molecular 
weight components are tightly associated with it, on the basis of SDS-P AGE 
and isoelectric focussing of the purified protein (Maler et al., 1985). MPR-300 
has since been cloned and sequenced (Lobel et al., 1987; Lobel et al., 1988; 
MacDonald et al., 1988; Oshima et al., 1988), and is clearly not an aggregate of 
small subunits, thus the latter explanation is more likely. The 27 kDa proteins 
observed here could fall into this category. , They were immunoprecipitated by 
six antibodies that also bound MPR-300, consistent either with precipitation of 
a protein complex, or cross reaction of the antibodies with two separate 
proteins. Four MPR-300-binding mAbs, however, did not immunoprecipitate 
the 27 kDa proteins, which supports the latter possibility. If this is the case, the 
27 kDa bands are more likely to represent degradation products of MPR-300 
than additional, unrelated M6P-binding proteins, as they were recognised by 
six MPR-300-specific antibodies. 
3.4.2 Preparation of mAbs specific for MPR-300 
The aim of this study was to produce mAbs specific for rat MPR-300 and MPR-
46, so as to compare the cellular distribution of the two receptors in resting and 
activated T cells, and to examine the consequences of specifically inhibiting the 
binding of lysosomal enzymes to cell surface MPR-300. Hybridomas were 
prepared using the spleens of mice immunized with the affinity purified rat 
liver preparation, containing MPR-300, MPR-46 and the 27 kDa proteins. A 
total of 97 hybridomas produced antibodies specific for components of the 
purified preparation, as determined by an antibody capture assay on 
immobilized MPR. Of 16 hybridomas selected for further characterization, 12 
l -
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bound to the cell surface of Clone 9 hepatocytes, which express both MPR-300 
and MPR-46, indicating a specificity for the extracytoplasmic domain of either 
receptor. None of these antibodies, however, bound to the cell surface of McA 
RH7777 cells, which do not express MPR-300, suggesting that none were 
specific for MPR-46. This was confirmed by immunoprecipitation of the 
affinity purified preparation, as the antibodies precipitated MPR-300, but none 
bound MPR-46. Evidently, MPR-300 was the most immunogenic component of 
the receptor preparation. In order to generate antibodies to MPR-46, it may be 
necessary to separate the two receptors, and immunize with MPR-46 alone. 
Lack of an antibody to MPR-46 precludes a comparison of the expression of this 
receptor in resting and activated lymphocytes; subsequent chapters will 
consider activation-related changes in expression of MPR-300 only. 
3.4.3 Effect of mAbs on ligand binding to MPR-300 
The second reason for producing mAbs to MPR-300 was to provide a means of 
specifically inhibiting the interaction between cell surface MPR-300 and 
extracellular lysosomal enzymes, so as to assess the contribution made by cell 
surface-expressed lysosomal enzymes to basement membrane degradation. 
The 12 hybridomas with specificity for MPR-300 were examined for their ability 
to interfere with binding of M6P-bearing ligands, using the assay described in 
Chapter 2. Three mAbs showed a slight effect ( <10°/o inhibition) on the binding 
of fluorescein-labelled PPME, a large, M6P-rich polysaccharide, to the cell 
surface of Clone 9 hepatocytes, and a further three inhibited it's receptor-
mediated endocytosis by approximately 20°/o. Only one mAb, however, 
inhibited both binding and uptake (1B6/15E4). The poor reproducibility 
between the binding and uptake assays, and the low level of inhibition 
exhibited by mAb 1B6/15E4 suggested that none of these antibodies interfered 
with ligand binding in a biologically significant manner. Prior ligand binding 
to the receptor also had little effect on binding of the mAbs. The small, 
monovalent PMP inhibited the binding of 4 antibodies by 20-40°/o, while the 
large, multivalent PPME inhibited binding of 5 antibodies by 30-50°/o. Only 2 
mAbs (1C2/13Cll and 5G8), both in different epitope groupings, were affected 
by both ligands, and neither of these inhibited ligand binding by more than 
10°/o. Together, the two sets of experiments suggest that the ligand and 
antibody binding sites do not lie close enough on the receptor surface to 
seriously interfere with one another. As no mAbs showed a clear ability to 
inhibit ligand binding to MPR-300, it was not possible to pursue a study of the 
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consequences of neutralizing this interaction on the ability of T cells to induce 
EAE or to degrade basement membrane components. 
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Production of antibodies with specificity for the M6P binding site of rat MPR-
300 may be difficult to achieve in such closely related a species as the mouse. 
The human, bovine, rat and murine receptor sequences are known to share 80-
900/o sequence homology (Ludwig et al., 1994; Oshima et al., 1988), and while 
the murine and rat sequences have not been directly compared, they may share 
greater homology than this. The M6P-binding site itself is also likely to be 
conserved between species. Thus, similarity in the protein structures of rat and 
murine MPR-300 in the vicinity of the M6P binding site may be too great to 
generate strongly binding antibodies to this region. Examination of the 
remaining hybridoma supernatants, particularly those with lower affinity for 
MPR-300, may yield some that inhibit ligand binding. Alternatively, 
generation of polyclonal antibodies in a more distantly related species may be 
more successful. The possiblity also remains that binding of mAbs to cell 
surface MPR-300, alone or in combination, may lead to a loss of receptors from 
the cell surface as was described by Nolan et al. (1987). 
3.4.4 The effect of a MPR-300-specific mAb on passively-
transferred EAE 
In a preliminary experiment, the effect of one mAb on passively-transferred 
EAE was examined, despite its inability to inhibit ligand binding. Inspection of 
the raw data suggested that treating rats with mAb 1G7 /9H4 after transfer of 
MBP-specific T cells did not reduce disease, but that preincubating the effector 
T cells with mAb 1G7 /9H4 before transfer into recipient rats lessened disease 
severity. The experiment did not include a group in which T cells were 
pretreated with mAb 1G7 /9H4 and recipient rats received control mAb, which 
might have indicated whether preincubating the cells with antibody was itself 
sufficient to inhibit disease. The difference between the group inoculated with 
mAb-pretreated T cells (group B), and the two control groups (A and C) was 
not statistically significant, however, so speculation about whether binding of 
mAbs to MPR-300 in the preincubation step merely targeted them for 
destruction by the immune system, or whether it actually had an effect on T cell 
migration into the CNS, is inappropriate at this stage. The experiment is, 
however, suggestive that mAbs with specificity for MPR-300 may inhibit 
inflammation in EAE, and as such is worth repeating, possibly with different 
mAbs. MAb 1G7 /9H4 was selected on the basis on its high affinity for MPR-
300, however, the two mAbs whose binding was inhibited slightly by prior 
.... 
L ... 
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binding of PMP and PPME could be tested also. Use of antibody F(ab )2 
fragments would also exclude the possibility of antibody-dependent cellular 
cytotoxicity directed towards the MBP-reactive T cells. 
3.5 SUMMARY 
Lysosomal enzymes expressed on extravasating leukocytes by means of cell 
surface MPR-300 have been proposed to participate in degradation of the 
subendothelial basement membrane. As activated T cells display more 
invasive behaviour than do resting lymphocytes, cell surface expression of 
lysosomal enzymes is proposed to be enhanced by cellular activation. This 
may be effected by an activation-induced redistribution of the existing MPR 
pool, such that MPR-300 is increased at the cell surface, providing more 
binding sites for extracellular enzymes, with or without an increase in 
intracellular MPR-46, which is involved in the secretion of newly synthesized 
lysosomal enzymes, and so could increase their concentration in the 
extracellular space. In order to compare expression of MPR-300 in resting and 
activated T cells, and investigate the contribution of MFR-associated lysosomal 
enzymes to the degradative phenotype, monoclonal antibodies specific for rat 
MPR-300 were prepared, and assessed for their ability to neutralize binding of 
extracellular lysosomal enzymes to cell surface MPR-300. 
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MPR-300 and MPR-46 were purified from rat liver by affinity chromatography 
on PMP-Sepharose 4B, and a mixture of the two receptors used to immunize 
BALBI c mice. A total of 97 hybridomas produced antibodies specific for 
components of the purified MPR preparation, as determined by an antibody 
capture assay on immobilized MPR, and 16 were selected for further 
characterization. Twelve of these antibodies bound to MPR in the context of 
the cell surface of Clone 9 hepatocytes, indicating their specificity for the 
extracytoplasmic domain of the receptor. None bound to the cell surface of 
McA RH7777 cells, which lack MPR-300, suggesting that none were specific for 
MPR-46. This was confirmed by immunoprecipitation of the affinity purified 
preparation; the antibodies precipitated MPR-300, but none bound MPR-46. 
Antibodies recognised at least 4 different epitopes on MPR-300, and one or two 
hybridomas from each group (seven in total) were cloned by limiting dilution. 
Clones of one hybridoma produced IgM antibodies, while the remainder 
produced IgG1. 
The 12 hybridomas (seven cloned and five uncloned) were examined for their 
ability to interfere with binding of M6P-bearing ligands to MPR-300, using the 
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assay described in Chapter 2. This was based on the binding or endocytosis of 
fluorescein-labelled PPME, a large, M6P-rich yeast polysaccharide. Three 
antibodies showed a slight effect on the binding of PPME to the cell surf ace of 
Clone 9 hepatocytes ( <10°/o inhibition). Three antibodies also inhibited PPME 
uptake by approximately 20°/o, however only one antibody (IgM 1B6/15E4) 
inhibited both binding and uptake of PPME. The effect of prior ligand binding 
to the M6P binding site on MPR-300 recognition by the antibodies was also 
assessed. The small, monovalent ligand pentamannose phosphate (PMP) 
inhibited the binding of 4 antibodies by 20-40°/o, while the large, multivalent 
PPME inhibited binding of 5 antibodies by 30-50°/o. Binding of only two 
antibodies (1C2/13Cll and 5GB) was inhibited by both ligands. Neither of 
these antibodies affected PPME uptake, however, and only 1C2/13Cll 
influenced PPME binding (10°/o inhibition). The lack of reproducibility between 
the various inhibition studies, and the relatively small effects observed, suggest 
that none of the 12 antibodies examined interfere with the M6P binding site. 
Examination of the ability of the antibodies to deplete MPR-300 from the cell 
surface showed that such an effect was mediated by a component of spent 
hybridoma medium, indicating that the antibodies would need to be p·urified in 
order to assess t_heir effect. It remains possible that a combination of mAbs may 
be able to crosslink MPR-300 and effect its disappearance from the cell surface. 
As none of the 12 mAbs assessed inhibited the binding of M6P-bearing ligands 
to MPR-300 to any significant degree, it was not possible to investigate the 
consequences of neutralizing this interaction on the ability of T cells to induce 
EAE or degrade ECM components. The effect of one mAb, selected on the basis 
of high affinity for MPR-300, on passively induced EAE was assessed, however 
results were inconclusive. Although lack of suitable mAbs precluded this 
aspect of the study, reagents were produced to allow a comparison of MPR 
distribution in resting and activated cells. No mAbs were specific for MPR-46, 
however the preparation of mAbs specific for MPR-300 will facilitate the study 
of activation-related changes in leukocyte expression of this receptor. 
l ... 
CHAPTER 4 
A COMPARISON OF MPR-300 EXPRESSION 
ON THE CELL SURF ACE 
OF RESTING AND ACTIVATED 
T LYMPHOCYTES 
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4.1 INTRODUCTION 
Activated T lymphocytes appear to be more active than resting cells in their 
ability to leave the circulation and enter extravascular tissues, as T cell blasts 
more readily enter the CNS (Hickey et al., 1991; Ludowyk et al., 1992), and are 
required for the adoptive transfer of EAE (Richert et al. , 1979). This can in part 
be explained by the increased adhesiveness of activated lymphocytes for 
vascular endothelium, their increased ability to transmigrate through the 
endothelial cell monolayer (Oppenheimer-Marks et al., 1990; Savion et al., 1984), 
and their enhanced locomotor capacity (Parrott and Wilkinson, 1981; Ratner et 
al., 1988; Wilkinson, 1986). However, the ability of T cells to induce EAE has 
also been correlated with heparanase secretion (Fridman et al., 1987; Naparstek 
et al., 1984; Savion et al., 1984; Vettel et al., 1991), suggesting that an ability to 
degrade the subendothelial basement membrane may also contribute to the 
invasive phenotype. As Parish et al. (1990) have proposed that lysosomal 
enzymes expressed at the cell surface of extravasating leukocytes participate in 
basement membrane degradation, an increase in the MPR-300-mediated 
expression of lysosomal enzymes on the surface of activated T cells would be 
consistent with this model. In Section 1.14, a scenario was presented by which 
this might occur, thus T cell activation could lead to increased cell surface 
expression of MPR-300, increased intracellular expression of MPR-46, or both. 
This study aimed to investigate this question by comparing MPR-300 
expression in resting and activated T cells. 
MPR-300 and MPR-46 have been detected in almost all cell types studied, the 
exceptions being several tumour-derived cell lines, such as Morris hepatoma 
7777 cells and the macrophage line P388Dl, both of which express only MPR-46 
(Gabel et al., 1983; Hoflack and Kornfeld, 1985a; Stein et al., 1987d). The bulk of 
both MPR-300 and MPR-46 is found on intracellular membranes, 
predominantly in the Golgi cisternae, trans-Golgi network and endosomes, 
with 10°/o or less on the cell surface (Bleekemolen et al., 1988; Braulke et al., 1987; 
Brown et al., 1984; Brown and Farquhar, 1984a; Brown and Farquhar, 1984b; 
Fischer et al., 1980a; Fischer et al., 1980b; Geuze et al., 1984a; Geuze et al., 1985; 
Geuze et al., 1988; Griffiths et al., 1988; Griffiths et al., 1990; Jin et al., 1989; 
Kaplan et al., 1977a; Prydz et al., 1990; Stein et al., 1987d; Willingham et al., 1983; 
Willingham et al., 1981). Most studies involving MPR localization have 
concentrated on fibroblasts (Braulke et al., 1987; Fischer et al., 1980a; Kaplan et 
al., 1977a), CHO cells (Willingham et al., 1983; Willingham et al., 1981) and 
tissues and cell lines of hepatic (Brown et al., 1984; Geuze et al., 1984a; Geuze et 
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al., 1985; Geuze et al., 1988; Stein et al., 1987d) and renal origin (Griffiths et al., 
1988; Griffiths et al., 1990; Prydz et al., 1990). Only a few studies have 
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addressed the question of MPR expression by leukocytes. MPR-300 has been 
demonstrated in rabbit alveolar macrophages, with an estimated 15-20°/o on the 
plasma membrane (Shepherd et al., 1984). The U937 human monocyte-like cell 
line expresses a relatively large amount of both MPR-300 and MPR-46, with 
approximately 12°/o of each on the cell surface (Bleekemolen et al., 1988). 
Similarly, MPR-300 is present on the cell surface of IM-9 cells, a myeloma-
derived cell line with characteristics of B lymphoblasts (Brown et al., 1986) and 
also on the human erythroleukaemic cell line K562 (Jin et al., 1989). Murine 
splenic T lymphocytes, however, express a low level of MPR-300 intracellularly 
with none reported on the cell surface (Olsen et al., 1990). With the exception of 
the U937 cell line, MPR-46 expression by these cells has not been determined. 
T cell activation has been shown to induce changes in the intracellular 
expression and localization of lysosomal enzymes in murine T cells (Olsen et al., 
1990). Activation is a complex process during which cells differentiate from 
quiescent (Go) to blast cells, involving extensive changes in cellular 
architecture. Re_sting lymphocytes are small (average diameter 5 µm), 
consisting of a l<:1rge nucleus surrounded by a thin layer of cytoplasm, and 
containing few discrete or morphologically.distinct organelles. They have few 
lysosome-like structures, with low levels of lysosomal enzyme activity in the 
cytosolic fraction (Astaldi et al., 1973; Hirschhorn et al., 1968; Olsen et al., 1990). 
Stimulation with antigen or mitogen results in a rapid increase in biosynthesis, 
leading to a substantial expansion and organization of the cytoplasm. 
Following Con A stimulation, T lymphocytes increase in size (average diameter 
12 µm) and acquire highly developed cytoplasmic structures, including an 
extensive RER, Golgi complex, mitochondria and numerous large vesicles. 
Large lysosomal structures are apparent, and lysosomal enzyme expression 
increases, becoming associated with vesicles rather than being diffuse in the 
cytoplasm (Abraham et al., 1986; Olsen, 1990). 
Lysosome biogenesis is accompanied by changes in the amount and 
intracellular distribution of MPR-300. In resting T cells, small quantities of this 
receptor are found in the cytoplasm as well as in small cytoplasmic vesicles 
(Olsen et al., 1990). Olsen and coworkers, however, demonstrated a 2-fold 
increase in total cellular MPR-300 following Con A stimulation, and found it to 
be located throughout the Golgi complex and in vesicles of the TGN. An 
implication in this study was that MPR-300 was detected on the plasma 
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membrane of Con A stimulated, but not resting, T cells. However, no data for 
cell surface MPR-300 on T cells has been published. 
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This chapter further examines the expression of MPR-300 on resting and 
activated T cells, and for comparison, neutrophils and monocytes, using a mAb 
selected from the panel produced in Chapter 3. The Parish model predicts an 
increase in cell surface expression of MPR-300 following activation, which 
could arise either through increased synthesis of the receptor, or by a 
redistribution of the existing receptor pool (Section 1.14). In the latter case, 
intracellular expression of MPR-300 would decrease by an amount 
corresponding to that diverted to the cell surface, thus it could be informative 
to compare both cell surface and intracellular MPR-300 in resting and activated 
lymphocytes. However, as the bulk of MPR-300 is expressed on intracellular 
membranes, and increased expression due to cell growth is to be expected after 
activation, a small intracellular decrease would probably be undetectable. 
Hence, this study focussed on expression of MPR-300 on the T cell surface. 
4.2 EXPERIMENT AL PROCEDURES 
4.2.1 Preparation of peripheral blood leukocytes 
Fresh whole blood was obtained by venipuncture from healthy human 
volunteers (up to 10 ml), and by cardiac puncture from anaethatised Fischer 
rats (up to 4 ml). Heparin (10 U /ml; Commonwealth Serum Laboratories, 
Melbourne, Australia) was used to prevent coagulation. Blood was centrifuged 
at 60xg for 15 min at RT and the platelet-rich plasma removed. The cell pellet 
was resuspended in PBS containing 10°/o FCS and re-centrifuged at 550xg for 15 
min at RT. The supernatant was discarded, and the upper cell layer, consisting 
mainly of leukocytes, transferred to a 50 ml plastic centrifuge tube. RBCs were 
lysed with 30 ml of 0.83°/o ammonium chloride for 5 min at 37°C. Leukocytes 
were then pelleted by centrifugation at 200xg for 5 min, resuspended in 5 ml 
cold PBS containing 10°/o FCS and counted using a haemocytometer. 
4.2.2 Isolation of leukocyte subpopulations 
To aid in the identification of leukocyte subsets from rat peripheral blood, 
populations defined on the basis of forward and side scatter were separated 
using a FACStar Plus (Becton Dickinson, Mountain View, CA). Leukocytes 
suspended in PBS were filtered through a fine (60 µm) nylon mesh (Ure Pacific, 
Switzerland) prior to sorting, and each population was collected into a 
siliconised glass tube containing 0.5 ml FCS. Cells were pelleted by 
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centrifugation at 200xg for 10 min and resuspended in 100 µl of the 
supernatant. Cytocentrifuge smears were prepared by centrifuging cells onto 
glass microscope slides. Smears were air-dried, fixed and stained with Diff-
Quick stain (Lab Aids, Narrabeen, Australia). The components of each 
population were determined by light microscopy. 
4.2.3 Preparation of lymphoid cell suspensions 
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Female Fischer rats (2-3 months old) were killed by CO2 asphyxiation and the 
thymus, spleen, Peyer's Patches, and cervical, mesenteric and peripheral lymph 
nodes removed and placed in ice-cold HBSS or serum-free RPMI 1640. Single 
cell suspensions were prepared by mincing the tissues finely, then pressing 
through a wire sieve with the plunger from a 5 ml plastic syringe. Cell clumps 
were removed by centrifuging for 8 sand discarding the pellet. RBCs and 
debris were removed by density separation using a mixture of Ficoll-Paque 
(Pharmacia, Uppsala, Sweden) and metrazoic acid (Sigma, St. Louis, MO) at a 
ratio of 9:1 (density= 1.0893 g/ml). Cells suspended in 8 ml of 10°/o FCS/RPMI 
1640 medium were underlaid with 2 ml of the Ficoll-Paque mixture in flat-
bottomed tubes (Disposable Products, Technology Park, Australia), and 
centrifuged at 290xg for 20 min at 20°C. The cells collecting at the interface, as 
well as the Ficoll-Paque medium above the ·RBC/ dead cell pellet, were 
collected and diluted with 10°/o FCS/RPMI 1640. Leukocytes were pelleted by 
centrifugation at 200xg for 5 min at 4°C, washed once with 0°/o FCS/RPMI 1640 
and counted. 
4.2.4 Activation of rat spleen cells with Con A 
Female Fischer rats (2-3 months old) were killed by CO2 asphyxiation and 
spleens removed using sterile technique. Single cell suspensions were 
prepared, and RBCs and debris removed as described in Section 4.2.3. Cells 
were resuspended at a density of 1 x 106 cells/ml in Lymphocyte medium 
(Table 4.1) supplemented with 2 µg/ml Con A. Cells were cultured at 37°C 
(10°/o CO2) for up to 4 days. When cells were to be cultured for 6 days, medium 
was replaced on day 3 with Lymphocyte medium supplemented with 
conditioned medium from Con A stimulated rat spleen cells (15°/o). 
Conditioned medium, containing IL-2, was prepared by stimulating rat spleen 
cells (lxl07) in 10°/o FCS /RPMI 1640 supplemented with 5 µg/ ml Con A for 4-6 
h. Cells were washed twice and resuspended at 5xl06 cells/ml in serum-free 
Table 4.1 
Constituents of lymphocyte culture medium 
To 1 litre of DMEM (Gibco #430-1600) 
(with 1 g/L D-glucose, L-glutamine, 110 mg/1 sodium pyruvate) 
Add: 
Glucose 
Folic acid 
L-Asparagine 
L-Arginine.HCl 
Sodium bicarbonate 
Penicillin 
Streptomycin sulfate 
Neomycin sulfate 
Before use add (per 500 ml): 
4g 
6mg 
36mg 
116mg 
2g 
120mg 
200mg 
200mg 
5 ml x 200 mM L-glutamine (2 mM final concentration) 
5 ml x 100 mM sodium pyruvate (1 mM final concentration) 
5 ml x 1 M Hepes, pH 7.4 (10 mM final concentration) 
0.5 ml 2-mercaptoethanol 
50 ml heat-inactivated FCS 
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RPMI medium supplemented with 100 µg/ ml BSA. After 40 h, the supernatant 
was collected and stored in aliquots at -20°C. 
4.2.5 Activation of human peripheral blood mononuclear cells 
with Con A 
Con A-stimulated human T cells, supplied by Dr H. Warren, were prepared as 
described by Warren and Pembrey (1981). Whole blood was collected from 
normal healthy donors (ACT Red Cross Blood Bank, Woden Valley Hospital) 
into sterile tubes containing preservative-free heparin (Commonwealth Serum 
Laboratories, Melbourne, Australia). It was diluted with an equal volume of 
PBS, and centrifuged at 400xg for 10 min at RT. Two thirds of the platelet-rich 
plasma was removed and an equivalent volume of PBS added. Aliquots (8 ml) 
of diluted blood were underlaid with 2 ml of Ficoll-Paque (Pharmacia Fine 
Chemicals, Uppsala, Sweden) in flat-bottomed plastic tubes (Disposable 
Products, Technology Park, SA, Australia), and centrifuged at 400xg for 10 min. 
The lymphocyte interface was collected, diluted with PBS and centrifuged at 
250xg for 7 min. The cells were washed twice more in PBS and resuspended in 
Eagle's medium (Grand Island Biological Co., NY #F-15) supplemented with 
10°/o FCS, 100 µg/ml penicillin, 100 µg/ml streptomycin, 80 µg/ml neomycin, 
24 mM sodium bicarbonate and 0.1 mM 2-mercaptoethanol. 
Cells were stimulated by culturing lymphocytes at a density of lxl06 cells/ml 
in the above medium supplemented with 20 µg/ ml Con A (Sigma, St. Louis, 
MO) at 37°C (10°/o CO2), After 4 days, cells were washed three times with 
medium, and resuspended at a density of 2xl05 cells/ml in culture medium 
supplemented with a concentrate of conditioned medium from PHA-
stimulated human tonsil lymphocytes (Warren and Pembrey, 1981). After a 
further two days in culture, cells were either used, or frozen and stored in 
liquid nitrogen. Frozen cells were thawed and grown in culture medium, 
supplemented with tonsil lymphocyte-conditioned medium, for one to two 
days. 
4.2.6 Elicitation of peritoneal exudates 
Dehydrated fluid thioglycollate medium (Difeo Laboratories, Detroit, MI) was 
reconstituted at 59.6 g/1 in boiling water, sterilised and left in the dark to 
mature for at least six weeks. Peritoneal exudates were elicited by injecting 
female Fischer rats (2 months old) i.p. with 7 ml of sterile thioglycollate or 
mineral oil. After one to six days, the exudate was extracted by peritoneal 
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lavage using 25 ml of ice-cold HBSS. Cells were harvested by centrifugation at 
200xg for 5 min at 4°C and resuspended in 10°/o FCS/RPMI 1640 medium. 
4.3.7 Flow cytometry 
Leukocyte subsets in peripheral blood, lymphoid tissues and peritoneal 
exudates were distinguished by flow cytometry, on the basis of size (forward 
scatter) and internal granularity (side scatter), as described in Section 4.3.1. Ten 
thousand cells from each sample were collected, and cells from appropriate 
subsets analysed by setting polygonal regions around the populations of 
interest. 
Cell surface MPR-300, CD4 and CD8 were detected by immunofluorescent flow 
cytometry. Cells were stained with a primary antibody: mAb 1G7 /9H4 (rat 
MPR-300), rabbit antiserum cross reactive with human MPR-300 (a gift from Dr 
G.G. Sahagian), mAb W3/25 (rat CD4), mAb OX8 (rat CD8), mAb MT321 
(human CD4) or mAb OKT8 (human CD8). CD45 (OX22), LFA-1 and the IL-2 
receptor were also detected, using mAbs supplied by Dr D. Willenborg. Cells 
were washed three times with 10°/o FCS/RPMI 1640,then incubated with a 
saturating concentration of fluorescein-conjugated secondary antibody: sheep 
anti-mouse lg F(ab')2 fragment (Silenus, Hawthorn, Australia) or swine anti-
rabbit lg antibody (Dakopatts, Denmark). Incubations were in V-bottomed 
plastic microtitre plates using 2xl05 cells in 40 µl volumes. Both incubations 
were for 30 min on ice. After the final incubation, cells were washed twice with 
10°/o FCS/RPMI 1640 and once with PBS. Cells were fixed with 1 °/o 
paraformaldehyde and analysed for fluorescence on a Becton Dickinson 
FACScan (Becton Dickinson, Mountain View, CA) using Lysys II software. 
B cells in lymphocyte populations also stained due to cross reaction of 
fluoresceinated secondary antibodies with lg present on the B cell surface. 
Several methods were used to prevent this in tissue preparations containing a 
large proportion of B cells. During analysis of cells from rat lymphoid tissues, 
undiluted secondary antibodies were preadsorbed with an equal volume of rat 
serum overnight at 4°C, removing any specificity for rat lg. Fresh spleen cells 
in initial experiments involving Con A activation were double-stained with 
biotinylated sheep anti-rat lg antibody (Pierce, Rockford, IL) followed by a 
streptavidin-phycoerythrin conjugate (PE) (Serotec, Star 4B, Oxford, United 
Kingdom), in addition to staining with mAb 1G7 /9H4 and fluorescein-
conjugated secondary antibody. A gate was set on PE-negative cells during 
analysis, and only these cells were analysed for expression of MPR-300. Fresh 
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spleen cells in later Con A experiments were depleted of B cells by panning 
(Section 5.2.1.2). 
Intracellular expression of MPR-300 was determined by immunofluorescent 
flow cytometry of permeabilised cells. Cells were permeabilized with saponin 
using a modification of the method of Goldenthal et al. (1985). Cells were 
washed once with serum-free RPMI 1640, fixed with 4°/o paraformaldehyde for 
5 min at 4 °C, and washed twice with RPMI 1640. Cells were incubated with 
HBSS containing 0.5°/o BSA and 0.1 °/o saponin for 30 min at RT. The blocking 
solution was removed, the cells washed once with 10°/o FCS/RPMI 1640 
containing 0.2°/o saponin, and resuspended in the same medium at 107 cells/ml. 
Aliquots (20 µl) were placed in the wells of V-bottomed microtitre plates and 
stained as for cell surface staining, except that all solutions aside from the 
primary antibody contained 0.1 °/o saponin and all steps were performed at RT. 
After the final incubation, cells were washed three times with 10°/o FCS/RPMI 
1640 containing 0.1 °/o/saponin, then once with PBS, and fixed with 1 °/o 
paraformaldehyde. 
In order to compare the results of separate experiments, expression of MPR-300 
was quantified as an "MPR-300 expression index" (MEI), this being the ratio 
between the median fluorescence intensity ·due to MPR-300 staining and that 
due to an appropriate isotype control antibody. Mean MEI values from 
replicate experiments involving unstimulated cells were compared with a 
theoretical MEI of 1.0 (indicating no MPR-300 expression), using Student's t test 
(Swinscow, 1978). Mean MEI values from stimulated cells were compared with 
unstimulated control populations. p values below 0.05 were considered 
statistically significant. 
4.3 RESULTS 
4.3.1 Identification of peripheral blood leukocyte subsets 
In order to analyze MPR-300 expression on different peripheral blood 
leukocyte populations, leukocytes prepared from human and rat blood were 
resolved into component populations by flow cytometry on the basis of 
forward and side light scatter (Givan, 1992; Salzman et al., 1975; Thompson et 
al., 1986). Fig. 4.l(a) illustrates the characteristic light scatter by lymphocytes, 
monocytes and neutrophils from human peripheral blood. The three major 
leukocyte populations in rat peripheral blood are shown in Fig. 4.l(b). While 
neutrophils were clearly distinguishable in the latter, the monocyte and 
lymphocyte populations were less well separated than in the human scatter 
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Forward scatter 
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Peripheral blood leukocytes from human (a) and rat (b ). 
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Leukocytes were isolated from lysed whole blood and analyzed for 
forward and side scatter by flow cytometry. Populations identified 
as lymphocytes, monocytes and neutrophils are designated L, M and 
N respectively. 
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profile. To confirm the identities of the three populations in rat peripheral 
blood, cells from each region were isolated by sorting and their identities 
determined microscopically. All three populations were highly pure: the 
lymphocyte population contained 96°/o lymphocytes, (3°/o neutrophils and 1 °/o 
monocytes), the neutrophil population contained 93°/o neutrophils (5°/o 
lymphocytes, 1 °/o monocytes, 1 °/o eosinophils), and the monocyte population 
exhibited similar purity. As monocytes were so few in rat peripheral blood 
(approximately 4°/o of total leukocytes), and difficult to clearly distinguish from 
the lymphocytes, these two subsets were considered as one "mononuclear cell" 
population for the purposes of determining MPR-300 expression. 
4.3.2 MPR-300 expression by peripheral blood leukocytes 
Cell surface expression of MPR-300 on human and rat peripheral blood 
leukocytes was determined by immunofluorescent flow cytometry. Fluorescent 
staining of lymphocytes, monocytes and neutrophils was determined by gating 
appropriate populations on the basis of forward and side light scatter, as 
outlined above. Representative fluorescence histograms for the three cell types 
are shown in Fig. 4.2, while the results of multiple experiments are summarised 
in Fig. 4.3. Human neutrophils expressed a relatively high level of MPR-300 on 
the cell surface, however, lymphocytes and ·monocytes expressed minimal, if 
any, cell surface MPR-300. None of the rat leukocyte populations expressed 
MPR-300 on the cell surface. 
4.3.3 MPR-300 expression by rat cells from different lymphoid 
organs 
The majority of cells from lymphoid tissues are small resting lymphocytes, with 
the exception of the spleen, which contains haemopoietic cells of many lineages 
(Sprent, 1993). Mononuclear cells isolated from rat spleen, thymus, Peyer's 
patches and mesenteric and cervical lymph nodes expressed little or no MPR-
300 on the plasma membrane, with no MEI values significantly different from 
1.0 (Table 4.2). MPR-300 expression on cells from peripheral lymph nodes, 
although statistically significant (p<0.05), was very low and probably 
unimportant. Immunofluorescent staining of permeabilized cells showed that 
all expressed MPR-300 on their intracellular membranes (Table 4.2). Mean MEI 
values from spleen and thymus cells were statistically significant (p<0.01), but 
due to large variation between replicates, the mean MEI for mesenteric lymph 
node cells was not. There were insufficient replicates of cells from the 
peripheral and cervical lymph nodes and Peyer's Patches for statistical analysis. 
Fig. 4.2 
Cell surface expression of MPR-300 on rat (a, d) and human (b, c, e) 
peripheral blood lymphocytes, monocytes and neutrophils. Leukocytes 
were resolved into subpopulations by flow cytometry on the basis of 
forward and side light scatter (Fig. 4.1). Expression of MPR-300 was 
measured by immunofluorescent flow cytometry. Binding of rabbit 
antiserum (human MPR-300) and mAb 1G7 /9H4 (rat MPR-300) ( ) 
were compared to staining due to preimmune rabbit serum and an 
irrelevant mouse IgG1 mAb, respectively ( ). High background 
fluorescence of monocytes and neutrophils, compared with 
lymphocytes, was due to non-specific binding of antibodies as 
autofluorescence of unstained cells was low. 
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Lymphocytes 
* 
Neutrophils 
Cell type 
Monocytes 
Cell surface expression of MPR-300 by human ( II ) and rat ( ~ ) peripheral 
blood lymphocytes, monocytes and neutrophils. Expression of MPR-300 was 
measured by immunofluorescent flow cytometry, and the three cell 
populations distinguished on the basis of forward and side scatter (Fig. 4.1) . 
Rat lymphocytes and monocytes were analysed as a single "mononuclear" cell 
population due to the low percentage of monocytes and difficulty in 
distinguishing the two cell types. 
Results are expressed as the ratio between staining due to rabbit antiserum and 
preimmune rabbit serum (human MPR-300), and mAb 1G7 /9H4 and an 
irrelevant mouse IgG1 mAb (rat MPR-300). Each value is the mean+ SEM 
where n=7 (human) and n=3 (rat). A ratio of 1.0, represented by the dotted line, 
indicates no MPR-300 expression. Significant differences from 1.0 are indicated 
by* (p<0.05) and ** (p<0.01). 
Table 4.2 
Cell surface and intracellular expression of MPR-300 by cells 
isolated from a variety of rat lymphoid tissuesa 
Lymphoid tissue Cell surface MPR-300 Intracellular MPR-300 
Spleen 1.0+0.1 (n=lO) 2.5+0.2*** (n=8) 
Thymus 1.4±0.2 (n=4) 3.9+0.2** (n=4) 
Peripheral lymph nodes 1.2±0.0* (n=3) 2.1 (n=2) 
Mesenteric lymph nodes 1.1+0.1 (n=4) 2.4±0.5 (n=4) 
Cervical lymph nodes 1.1 (n=2) 3.4 (n=2) 
Peyer's patches 1.0 (n=2) 2.0 (n=2) 
Clone 9 hepatocytes 6.4 (n ·2) 28.9 (n=2) 
* p<0.05 
** p<0.01 
*** p<0.001 
a Expression of MPR-300 was measured by immunofluorescent flow 
cytometry, and is expressed as the ratio between staining due to mAb 
1G7 /9H4 (rat MPR-300) and an irrelevant mouse IgG1, such that a ratio 
of 1.0 indicates no MPR-300 expression. Each value is the mean±SEM of 
the indicated number of samples. 
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, 
Representative fluorescence histograms (Fig. 4.4) compare MPR-300 expression 
by spleen and mesenteric lymph node cells with that of the Clone 9 hepatocyte 
cell line. Cell surface expression of MPR-300 on Clone 9 cells, but not lymphoid 
cells, is clearly evident. Intracellular MPR-300 expression by all lymphoid cells 
was detectable but low in comparison with Clone 9 hepatocytes, whose high 
intracellular expression is due at least in part to a larger cytoplasmic volume. 
4.3.4 MPR-300 expression by Con A stimulated T lymphocytes 
As described above, freshly isolated lymphocytes from rat spleen expressed no 
detectable cell surface MPR-300. In vitro stimulation with Con A, however, 
induced expression of MPR-300 on the plasma membrane of T lymphocytes in 
a time-dependent manner. Representative fluorescence profiles are shown in 
Fig. 4.5 (a, c, e), and results of multiple experiments are summarised in Fig. 4.6 
(a). MPR-300 expression by unstimulated rat splenic T lymphocytes was 
minimal. Cells were re-examined after 3, 4 and 6 days stimulation with Con A. 
After 3 days, MPR-300 was present on the cell surface, with a mean MEI value 
of 2.1±0.4. Its expression was slightly diminished on day 4, and had dropped 
further by day 6, to a level where it was no longer significantly different from 
the unstimulated spleen cell population (p>0.05) . In a single experiment, MPR-
300 had not yet appeared after 18 h in culture (data not shown), suggesting that 
expression of MPR-300 on the cell surface is· a relatively late event following 
exposure to Con A. 
T cells from human peripheral blood were stimulated with Con A for 4 days, 
and then maintained in IL-2 supplemented medium for a further 2 days. At 
this point they did not express significant amounts of MPR-300 on their plasma 
membranes (Fig. 4.5 (f), Fig. 4.6 (b )) . In a single experiment, a very low level of 
MPR-300 was detected after 3 days of Con A stimulation (Fig. 4.5 (d)) . 
4.3.5 Expression of MPR-300 by thioglycollate-elicited rat 
peritoneal leukocytes 
In order to examine expression of MPR-300 on rat leukocytes activated by an in 
vivo stimulus, cells elicited into the peritoneal cavity by thioglycollate broth 
were compared with resident peritoneal cells. Four cell populations (regions 
Rl - R4), distinguishable by forward and side scatter, were resident in the 
peritoneal cavity prior to thioglycollate treatment (Fig. 4.7 (a)) . Within 48 h of 
thioglycollate injection, there was an 8-fold increase in cell number, from an 
initial level of approximately 14x1Q6 cells. Increases in each of the four resident 
populations contributed to this, however a fifth population (RS) formed the 
Fig. 4.4 
Cell surface and intracellular expression of MPR-300 by rat Clone 9 
hepatocytes (a, b), and lymphocytes isolated from rat spleen (c, d) and 
mesenteric lymph nodes (e, f). MPR-300 expression was measured by 
immunofluorescent flow cytometry: intact and saponin-permeabilized cells 
were stained with mAb 1G7 /9H4 ( ) and compared with cells exposed 
to an irrelevant mouse IgCl mAb (- ). 
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Cell surface expression of MPR-300 by T cells from rat spleen (a, c, e) and 
human peripheral blood (b, d, f) after stimulation with Con A. Expression 
of MPR-300 on freshly isolated cells (a, b) and cells exposed to Con A for 3 
(c, d) and 6 (e, f) days was measured by immunofluorescent flow 
cytometry. Binding of mAb 1G7 /9H4 (rat MPR-300) or rabbit antiserum 
(human MPR-300)(-) was compared with staining due to an irrelevant 
mouse IgG1 mAb or preimmune rabbit serum, respectively(- ). 
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Change in cell surface expression of MPR-300 by rat splenic T cells (~)and 
human peripheral blood T cells ( • ), following varying periods of Con A 
stimulation. Lymphocytes isolated from rat spleen or human blood were 
cultured in the presence of Con A (2 µg/ml and 20 µg/ml respectively) for up 
to 4 days. Rat T cells to be examined on day 6 were removed from the spent 
medium on day 3 and cultured in the presence of conditioned medium from 
Con A-stimulated rat spleen cells (15°/o) for the remaining 3 days. Human T 
cells were removed from Con A on day 4 and cultured in the presence of 
conditioned medium from PHA-stimulated human tonsil lymphocytes for the 
remaining 2 days. 
Expression of MPR-300 was measured by immunofluorescent flow cytometry. 
Results are expressed as the ratio between staining due to mAb 1G7 /9H4 and 
an irrelevant mouse IgG1 mAb (rat MPR-300), and between rabbit antiserum 
and preimmune rabbit serum (human MPR-300). A ratio of 1.0, represented by 
the dotted line, indicates no MPR-300 expression. Each value is the mean+ 
SEM (n=3 to 8). Significant increases from the level of MPR-300 expressed by 
resting T cells (day 0) are indicated by* (p<0.05). 
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Forward scatter 
192 256 
Leukocytes isolated from the peritoneal cavity of an untreated rat (a) and 
three days after intra peritoneal injection of thioglycollate (b ). Leukocytes 
were harvested by peritoneal lavage and analyzed for forward and side 
scatter by flow cytometry. Subpopulations are indicated by regions Rl to 
RS. 
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major component (Fig. 4.7 (b ); Fig. 4.8). This had all but disappeared by day 6, 
and the four original populations declined to basal levels. 
Rl (Fig. 4.7) was identified as a lymphocyte population on the basis of size 
(forward scatter) and expression of CD4, CD8 and CD45 (OX22) antigens (data 
not shown). Staining of cell surface lg by fluoresceinated rabbit anti-mouse lg 
F(ab')2 indicated 1-2°/o of the population to be B cells; the remainder 
presumably being T cells. Although this population was only a small 
component of the resident population (3°/o), it increased by four-fold after 
thioglycollate injection, peaking on day 2 and rapidly returning to normal 
levels (Fig. 4.8). Expression of the lL-2 receptor and LFA-1 on this population 
also increased following thioglycollate injection, by up to 3-fold and 4-fold 
respectively, and remained high for the duration of the experiment (data not 
shown). 
R2 (Fig. 4.7) was assumed to be a neutrophil population on the basis of its high 
side scatter, by comparison with the characteristic scatter given by peripheral 
blood neutrophils (Fig. 4.1 (b)). The remaining populations (R3-R5) probably 
represent the various monocyte/macrophage populations known to be present 
in the rat peritoneal cavity and in thioglycollate-induced exudates (Beelen and 
Walker, 1983). 
MPR-300 was not expressed on the cell surface of any of the resident cells, but 
appeared on lymphocytes (Rl) following thioglycollate injection (Fig. 4.9). 
Expression varied over the 6 day period, peaking between days 3 and 4 (Fig. 
4.10). MPR-300 was also expressed on the lymphocyte population 4 days after 
i.p. injection of mineral oil (data not shown). The only other population to 
express a detectable amount of MPR-300 was R4, which transiently expressed 
the receptor two days after thioglycolate injection. 
4.4 DISCUSSION 
Most cell types examined in earlier studies constitutively express MPR-300 on 
the plasma membrane (Section 4.1). In contrast, this study showed that MPR-
300 is not expressed on the cell surface of unstimulated T lymphocytes, nor on 
most other leukocytes in the resting state. Rat T cells were found to express 
MPR-300 on the cell surface in two instances: following in vitro stimulation with 
Con A, and at a site of inflammation. 
While most other cell types express up to 10°/o of total MPR-300 on the plasma 
membrane (Section 4.1), there was a clear exclusion of this receptor from the 
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Expression of MPR-300 on peritoneal lymphocytes from an untreated rat (a) 
and 4 days after intraperitoneal injection of thioglycollate (b). Leukocytes 
were harvested by peritoneal lavage and expression of MPR-300 measured 
by immunofluorescent flow cytometry. Binding of mAb 1G7 /9H4 (rat 
MPR) (-) was compared with binding of an irrelevant mouse IgGl mAb 
(--· ...... ..... ). The lymphocyte population was distinguished on the basis of 
forward and side scatter (Fig. 4.7). 
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Cell surface expression of MPR-300 by peritoneal leukocytes following 
intraperitoneal injection of thioglycollate. Leukocytes were harvested by 
peritoneal lavage, and MPR-300 expression measured by 
immunofluorescent flow cytometry. Leukocyte subpopulations were 
distinguished on the basis of forward and side scatter (Fig. 4.7): 
lymphocytes ( • ), neutrophils ( D ), R3 ( o ), R4 (A) and RS ( •) are shown. 
Results are expressed as the ratio between staining due to mAb 1G7 /9H4 
(rat MPR-300) and an irrelevant mouse IgGi, such that a ratio of 1.0 
indicates no MPR-300 expression. Each value is the mean±SEM of triplicate 
samples from single rats. 
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cell surface of leukocytes from peripheral blood and lymphoid tissues, the 
latter consisting chiefly of small resting lymphocytes (Sprent, 1993). An 
exception was the expression of MPR-300 by human peripheral blood 
neutrophils, an unexpected result given it's absence from other leukocytes. The 
reason for this species difference between human and rat neutrophils is not 
known. MPR-300 expression on human neutrophils, however, seems consistent 
with an earlier study of PPME binding to this cell type, in which 90°10 of 
binding was associated with L-selectin, leaving 10°10 unaccounted for Gutila et 
al., 1990). Since MPR-300 is expressed on the neutrophil cell surface, it may 
have been responsible for the additional binding. Interestingly, the same study 
showed that while L-selectin was lost from neutrophils stimulated with CSa, 
PPME continued to bind at high levels, raising the possibility that cell surface 
expression of MPR-300 may increase on neutrophils after activation. 
Although MPR-300 was not expressed on the surface of resting leukocytes, it 
was induced on rat T cells by stimulation with the polyclonal mitogen Con A. 
It appeared on splenic T cells after 3 to 4 days exposure to Con A, dropping 
slightly by day 6. Earlier time points were not studied in detail, but suggested 
that this effect does not occur for at least 18 h after Con A stimulation. · The 
appearance of MPR~300 on the lymphocyte surface corresponds with the 
increase in total cellular expression observed by Olsen et al. (1990) after 
stimulating spleen cells for 3 days with Con A. Evidently, the reorganization of 
MPR-300 from a diffuse, cytoplasmic arrangement in resting cells to a more 
organised distribution through the Golgi and TGN of activated cells (Olsen et 
al., 1990), includes the cell surface. This change in MPR-300 localization is 
consistent with its proposed role in the development of EAE. When Con A-
stimulated spleen cells from rats immunised with MBP are used to passively 
transfer EAE, stimulation is usually carried out for 3 days prior to transfer. 
Con A-activated T cells enter the CNS in less than 24 h (Hickey et al., 1991), 
indicating that they have acquired a migratory phenotype and are capable of 
entering the CNS three to four days after initiation of Con A stimulation. This 
coincides with the time when MPR-300 is present on the plasma membrane, so 
is compatible with a role for MPR-300 in T cell migration into the CNS. 
In contrast to rat splenic T cells, human peripheral blood lymphocytes 
stimulated with Con A did not express MPR-300. A possible explanation for 
this will be considered in Chapter 5. Interestingly, a recent study showed that 
M6P inhibited heparanase-mediated ECM degradation by PMA-stimulated 
human peripheral blood lymphocytes (Bartlett et al., 1995a), suggesting that 
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PMA stimulation may induce cell surface expression of MPR-300. If this is the 
case, MPR-300 must appear very rapidly on human lymphocytes, as this effect 
was observed over a stimulation period of only 24 h. 
While the appearance of MPR-300 on the cell surface of rat T cells stimulated 
with Con A is consistent with the proposed model of T cell migration, in which 
activated T cells bind degradative enzymes to their surface via MPR-300, Con A 
does not provide a physiological activation stimulus. Peritoneal exudate cells 
were therefore examined to see whether MPR-300 expression could be induced 
by an in vivo activating stimulus. 
None of the leukocyte populations present in the peritoneal cavity prior to 
thioglycollate injection expressed MPR-300 on the cell surface; nor did elicited 
macrophages and neutrophils. Bartlett et al. (1994) recently showed that M6P 
inhibited thioglycollate-induced entry of leukocytes into the murine peritoneal 
cavity, exerting its inhibitory effect predominantly on neutrophils, which is 
intriguing in view of the lack of MPR-300 on inflammatory neutrophils. This 
may represent yet another species difference, between rat and murine 
neutrophils. Alternatively, neutrophils may express MPR-300 only transiently 
during the extravasation process. 
Although lymphocytes were only a minor component of the cellular exudate, 
they alone expressed MPR-300. Increased expression of the IL-2 receptor and 
LFA-1, both markers of activation (Desroches et al., 1991; Kurzinger et al., 1981; 
Robb, 1984), indicates that lymphocytes isolated from the inflamed peritoneum 
were more highly activated than the original population. In addition, other 
investigators have shown that lymphocytes from peritoneal exudates are 
capable of migration into inflamed tissues: such cells injected into recipient rats 
migrate very well into DTH lesions (Issekutz et al., 1986) and arthritic joints 
(lssekutz and Issekutz, 1991), and can transfer contact sensitivity (Ptak and 
Asherson, 1969). Expression of MPR-300 by these cells thus appears consistent 
with our proposed model, as the activated, and potentially migratory, 
lymphocyte population expressed MPR-300 while the inactive "resident" cells 
did not. 
It is not clear, however, how and where the exudate lymphocytes became 
activated, at what point MPR-300 appeared on the cell surface, and whether it 
was involved in their entry into the peritoneal cavity. This leads to the 
question of whether expression of MPR-300 on the lymphocyte surface is an 
unrelated consequence of activation, or whether it does in fact contribute to the 
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capacfty of the cell to migrate into extravascular tissues. One possibility is that 
the activated lymphocyte population in the peritoneal exudate was derived 
from the "resident" population, rather than from the inflammatory infiltrate. In 
this case, expression of MPR-300 would reflect activation only, without 
necessarily having any correlation with the ability of these cells to migrate. 
Several studies suggest that resident lymphocytes could become activated to 
some extent as a result of the inflammatory reaction: supernatants from non-
immunological inflammatory exudates (both pleural and peritoneal) have been 
shown to induce DNA synthesis in spleen cells and thymocytes in vitro 
(Florentin et al., 1979; Giraud et al., 1983); similarly with medium from 
peritoneal exudate macrophages grown in culture (Calderon et al., 1975; 
Calderon and Unanue, 1975). Lymphocyte proliferation has also been observed 
within the peritoneal cavity after subcutaneous injection of thioglycollate, 
although it was unclear whether cells within the peritoneal cavity were 
stimulated to divide, or whether they were stimulated and commenced DNA 
synthesis in some extraperitoneal site, and migrated into the peritoneum while 
in S phase (Yoffey and Yaffe, 1985). 
A second possibility is that the activated lymphocytes were derived from the 
cellular exudate, in which case MPR-300 expression could well correlate with 
their ability to migrate into the peritoneal c~vity. In spite of the low numbers of 
exudate lymphocytes observed here and by Beelen & Walker (1983), other 
investigators have demonstrated the entry of circulating lymphocytes into the 
inflamed peritoneal cavity , and shown that recently activated lymphocytes 
enter this site more readily than resting cells do. After labelling proliferating 
lymphocytes in vivo with [3H]-thymidine, total lymphocytes collected from the 
thoracic duct of healthy rats (Beacham and Danielle, 1982; Koster and 
McGregor, 1970), or rats infected with the intracellular bacterium L. 
monocytogenes (Koster and McGregor, 1971; Koster et al., 1971), were injected 
intravenously into recipient rats with induced peritoneal inflammation. Large 
proliferating lymphocytes and their smaller progeny entered the inflamed 
peritoneum more readily than did small, non-proliferating cells. Lymphocytes 
entering the inflamed peritoneal cavity of Listeria-infected mice were also 
sensitive to the antimitotic drug vinblastine (North and Spitalny, 1974). Given 
this, it seems likely that the activated lymphocytes examined in the present 
study originated in the circulation, in an activated state, rather than arising in 
situ through non-specific activation. In fact, the small number of lymphocytes 
observed in the peritoneal exudate could then be due to a lack of activated cells 
in the circulation; intravenous injection of activated cells or prior immunization 
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of the rats might have seen a larger lymphocyte influx into the peritoneal 
cavity. 
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If activation is required for lymphocyte entry into the inflamed peritoneal 
cavity, then circulating lymphocytes with the capacity to migrate may already 
express MPR-300 on the cell surface, as proposed by Parish et al. (1990) and 
supported by the effect of Con A on rat spenic T cells. Although no MPR-300 
was detected on peripheral blood lymphocytes, we did not examine these cells 
in an animal undergoing an inflammatory reaction, and the numbers of 
suitably activated cells, with the capacity to migrate, could be too low in a 
healthy animal to detect. However, stimulation of a MBP-specific T cell line 
with antigen does not induce the cell surface expression of MPR-300 (D. 
Willenborg, unpublished results), suggesting that antigen-driven activation, 
unlike Con A-stimulation, may be insufficient to induce redistribution of MPR-
300 to the plasma membrane. This introduces the possibility that some aspect 
of the migration process itself induced the expression of MPR-300 on the 
elicited lymphocytes. It is accepted that after leukocytes adhere to 
endothelium, an "activation" process is triggered by interaction with 
endothelial adhesion molecules (E-selectin)(Lo et al., 1991) or surface-associated 
chemoattractants such as IL-8 (Tanaka et al., 1993b) and platelet activating 
factor (Zimmerman et al., 1992), which converts integrins to a functionally 
active form, facilitating strong adhesion. 
Similarly, interaction with endothelial cells could potentially stimulate a 
redistribution of lymphocyte MPR-300 to the plasma membrane, which can 
occur very rapidly, in as little as 5-15 min (Braulke et al., 1989). Interaction with 
endothelial cells or ECM components could then induce expression of MPR-300 
on the lymphocyte surface, just prior to being needed for basement membrane 
degradation. This scenario has considerable appeal, as there is no need for 
circulating lymphocytes to constitutively express the enzymes required for 
basement membrane degradation on the cell surface. This prompted an 
investigation, described in Chapter 5, to determine whether interaction with 
endothelial cells affects expression of MPR-300 on the plasma membrane of T 
lymphocytes. 
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4.5 SUMMARY 
Activated T cells appear to express a more invasive phenotype than do 
lymphocytes in the resting state, and activation has been correlated with 
increased adhesion to endothelial cells, and enhanced secretion of hydrolytic 
enzymes. Parish et al. (1990) have proposed that activation also induces an 
increase in the cell surface expression of lysosomal enzymes, which may 
participate in degradation of the subendothelial basement membrane by 
extravasating lymphocytes. This could be achieved through an activation-
induced increase in cell surface expression of MPR-300, with or without a 
concommitant increase in the intracellular expression of MPR-46. 
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Cell surface expression of MPR-300 was examined on resting and activated T 
cells from a variety of sources. While MPR-300 is constitutively expressed on 
the plasma membrane of most cell types, there was a clear exclusion of this 
receptor from the plasma membrane of lymphocytes from secondary lymphoid 
tissues and the peritoneal cavity, and leukocytes from rat and human 
peripheral blood, with the exception of human neutrophils. Expression of 
MPR-300 was induced on the surface of rat T lymphocytes by several activating 
stimuli. Stimulation of splenic T cells with Con A induced the appearance of 
MPR-300 in a time-dependent manner. Expression was highest after 3-4 days 
stimulation, and was declining by day 6. Similar treatment did not affect 
human peripheral blood T cells, however. MPR-300 was also detected on the 
plasma membrane of activated T cells present in a thioglycollate-induced 
inflammatory peritoneal exudate. 
This study demonstrates that resting T cells do not express MPR-300 at the cell 
surface, but can be induced to do so by several activating stimuli. Expression 
of MPR-300 on the plasma membrane of Con A-stimulated rat cells 
demonstrates a positive correlation between cell surface expression of MPR-
300, and the ability of the cells to enter the CNS, as Con A-stimulated spleen 
cells from rats sensitized with MBP can transfer EAE 3-4 days after their initial 
exposure to Con A. Lymphocytes from peritoneal exudates have also been 
shown to be capable of migration into inflamed tissues elsewhere in the body. 
This correlation between T cell activation, the ability to enter extravascular 
tissues, and expression of MPR-300 on the plasma membrane, is consistent with 
the hypothesis that activated T cells express an invasive phenotype which 
includes the enhanced expression of lysosomal enzymes at the cell surface. 
CHAPTER 5 
EFFECT OF ADHESION TO 
ENDOTHELIAL CELLS 
ON MPR~300 CELL SURFACE EXPRESSION 
BY HUMAN . AND RAT T LYMPHOCYTES 
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5.1 INTRODUCTION 
Leukocyte migration from the circulation into peripheral tissues is a complex 
process, involving three major steps (Section 1.5). Cells initially adhere to the 
vascular endothelium, pass through the endothelial monolayer, and then 
degrade the underlying basement membrane before passing into the 
interstitium. The adhesion step, which is conceptually similar for all 
leukocytes, involves sequential binding by members of the selectin and integrin 
families. Weak selectin-mediated interactions loosely tether leukocytes to the 
vascular wall, and subsequent integrin-mediated binding converts the transient 
interaction to strong adhesion (Kincade, 1993). 
Although once viewed as passive bystanders during extravasation (Cronstein 
and Weissman, 1993), endothelial cells are now recognised as active 
participants in this process. Circulating leukocytes are able to adhere 
transiently to endothelium, but cannot extravasate into the tissues without 
some induced phenotypic change (Pardi et al., 1992; Pober and Cotran, 1991a). 
Recent work has highlighted the importance of endothelial-derived signals in 
initiating such changes. Triggering of integrin-mediated adhesion provides a 
good example. Although constitutively expressed on leukocytes, integrins 
require cellular "activation" before they develop optimum functional activity 
(Anderson and Springer, 1987; Buyon et al., 1988; Kishimoto et al., 1989b; Smith 
et al., 1988; Vedder and HArlan, 1988; Wright and Meyer, 1986). This increase 
in binding avidity probably results from a conformational change (Kishimoto et 
al., 1989a; Lo et al., 1989; Wright and Meyer, 1986). Activation of integrins can 
be triggered through many membrane receptors, of which at least 12 have been 
identified (Pardi et al., 1992; Tanaka and Shaw, 1992). Some of these are 
preferentially expressed on different leukocyte subsets, providing a means of 
selectively involving those cell types in the adhesion cascade (Hogg, 1993). 
It has become apparent that, in the case of circulating leukocytes tethered to the 
vascular wall, integrins are triggered by ligands present on the apposing 
endothelial surface. Endothelial cells stimulated with thrombin or histamine 
express platelet activating factor (P AF) on the surface (Defilippi et al., 1993; 
Zimmerman et al., 1990), which binds to a G protein-linked receptor on 
neutrophils, and "functionally upregulates" integrin-mediated adhesion to 
endothelium in vitro (Lorant et al., 1991). On cytokine-stimulated endothelial 
cells, E-selectin itself enhances the activity of CD1lb/CD18 on neutrophils (Lo 
et al., 1991). Several members of the chemokine family of cytokines also trigger 
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integrrn-mediated adhesion in vitro. IL-8 is chemotactic for both neutrophils 
and T cells (Larsen et al., 1989; Matsushima and Oppenheim, 1989), is produced 
by endothelial cells stimulated with TNF, IL-1~, or LPS (Streiter et al., 1989), 
and binds to endothelium in vivo (Rot, 1992). In vitro studies have shown that 
IL-8 upregulates the expression and binding avidity of ~2 surface integrins on 
neutrophils (Detmers et al., 1990; Huber et al., 1991). Triggering of lymphocyte 
adhesion has been demonstrated with macrophage inflammatory protein-1~ 
(MIP-1~), which induces adhesion of CDS T cells to endothelial VCAM-1 via ~1 
integrins (Tanaka et al., 1993a; Tanaka et al., 1993b; Tanaka et al., 1993c). MIP-1~ 
has been detected on endothelium in lymphoid tissue and at sites of 
inflammation, (Tanaka et al., 1993a), and is believed to bind to proteoglycan 
glycosaminoglycan sidechains on the endothelial cell surface (Tanaka et al., 
1993a; Tanaka et al., 1993b ). Tanaka & coworkers have proposed that 
endothelial presentation of pro-adhesive cytokines may be a general 
mechanism in the triggering of leukocytes. 
Endothelial cells are clearly capable of interacting with adherent leukocytes in a 
manner which enhances their capacity to extravasate, as described above, by 
presenting an activating signal which increases the affinity of leukocyte 
integrins for their endothelial ligands. Expression of MPR-300 on the plasma 
membrane was proposed by Parish et al. (19~0) to contribute to the ability of 
extravasating lymphocytes to degrade subendothelial basement membrane, by 
providing a means of attaching lysosomal enzymes to the cell surface. In the 
previous chapter, MPR-300 was shown to be inducible on the surface of rat T 
cells by several activating stimuli. In a manner analogous to the "functional 
activation" of leukocyte integrins, interaction with endothelium could also 
provide a stimulus for the upregulation of MPR-300 on the lymphocyte cell 
surface. The aim of this chapter was to investigate this possibility. 
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5.2 EXPERIMENT AL PROCEDURES 
5.2.1 Preparation of leukocyte suspensions 
5.2.1.1 Human leukocytes 
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Human peripheral blood leukocytes were prepared as described in Section 
4.2.1. Activated T cells were prepared by stimulation with Con A or anti-CD3. 
Con A-stimulated cells, prepared as described in Section 4.2.5, were supplied 
by Dr. Hilary Warren (Woden Valley Hospital, ACT, Australia). In most 
experiments, they were used 6 days after initial exposure to Con A. Anti-CD3-
stimulated T cells were activated on anti-CD3 coated plates (Taub et al., 1993). 
Mononuclear cells isolated from human blood (Section 4.2.5) were resuspended 
in 10°/o FCS/RPMI medium at a concentration of 4 x 106 cells/ml, and 
incubated in plastic dishes coated with OKT3 mAb for 8 h at 37°C. Petri dishes 
(100 mm) were prepared by coating overnight at 4 °C with 10 ml of sheep anti-
mouse lg antibody (Silenus, Hawthorne, Australia), diluted to 10 µg/ml in PBS. 
Plates were washed four times with PBS, once with 1 °/o FCS in PBS, then 
incubated with OKT3 culture supernatant diluted 1:10 with 1 °/o FCS/PBS for 1 
hat 4°C. 
5.2.1.2 Rat splenic T cells 
Mononuclear cells were isolated from rat spleen as described in Section 4.2.3. B 
cells were removed by adhesion to immobilized antibody specific for rat lg. 
Petri dishes (10 cm) were coated with 10 ml of a rabbit anti-rat lg antibody 
(Silenus, Melbourne, Australia), diluted to 20 µg/ml in PBS, by incubating 
overnight at 4°C. Plates were washed four times with PBS and once with 5°/o 
FCS/PBS. Spleen cells suspended in 5 ml of 5°/o FCS/PBS (up to 30 x 106 cells 
per plate) were added, and the plate centrifuged for 10 min at 200xg, then 
incubated on a flat surface for 30 min at 37°C. Non-adherent cells were 
removed, and the plate washed vigorously three times. The pooled non-
adherent cells were centrifuged and resuspended in 10°/o FCS/RPMl medium. 
Con A-stimulated spleen cells were prepared as described in Section 4.2.4. 
CHAPTERS Experimental procedures 
5.2.2 ··Preparation of endothelial cell monolayers 
5.2.2.1 Human umbilical vein endothelial cells 
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Human umbilical vein endothelial cells were prepared by the method of Jaffe et 
al. (1973), with some minor modifications. Umbilical cords were obtained from 
the Woden Valley Hospital Maternity Unit, ACT. After removing damaged 
portions, one end of the cord was cannulated with a size 10 foley catheter 
(Boston & Pacific Co., Boston, MA), and blood removed from the vein by 
perfusing with 100 ml PBS. After clamping the other end with forceps, the vein 
was infused with type IV collagenase (50 U /ml; Worthington Biochemical 
Corporation, Melbourne, Australia), and the cord incubated in a shaking 
waterbath at 37°C for 15 min. Endothelial cells were then flushed from the vein 
by perfusion with 20 ml of Medium 199 (Flow Laboratories, Irvine, UK) 
supplemented with 20°/o FCS and 60 U /ml garamycin ((Schering Corp., 
Kenilworth, NJ). The cells were centrifuged at 250xg for 10 min, and the pellet 
resuspended in 5 ml of fresh medium containing 20°/o FCS, 60 U / ml garamycin, 
4 mM L-glutamine, 13.5 U / ml heparin (David Bull Laboratories, Melbourne, 
Australia) and 100 µ1/ ml endothelial cell growth supplement (Sigma, St. Louis, 
MO). The cells were cultured in a gelatin-coated (0.1 °/o) 25 cm2 tissue culture 
flask at 37°C in a 5°/o CO2 atmosphere. Medium was replaced twice per week. 
Once confluent, cells were passaged using 0.1 °/o trypsin and 0.1 °/o EDTA in PBS. 
Cells from passage 1 were used in most experiments (approximately 7-12 days 
in culture). 
5.2.2.2 Rat brain endothelial cells 
Microvascular endothelial cells were obtained from rat brain using a 
modification of the method of Tontsch and Bauer (1989). Twelve day old rats 
were killed by CO2 asphyxiation, and the cortices dissected and rinsed with 
cold sucrose buffer (0.32 M sucrose in PBS). Tissue was chopped into 1 mm 
cubes and homogenized in 3 volumes of ice-cold sucrose buffer, using a 
homogenizer with a loosely fitting pestle (7 strokes). The homogenate was 
diluted fourfold with cold sucrose buffer and centrifuged at lOOOxg for 10 min 
at 4 °C. The supernatant was discarded, along with the white layer of myelin in 
the upper part of the pellet. The remaining pellet was resuspended in the same 
volume of cold sucrose buffer and recentrifuged, and this procedure repeated a 
third time. The pellet was finally resuspended in the same volume of sucrose 
buffer, and centrifuged at lOOxg for 1 min at 4 °C. The supernatant (I) was 
reserved, and the pellet resuspended in sucrose buffer and centrifuged at lOOxg 
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for 1 min at 4°C. The pellet was reserved (III) and the supernatant (II) pooled 
with supernatant I. The pooled supernatants were centrifuged at 340xg for 1 
min at 4°C, the supernatant discarded, and the pellet (IV) reserved. Pellets III 
and IV were each resuspended in sucrose buffer (half the original volume), 
combined and centrifuged at lOOOxg for 10 min at 4 °C. The supernatant was 
discarded and the pellet washed with cold PBS. Microvessels were dissociated 
with type I collagenase (Sigma, St. Louis, MO; #C-0130) by shaking the 
resuspended pellet in 7 ml of collagenase solution (200 U / ml) for 30 min at RT. 
Cells were centrifuged at 200xg for 10 min at RT, and resuspended in Medium 
199 supplemented with 20°/o FCS, 60 U /ml garamycin, 4 mM L-glutamine, 13.5 
U /ml heparin and 100 µ1/ml endothelial cell growth supplement (Sigma, St. 
Louis, MO). Cells were cultured in fibronectin-coated (10 µg/ml) 25 cm2 flasks 
for 24-48 h, then washed with PBS and cultured in fresh medium until 
confluent. They were identified as endothelial cells by immunofluorescent flow 
cytometry, using a mAb specific for Factor VIII-related antigen {Dako, 
Carpinteria, CA}. Cells were passaged using 0.1 °/o trypsin-0.1 °/o EDTA, and 
subsequent passages were grown in gelatin-coated flasks. Cells from passage 2 
were used in all experiments (approximately 30-36 days in culture). 
5.2.3 Adhesion of leukocytes to endothelial cell monolayers 
Endothelial cells were grown to confluence 'in 25 cm2 tissue culture flasks. 
Leukocytes were suspended in 5 ml of endothelial culture medium (Section 
5.2.2.1) at densities ranging from 6xl05 to lxl06 cells/ml, depending on the 
number of cells available, and incubated with the endothelial cells for 2 to 20 h. 
Control cells were incubated in fresh endothelial culture medium for the same 
period. In some experiments, leukocytes were also incubated with the spent 
medium removed from the endothelial cell cultures. 
Non-adherent cells were removed from the flasks, which were then washed 
twice with PBS and the washings pooled with the non-adherent cells. 
Adherent cells were released by incubating the washed flasks with 0.4°/o 
EDTA/PBS (5 ml), reflecting the dependence of T cell-endothelial adhesion on 
divalent cations (de Bono, 1976). Flasks were incubated for 5 to 10 min at 37°C, 
and bound cells were released by gentle pipetting with a 5 ml pipette, the 
process being monitered by light microscopy. A considerable number of 
HUVE cells were also released by EDTA treatment, however T cells were 
released from rat brain endothelial cell monolayers without causing significant 
detachment of endothelial cells. Adherent, non-adherent and control 
leukocytes were centrifuged at 200xg for 3 min, resuspended in 1 ml of 10°/o 
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FCS/RPMI medium and counted using a haemocytometer. In preparations of 
adherent human cells, endothelial cells were distinguished from the leukocytes 
on the basis of size and appearance, and were not included in the cell count. 
5.2.4 Stimulation of T cells with chemokines 
T cells were prepared from rat spleen as described above (Section 5.2.1.2) and 
resuspended in endothelial cell medium at a density of 1 x 106 cells/ml. The 
chemokines MCAF, RANTES, MIP-la and MIP-1~ (Genzyme Corporation, 
Cambridge, MA) were added to the cells at concentrations of 50 ng/ml; IL-8 
was added at 100 ng/ml. Cells were incubated for 2 or 4 hat 37°C. Cells were 
then washed twice in 10°/o FCS/RPMI and resuspended at a density of 107 
cells/ml. 
5.2.5 Flow cytometry 
Leukocyte subsets in peripheral blood were distinguished by flow cytometry, 
on the basis of size (forward scatter) and internal granularity (side scatter). 
Endothelial cells in preparations of adherent human leukocytes were 
distinguished from leukocytes on the basis of their higher forward and side 
scatter. Ten thousand cells from each sample were collected, and cells from 
appropriate subsets analysed by setting polygonal regions around the 
population of interest. 
Cell surface MPR-300, CD4 and CD8 were detected by immunofluorescent flow 
cytometry, as described in Section 4.3.7. 
In order to compare the results of separate experiments, expression of MPR-300 
was quantified as an "MPR expression index" (MEI), this being the ratio 
between the median fluorescence intensity due to MPR-300 staining and that 
due to an appropriate isotype control antibody. Mean MEI values for different 
treatments were compared using Student's t test (Swinscow, 1978). p values 
less than 0.05 were considered statistically significant. 
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5.3 RESULTS 
5.3.1 Effect of adhesion to endothelial cells on cell surface 
expression of MPR-300 by human peripheral blood leukocytes 
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As previously shown (Section 4.3.2), human peripheral blood lymphocytes and 
monocytes do not express MPR-300 on their cell surface, while neutrophils do. 
In this study, MPR-300 expression by leukocytes was assessed after a 4 h 
incubation with confluent HUVE cell monolayers. On average, 30°/o of 
peripheral blood leukocytes adhered to the HUVE cells in this time, and the 
percentages of adherent cells within each subpopulation are summarized in 
Table 5.1. Cell surface expression of MPR-300 on adherent, non-adherent and 
untreated populations was assessed by immunofluorescent flow cytometry 
(Fig. 5.1). Adhesion to endothelial cells did not affect MPR-300 expression on 
lymphocytes and monocytes, as neither adherent or non-adherent populations 
differed significantly from untreated control cells. Expression on adherent 
neutrophils was reduced compared to control levels, however this decrease 
was not significant at the 5°/o level. 
5.3 2 Effect of adhesion to endothelial cells on cell surface MPR-
300 expression by Con A-stimulated human T lymphocytes 
As adhesion to endothelial cells did not induce MPR-300 expression on resting 
T cells, Con A-stimulated T cells were examined to see whether pre-activation 
made them more responsive to interaction with endothelium. Incubation of 
activated T cells with HUVE cell monolayers for varying periods resulted in 
adhesion of up to 50°/o (Table 5.1). Cell surface expression of MPR-300 on 
adherent, non-adherent and control T cells was assessed by immunofluorescent 
flow cytometry, and representative fluorescence histograms illustrating the 
effect of a 4 h incubation are shown in Fig. 5.2. Adherent cells clearly expressed 
MPR-300 on the cell surface, non-adherent cells showed a slight expression, 
while control cells showed none. 
This effect was not reproduced in all experiments. However, blood from a 
number of donors was used in the preparation of Con A-stimulated T cells, and 
yet more donors of umbilical cords in the preparation of HUVE cells. 
Considerable variation was found between T cell donors: of four donors used 
in a total of nine experiments, T cell preparations from two showed increased 
expression of MPR-300 after adhesion to HUVE cell monolayers. Variation in 
HUVE cell donors may have contributed to variable results also, as one of the 
Table 5.1 
Leukocyte adhesion to cultured endothelial cells 
Leukocyte Incubation time (h) Adherent cells (0/o)a Replicates (n) 
Human peripheral 4 30+4 
blood leukocytesb 
- lymphocytes 26+4 5 
- monocytes 67+6 5 
- neutrophils 21+3 3 
Con A-stimulated 2 50+5 4 
human T cellsb, c 
4 36+6 9 
8 39+10 4 
20 41±2 3 
Rat sp lenic T cells d 2 10+1 6 
4 8±2 5 
8 3.1 1 
Con A-stimulated 2 40+12 3 
rat splenic T cellsd, e 
4 39+6 3 
Con A-stimulated 2 58+7 3 
rat splenic T cellsd, f 
4 54±8 3 
a Adherent cells were calculated as a percentage of the total number of cells 
recovered from each flask. 
b Cells incubated with HUVE cell monolayers. 
C Stimulated for 6-8 days. 
d Cells incubated with rat brain endothelial cell monolayers. 
e Stimulated for 3 days. 
f Stimulated for 6 days. 
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Fig. 5.1 
Effect of adhesion to endothelial cells on cell surface expression of MPR-300 
by human peripheral blood leukocytes. Leukocytes isolated from venous 
blood were incubated with HUVE cell monolayers for 4 hat 37°C. Adherent 
and non-adherent cells were obtained as described in Section 5.2.3, and 
compared with untreated leukocytes. Expression of MPR-300 was measured 
by immunofluorescent flow cytometry. Leukocyte subpopulations were 
distinguished on the basis of forward and side scatter (Section 4.3.1). Results 
are expressed as the ratio between staining due to rabbit antiserum (human 
MPR-300) and preimmune rabbit serum. A ratio of 1.0, represented by the 
dotted line, indicates no MPR-300 expression. Each value is the mean+ SEM 
(n=6). 
Fig. 5.2 
Cell surface expression of MPR-300 by Con A-stimulated T cells after 
exposure to endothelial cells. T cells isolated from human peripheral 
blood were stimulated as described in Section 4.2.5, and incubated with 
HUVE cells monolayers for 4 hat 37°C. Adherent (a) and non-adherent 
(b) cells were obtained as described in Section 5.2.3, and are compared 
with untreated T cells (c). 
Expression of MPR-300 was measured by immunofluorescent flow 
cytometry. Binding of r~bbit antiserum (-) was compared to staining 
due to preimmune rabbit serum(- ). 
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better T cell preparations, used several times, gave a negative result only once. 
All experiments using this preparation were included in pooled data described 
below, while the poorly responsive preparations from the aforementioned 
donors were excluded. 
Fig. 5.3 illustrates pooled results from 7 experiments examining the cell surface 
expression of MPR-300 by activated T cells after varying lengths of exposure to 
HUVE cell monolayers. Control cells expressed little MPR-300, reflecting 
similar observations in Section 4.3.4. Non-adherent T cells, or those which 
adhered and were released, expressed low levels of MPR-300, this being 
greatest after 4 and 20 h. There were insufficient replicates at 2 h and 8 h to 
determine statistical significance, however at 4 hand 20 h, MPR-300 expression 
was not significantly greater than control levels (p>0.05). Adherent T cells 
showed higher levels of MPR-300 expression than either non-adherent or 
control cells. Expression varied over the 20 h period, being initially high, 
peaking at 4 h, then dropping to a lower level by 8 h, which was maintained 
until 20 h. Again, there were insufficient replicates at 2 and 8 h to determine 
statistical significance, however, MPR-300 expression at 4 h was significantly 
higher than in control cells (p<0.01), but at 20 h was not (p>0.05). 
In these experiments, T cells were used after a prolonged stimulation period, 
being exposed to Con A for 3 days and maintained in IL-2 for a further 3-5 
days. In an additional experiment, the ability of these cells to upregulate MPR-
300 after adhesion to HUVE cells was compared with that of 3 day T cell blasts 
from the same preparation. While cells stimulated for 6 days expressed MPR-
300 in response to endothelial adhesion, blast cells after 3 days Con A 
stimulation did not (data not shown). 
Confluent HUVE cells were used after one passage (approximately 7-12 days in 
culture). As it has been reported that HUVE cells after only 3-5 days in culture 
better resemble the in vivo endothelium (Khew-Goodall et al., 1993), the ability 
of a primary culture to upregulate cell surface expression of MPR-300 on Con 
A-stimulated T cells was compared with that of passage 1 cultures. The results 
for the primary culture fell within the range shown in Fig. 5.3 (data not shown), 
thus in this situation, primary cultures offered no apparent advantage over the 
more convenient passage 1 cultures. 
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Fig. 5.3 
Effect of adhesion to endothelial cells for varying lengths of time on cell 
surface expression of MPR-300 by Con A-stimulated peripheral blood T 
lymphocytes. Human T cells stimulated for 6 to 8 days (as described in 
Sections 4.2.5 and 5.2.1.1) were incubated for the indicated length of time 
with HUVE cell monolayers at 37°C. Adherent (•)and non-adherent 
(•)cells were obtained as described in Section 5.2.3, and were 
compared with control T lymphocytes ( • ). Expression of MPR-300 was 
measured by immunofluorescent flow cytometry. Results are expressed 
as the ratio between staining due to rabbit antiserum (human MPR-300) 
and preimmune rabbit serum, such that ratio of 1.0 indicates no MPR-300 
expression. Values represent mean+ SEM at 4 h (n=6) and at 20 h (n=3), 
and mean at 2 h and 8 h (n=2). Significant differences from control MEI 
values, calculated for 4 hand 20 h time points, are indicated by* 
(p<0.01). 
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5.3.3 Effect of adhesion to rat brain endothelial cells on cell 
surface MPR-300 expression by rat splenic T cells 
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The preceding experiments assessed cell surface expression of MPR-300 by 
human leukocytes, T cells in particular, obtained from peripheral blood. In a 
second series of experiments, rat splenic T cells were examined for MPR-300 
expression after adhesion to rat endothelial cells. Freshly isolated T cells were 
incubated with rat brain endothelial cells for 2 or 4 h periods, and up to 10°/o 
adhered to the endothelial monolayers (Table 5.1). In two out of six 
experiments, a subset of the adherent population (14°/o and 22°/o respectively) 
showed a dramatic increase in MPR-300 expression after a 2 h incubation with 
endothelial cells (Fig. 5.4 (a)). An increase was also observed in the non-
adherent population (Fig. 5.4 (b)). In the second of these experiments, T cells 
were also incubated with spent medium from the endothelial cell cultures; they 
too showed increased MPR-300 expression on a subset of the cells (data not 
shown). On both occasions, this increase was short-lived, having disappeared 
by the 4 h time point. Another two experiments showed a much smaller 
increase in a subpopulation of the adherent, but not non-adherent, T cells (after 
2 h in one experiment, 4 h in the other; data not shown). In the remaining two 
experiments, no MPR-300 expression was observed. In all six experiments, the 
negative subset of T cells exhibited only a slight increase in MPR-300 
expression, which was not significantly different to control levels (p>0.05). 
These experiments suggest that interaction with endothelial cells has the 
potential to induce transient expression of MPR-300 on a subset of 
unstimulated rat splenic T cells, but that the conditions required for this were 
not always reproduced. 
In contrast to human T cells, Con A-stimulated rat T cells (3 days and 6 days), 
which already express MPR-300 on their surface (Section 4.3.4), failed to show 
additional expression following exposure to endothelial cells. A brief (8 h) 
stimulation with Con A, itself insufficient to induce MPR-300 expression, also 
did not enhance the ability of endothelial cells to upregulate MPR-300 
expression ( data not shown). 
5.3.4 Effect of chemokines on cell surface expression of MPR-300 
by human and rat leukocytes 
Upregulation of cell surface MPR-300 on rat splenic T cells by spent medium 
from endothelial cell cultures implied the involvement of a soluble factor, 
derived either from the endothelial cells or some other contaminating cell type. 
Fig. 5.4 
Cell surface expression of MPR-300 by freshly isolated T cells following 
exposure to endothelial cells. T cells isolated from rat spleen were incubated 
with cultured rat brain endothelial cells for 2 hat 37°C. Adherent (a) and 
non-adherent (b) cells were obtained as described in Section 5.2.3, and are 
compared with untreated T cells (c). 
Expression of MPR-300 was measured by irnmunofluorescent flow 
cytometry. Binding of mAb 1G7 /9H4 (rat MPR-300) (-) was compared to · 
staining due to an irrelevant mouse IgG1 antibody (- ). 
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Endothelial cells can synthesize and secrete a range of soluble chemotactic 
factors, which have the potential to influence adhesion and/ or migration of 
leukocytes. In a preliminary attempt to assess the effect of such factors on 
MPR-300 expression, both rat and human leukocytes were exposed to a range 
of human recombinant chemokines. MCAF, RANTES, MIP-la and MIP-lP did 
not induce expression of MPR-300 on rat splenic T cells at physiologically 
relevant concentrations. As these chemokines were human in origin, this could 
perhaps be accounted for by species specificity in their biological activity, as 
well as cell-type specificity. However, treatment of human peripheral blood 
mononuclear cells with MCAF, RANTES, MIP-la, MIP-lP and IL-8 also failed 
to influence cell surface MPR-300 expression, even after brief stimulation of the 
cells on anti-CD3 coated plates, a procedure which renders T cells responsive to 
the chemokines MIP-la and MIP-lP (Taub et al., 1993) (data not shown). 
As the conditions required for MPR-300 expression were not reproduced in 
each experiment, and the purity of the endothelial cell cultures varied, a 
contaminating cell type may have produced the soluble factor, especially as the 
two most pure endothelial cell cultures gave negative results. Astrocytes were 
identified as a major contaminant in many endothelial cell preparations; 
astrocyte-conditioned medium was tested for its ability to induce cell surface 
expression of MPR-300, but was unable to do so (data not shown). 
5.4 DISCUSSION 
This study demonstrates that interaction with endothelial cells can induce cell 
surface expression of MPR-300 on T lymphocytes, and in the case of human 
cells, that pre-activation of the T cells appears to be required. As shown in 
Chapter 4, human peripheral blood T cells do not express MPR-300 on the cell 
surface, either in the resting state or after Con A stimulation. However, Con A-
stimulated T cells showed a marked increase in MPR-300 expression after 
adhering to HUVE cell monolayers, while unstimulated peripheral blood 
lymphocytes did not. The data presented here suggest that two signals are 
required, such that interaction with endothelium can induce expression of 
MPR-300 on T cells which have recently been activated. An interesting study 
would be to determine the temporal relationship between T cell activation and 
the ability to upregulate expression of MPR-300 following adhesion to 
endothelial cells. Results from one experiment suggest that after Con A 
stimulation for 3 days, T cell blasts were not affected by adhesion to 
endothelium, whereas extensive data showed that after 6 days, when 
blastogenesis has peaked and cells are returning to a characteristic small 
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lymphocyte morphology (Picker et al., 1993b ), cells were able to express MPR-
300. T cells in peripheral blood, however, lacked this ability, although at least 
50°/o demonstrate evidence of previous activation on the basis on CD45RO 
expression (Picker et al., 1993b). This suggests a finite window of time during 
which T cells can respond to endothelial adhesion by expressing MPR-300 at 
the cell surface. 
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The ability of pre-activated T cells to express MPR-300 on the plasma 
membrane after adhesion to endothelial cells can be seen as evidence for, and 
an extension of the original hypothesis, which proposed that activation 
enhances the invasive potential of T cells by increasing the MPR-mediated 
expression of lysosomal enzymes at the cell surface. This study suggests that 
while activation is one requirement, an endothelial-derived signal is also 
needed to induce cell surface expression of MPR-300. This is an attractive 
possibility, as there is no need for circulating T cells to constitutively express 
the enzymes required for degrading the subendothelial basement membrane. 
Instead, cell surface expression of MPR-300, and consequently lysosomal 
enzymes, may be restricted to T cells in contact with the vascular endothelium. 
As discussed in .Section 5.1, endothelial cells are capable of presenting 
"activating" signals to adherent leukocytes, which enhance their ability to 
extravasate, a clear example being the triggering of integrin-mediated binding. 
Upregulation of MPR-300 on adherent T cells could play an analogous role in 
enhancing their invasive capacity, such that circulating T cells adhere to 
endothelium, are induced to express MPR-300 on the plasma membrane, 
migrate beneath the endothelial cell layer where MPR-associated enzymes 
contribute to basement membrane degradation, and finally down-regulate 
expression of MPR-300 when it is no longer required. 
The proposed endothelial-derived signal could induce expression of MPR-300 
at the cell surface by stimulating either increased synthesis of the receptor, or a 
translocation from the intracellular pool to the plasma membrane. The latter 
has been demonstrated in response to extracellular signals in several cell types, 
including fibroblasts, adipocytes and hepatoma cells. Ligands for MPR-300 
(M6P and IGF-II), growth factors (IGF-I and EGF), insulin and phorbol esters all 
induce a rapid and transient translocation of MPR-300, effecting a 1.5 to 4-fold 
increase in cell surface expression (Appell et al., 1988; Braulke et al., 1990; 
Braulke et al., 1989; Corvera et al., 1988; Hu et al., 1990; Oka et al., 1984; Oka et 
al., 1985; Wardzala et al., 1984). The mechanism by which this redistribution 
occurs is not understood, however it can be triggered by at least two signal 
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transduction pathways. M6P stimulates a pathway that is sensitive to cholera 
and pertussis toxins (Braulke et al., 1989), while stimulation by IGF-II, IGF-I and 
EGF appears to involve protein kinase C (Braulke et al., 1990). These studies 
illustrate that external stimuli can modulate the distribution of MPR-300, 
increasing its expression at the cell surface, and at least two signal transduction 
pathways can mediate this effect. G protein and protein kinase C pathways are 
activated by many receptor-ligand interactions, providing a potential 
mechanism for the redistribution of MPR-300 by a variety of stimulatory 
molecules. Thus, it seems quite plausible that an endothelial-associated 
molecule could influence the distribution of MPR-300 in adherent T cells. 
Several differences were evident in the responses of human and rat T cells to 
both activation and interaction with endothelium. Like human peripheral 
blood lymphocytes, rat splenic T cells in the resting state did not express MPR-
300 on the cell surface, however unlike human T cells, they were induced to do 
so by stimulation with Con A (Section 4.3), and adhesion of Con A-stimulated T 
cells to rat brain endothelium produced no further increase. Thus, while pre-
activation and interaction with endothelium were required to induce MPR-300 
expression on human T cells, Con A acting alone was able to provide rat T cells 
with the necessary stimulus. Con A is thought to activate cells by interacting 
with the TCR/CD3 complex, but also binds many other cell surface 
glycoproteins (Weiss, 1993). In binding to rat cells, Con A may mimic the 
endothelial-derived signal as well as supplying an activating signal. Adhesion 
of antigen-stimulated T cell clones to endothelium might help to clarify this. 
Antigen-stimulated cells do not express MPR-300 (D. Willenborg, unpublished 
observations), so the appearance of MPR-300 after adhesion would support the 
concepts that activation and endothelial-derived signals are required by rat T 
cells as well as human, and that the observed differences in rat and human T 
cell behaviour were due to different interactions with Con A. 
On several occasions, when unstimulated splenic T cells were incubated with 
rat brain microvascular endothelial cells, a subset of the adherent cells 
expressed MPR-300 very strongly. This contrasts with the human T cell data, 
as interaction with HUVE cells failed to induce MPR-300 expression on 
unstimulated peripheral blood T cells. Picker et al. (1993b) have shown, 
however, that secondary lymphoid tissues, including the spleen, contain a 
small population of activated T cell blasts, which is absent from peripheral 
blood. The subpopulation of rat spleen cells which expressed MPR-300 after 
adhesion to endothelial cells may thus have been in an activated state. 
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Variation in the size of this activated population might also have contributed to 
the inconsistency of MPR-300 expression between experiments. 
It is notable that rat cells expressed a much higher level of MPR-300 than did 
human cells, which again may reflect some difference in the T cell source, or in 
the source of endothelial cells. There are established differences between 
endothelial cells cultured from large vessels, and microvascular endothelium, 
as measured by cell surface markers (Gerlach et al., 1985; Male, 1990 #522; 
McCarthy et al. 1991). In addition, brain microvessel endothelium differs from 
both large vessel endothelium and endothelium in other tissues; as well as the 
continuous tight junctions which contribute to the blood-brain-barrier, it 
expresses a variety of cell surface proteins not seen on other endothelia (Male et 
al., 1990). The rat brain endothelial cells may then have provided a different or 
more effective stimulus to the T cells. 
An obvious difference in the interaction between T cells and endothelium from 
rat and human was the nature of this association. While HUVE cells induced 
MPR-300 on human T cells by a method dependent on cell-cell contact, rat 
brain endothelium appeared to employ a soluble factor. This factor was 
secreted constitutively by cultured endothelial cells, as it was present in the 
spent medium of cells which had had no contact with T cells. In an in vivo 
situation, a secreted factor would presumably act at close range, as it would be 
rapidly diluted and washed away by the blood flow, a point that has been 
emphasized by Tanaka et al. (1993c). As these investigators demonstrated with 
MIP-1~, it may be presented to adherent cells while immobilized on the 
endothelial surface, however, in the static in vitro situation, sufficient of this 
factor was evidently produced to act on non-adherent cells as well. 
Cultured endothelial cells can synthesize and secrete a range of soluble 
chemotactic factors, able to influence adhesion and/ or migration of leukocytes, 
although this usually occurs in response to cytokine stimulation. These fall into 
two classes: the colony-stimulating factors GM-CSF and G-CSF (Broudy et al., 
1988; Broudy et al., 1986; Munker et al., 1986; Sieff et al., 1987; Zsebo et al., 1988), 
and several members of the chemokine family of cytokines. HUVE cells 
stimulated with INF-a, IL-1~ or LPS secrete IL-8 (Streiter et al., 1989) and 
MCAF (also called MCP-1) (Sica et al., 1990), while IFN-yinduces production of 
IP-10 (Duram and Oppenheim, 1993). Of these, only IL-8 and IP-10 are 
chemotactic for T lymphocytes (Duram and Oppenheim, 1993; Larsen et al., 
1989). Recombinant human IL-8, and several other commercially available 
chemokines were screened for their ability to induce MPR-300 expression on 
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both rat and human T cells, but were unable to reproduce the effect of the 
endothelial cell-derived factor. This is not unexpected, as unstimulated 
endothelial cell cultures were used in this study, while endothelial cells have 
only been observed to secrete chemokines after some form of activation. 
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The possibility remains that some contaminating cell type stimulated the 
endothelial cells to produce the soluble factor, or even produced it itself. The 
conditions required for induction of MPR-300 expression were not reproduced 
in all experiments, which supports the possibility of an interaction between 
endothelium and a second cell type, whose presence varied in different 
preparations. Astrocytes were identified as a contaminant in some of the rat 
brain endothelial cell cultures, however, astrocyte-conditioned medium did not 
reproduce the effect of the endothelial supernatant, indicating that astrocytes 
were not themselves the source of the soluble factor. They might, however, 
stimulate the endothelial cells to produce this factor by contact-dependent or 
-independent means. The latter could be tested in the adhesion assay by 
adding astrocyte-conditioned medium to a relatively astrocyte-free endothelial 
culture. 
An important question which remains is why rat brain endothelium influenced 
T cells via a soluble mediator, when HUVE, cells acted by a contact-dependent 
mechanism. No definitive answer is possible at this stage, other than to suggest 
that differences between the two types of endothelium may be responsible 
(Male et al., 1990). Lymphocyte extravasation normally occurs in the 
microvasculature, not in large vessels, and so HUVE cells do not normally 
support lymphocyte traffic in vivo. The rat brain microvascular endothelial 
cultures may thus be more representative of endothelium in the postcapillary 
venules, and better able to provide appropriate stimuli to adherent 
lymphocytes. Therefore the soluble factor produced by the rat cells may well 
be the more physiologically relevant phenomenon of the two. 
In conclusion, this study supports the proposal that interaction with 
endothelium provides one stimulus for the upregulation of MPR-300 on the T 
cell surface, as this receptor was expressed on human T lymphocytes after 
adhesion to cultured HUVE cells. This effect appeared to be limited to recently 
activated T cells, suggesting that two stimuli, activation and a second, 
endothelial-derived signal are required for expression of MPR-300 on the T cell 
surface. This study suggests that a modification to the Parish model is 
necessary, as activation alone appears insufficient to induce MPR-300 
expression. Activation appears to prime the T cells in some way, such that after 
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they adhere to vascular endothelium, interaction with endothelial cells can 
induce MPR-300 expression on the T cell surface. In the case of the rat EAE 
model used by Parish et al. in developing their hypothesis, no modification is 
necessary as Con A-stimulated T cells were used to passively transfer EAE to 
naive recipients. According to the data presented in this study, these cells 
expressed cell surface MPR-300 prior to transfer, and so a second stimulatory 
signal would not have been required for their entry into the CNS. 
5.5 SUMMARY 
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Endothelial cells are able to provide activating signals to adherent leukocytes, 
producing such effects as integrin-mediated tight binding, which enhance their 
capacity to extravasate and enter extravascular tissues. In this chapter, 
endothelial cells were examined for their ability to induce MPR-300 expression 
on the cell surface of adherent T cells. Expression of MPR-300 on the surface of 
human peripheral blood T cells, both resting and Con A-stimulated, was 
assessed after adhesion to HUVE cell monolayers. Neither cell type expressed 
MPR-300 initially, and adhesion to endothelial cells had no affect on resting 
peripheral blood T cells. Con A-stimulated cells, however, showed a marked, 
transient increase in MPR-300 expression at the cell surface. This effect was 
maximal after 4 h adhesion, and required cell contact. These data suggest that 
two signals are required to induce expression of MPR-300 on the T cell surface, 
such that interaction with endothelium provides a second signal to cells which 
have been pre-activated. 
Some differences were evident in the response of rat splenic T cells to 
interaction with rat brain microvascular endothelial monolayers. A 
subpopulation of unstimulated T cells, possibly representing an in vivo 
activated population, expressed MPR-300 after co-incubation with endothelial 
cells, and this effect was mediated by a soluble factor. Treatment of rat and 
human T cells with the recombinant chemokines MCAF, RANTES, MIP-la and 
MIP-lP had no effect on their expression of MPR-300, suggesting that these 
substances were not responsible. The soluble factor secreted by rat brain 
endothelial cells remains to be identified. 
The response of rat T cells to endothelium further differed in that Con A 
stimulation itself induced expression of MPR-300, and interaction with 
endothelium produced no further increase. This may be reconciled with the 
behaviour of human peripheral blood T cells if the two cell types interact 
CHAPTER 5 Summary 126 
differently with Con A, such that in binding to rat T cells, Con A mimics the 
endothelial-derived signal as well as supplying the pre-activating signal. 
This study demonstrates that endothelial cells can upregulate the expression of 
MPR-300 on T cells, but suggests that this may be the second of two signals, the 
first in this case being supplied by prior stimulation with Con A. This suggests 
a modification to the hypothesis proposed by Parish et al. (1990), such that 
activation primes T cells in some way, enabling them to upregulate MPR-300 
expression in response to an endothelial-derived signal. This is an attractive 
possibility as it correlates with the increased capacity of activated T cells to 
enter extravascular tissues, but restricts cell surface expression of MPR-300, and 
consequently lysosomal enzymes, to T cells already adherent to the vascular 
endothelium, thus limiting the expression of degradative activity to 
lymphocytes that have, or are about to, commence the process of extravasation. 
CHAPTER 6 
GENERAL DISCUSSION 
--
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6. GENERAL DISCUSSION 
During the process of extravasation, leukocytes are thought to employ 
hydrolytic enzymes to degrade the sub-endothelial basement membrane, in a 
manner analogous to invasion by metastatic tumour cells. The ability of 
activated T cells to secrete serine proteases, as well as the endoglycosidase, 
heparanase, and of these to degrade the basement membrane in in vitro assays 
has been well documented. Following recent interest in the concept that the 
cell surface expression of degradative enzymes is important in the focussing 
and control of their activity in relation to locomotion of tumour cells through 
the ECM, Parish et al. (1990) proposed that extravasation of leukocytes may also 
depend on the cell surface expression, rather than secretion, of degradative 
enzymes. As extracellular lysosomal enzymes are known to bind to cell surface 
receptors (MPR-300), they proposed that basement membrane degradation by 
extravasating leukocytes may involve the cell surface expression of lysosomal 
hydrolases. In support of this hypothesis, they demonstrated that exogenous 
M6P, which displaces lysosomal enzymes from cell surface MPR-300, and CS, 
an inhibitor of oligosaccharide processing which prevents formation of the 
lysosomal enzyme M6P recognition marker, are both effective inhibitors of 
passively induced EAE and adjuvant arthrttis in rats, diseases in which the 
initiation of inflammation is dependent on the passage of transferred T 
lymphocytes from the circulation into extravascular tissues. The aim of this 
thesis was to examine the hypothesis, proposed by Parish et al. (1990), that 
extracellular lysosomal enzymes bind to MPR-300 at the cell surface of 
extravasating leukocytes, and contribute to their ability to degrade the 
subendothelial basement membrane. 
6.1 Specific inhibition of ligand binding to MPR-300 
Chapters 2 and 3 describe an attempt to duplicate the anti-inflammatory 
behaviour of M6P, evident in its effect on T-cell mediated EAE and adjuvant 
arthritis in rats, using mAbs specific for MPR-300. A panel of 12 mAbs with 
specificity for the extracellular portion of MPR-300 were produced, and 
screened for their ability to inhibit the binding of M6P-bearing ligands to the 
receptor. None proved to have neutralizing activity, however. Although the 
display of an anti-inflammatory effect by an antibody able to neutralize the 
MPR-300:lysosomal interaction would have provided convincing support for 
this hypothesis, it was not possible to pursue this aspect of the project. 
CHAPTER6 General Discussion 
6.2 The effect of activation on cell surface expression of 
MPR-300 by T cells 
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Activated T lymphocytes are more active than resting cells in their ability to 
leave the circulation and enter non-lymphoid tissues, as T cell blasts more 
readily enter the CNS (Hickey et al., 1991; Ludowyk et al., 1992), and are 
required for the adoptive transfer of EAE (Richert et al., 1979). This can in part 
be explained by their increased adhesiveness for vascular endothelium 
(Oppenheimer-Marks et al., 1990; Savion et al., 1984), and locomotor capacity 
(Parrott and Wilkinson, 1981; Ratner et al., 1988; Wilkinson, 1986), however the 
ability of T cells to induce EAE has also been correlated with heparanase 
secretion (Naparstek et al., 1984; Fridman et al., 1987; Willenborg and Parish, 
1988), suggesting that an ability to degrade the subendothelial basement 
membrane may also contribute to the invasive phenotype. Parish and 
coworkers proposed that the activated, more invasive phenotype may also 
correlate with increased expression of lysosomal enzymes at the cell surface, 
and thus with an increased expression of their cell surface binding sites. 
In Chapter 4, the cell surface expression of lysosomal enzyme binding sites, in 
the form of MPR-300, was compared on resting and activated T cells. MPR-300 
was not expressed on the cell surface of un~timulated lymphocytes, a notable 
absence in view of the seemingly ubiquitous expression of this receptor on the 
plasma membrane of all other cell types previously examined (excepting 
several transformed cell lines which do not express this receptor at all). In 
contrast, MPR-300 was expressed on the surface of rat splenic T cell blasts after 
3-4 days Con A stimulation, and on an activated T cell subpopulation present in 
a thioglycollate-induced peritoneal exudate. Other investigators have 
demonstrated the invasive capacity of similar lymphocyte populations. Con A-
stimulated spleen cells from MBP-immunized rats transfer EAE to naive 
recipients. As the cells are usually stimulated for 3 days prior to transfer, and 
enter the CNS within 24 h (Hickey et al., 1991), they evidently possess a 
migratory phenotype 3-4 days after initiation of Con A stimulation, correlating 
with the appearance of MPR-300 on the cell surface. Lymphocytes derived 
from inflammatory peritoneal exudates are capable of entering inflamed 
tissues, migrating to DTH lesions and arthritic joints when injected into 
recipient animals (lssekutz et al., 1986; Issekutz and Issekutz, 1991), and can 
also transfer contact sensitivity (Ptak and Asherson, 1969). This correlation 
between T cell activation and invasiveness, and expression of MPR-300 at the 
cell surface, is consistent with the proposal that activated T cells express an 
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invasive phenotype which includes the enhanced expression of lysosomal 
enzymes at the cell surface. 
129 
Several activating stimuli did not, however, increase the cell surface expression 
of MPR-300. Con A-stimulation did not affect its expression on T cells derived 
from human peripheral blood, and others have shown that it was not induced 
by antigen stimulation of a MBP-specific rat T cell line (D. Willenborg, 
unpublished observations). The latter express an invasive phenotype, as 
antigen-stimulated MBP-specific T cell lines transfer EAE even more effectively 
than do Con A blasts from immunized animals (Panitch, 1980; Richert et al., 
1981). Thus, while activation may enable lymphocytes to assume a more 
migratory phenotype, it does not necessarily directly induce MPR-300 
expression at the cell surface, raising questions about the original proposal that 
MPR-300 expression is correlated with invasive, activated phenotype. 
6.3 The effect of adhesion to endothelium on cell surface 
expression of MPR-300 by T cells 
Expression of MPR-300 on the surface of peritoneal exudate lymphocytes 
suggested that the extravasation process itself might be involved in 
upregulating MPR-300 expression. The endothelium is known to have an 
activating effect on adherent leukocytes, enhancing their capacity to proceed 
with the extravasation process. Functional activation of integrins, and therefore 
the conversion of loose tethering to tight adhesion, is triggered by leukocyte 
interaction with endothelial adhesion molecules such as E selectin (Lo et al., 
1991), or with endothelial-associated chemoattractants (Tanaka et al., 1993; 
Zimmerman et al., 1992). The endothelium could thus potentially provide an 
MPR-300-inducing stimulatory signal to adherent T cells. 
Chapter 5 describes an investigation of the effect of adhesion to endothelium on 
MPR-300 expression by T cells. The data presented in this study support the 
proposal that interaction with the endothelium results in MPR-300 expression 
on the T cell surface, with the qualifying requirement that the T cells be pre-
activated. Con A stimulated T cells, derived from human peripheral blood, 
showed a marked though transient expression of MPR-300 after adhering to 
HUVE cell monolayers, while unstimulated T cells did not. This suggests that 
two signals are required to induce expression of MPR-300 on the surface of T 
cells: one an initial activation event, and the second derived from interaction 
with the vascular endothelium. Expression of MPR-300 on the surface of 
activated peritoneal exudate T cells, described in Chapter 4, is compatible with 
CHAPTER6 General Discussion 130 
this interpretation as these cells entered the peritoneal cavity from the 
circulation, and so have had the opportunity to respond to an endothelial-
derived signal. The expression of MPR-300 on Con A-stimulated rat T cells, 
which suggested that activation alone could directly induce MPR-300 
expression, can also be reconciled with this interpretation. As adhesion of Con 
A-stimulated cells to endothelium produced no further increase in MPR-300 
expression, it may be that rat and human cells interact differently with Con A, 
such that it supplies rat cells with both the activating and otherwise 
endothelial-derived signals. 
The data presented in this thesis are compatible with the proposal by Parish et 
al. (1990) that the invasive phenotype displayed by activated T cells translates 
to the expression of lysosomal enzymes at the cell surface, but suggest a 
modification to this hypothesis. Expression of MPR-300 does appear to be 
restricted to recently activated T cells, but activation alone, though necessary, 
may be insufficient to induce this change directly. A second signal, derived 
from the endothelium, is also required. This revised model is compatible with 
the physiology of the extravasation process, as circulating lymphocytes have no 
need to constitutively express enzymes required for degrading the 
subendothelial basement membrane. It seems plausible that circulating T cells 
express MPR-300 on the plasma membrane only after adhering to the vascular 
endothelium, just before it is required, thus establishing the machinery 
required to complete the extravasation process. Interaction with the basement 
membrane itself could likewise trigger a similar effect, by analogy with the 
inductive effects of fibronectin and laminin degradation products on proteinase 
expression by synovial fibroblasts and tumour cells, transduced through 
fibronectin and laminin receptors respectively (Turpeenniemi-Hujanen et al., 
1986; Werb et al., 1989). 
6.4 Possible contributions of the Con A- and endothelial-derived 
signals to upregulation of MPR-300 expression on T cells 
What might be the relative contributions of the activating and endothelial-
derived signals to the upregulation of MPR-300 on the T cell surface? The pre-
activation step may prime the T cell in some way that enables it to respond 
directly and rapidly to a stimulus provided by the endothelium at a future 
time. The action of the endothelial-derived signal may resemble that of other 
external stimuli, including M6P, IGF-II and several growth factors, which have 
been shown to produce rapid increases in cell surface MPR-300 on fibroblasts 
by stimulating one of at least two signal transduction pathways, mediated by G 
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proteins (Braulke et al., 1989) or protein kinase C (Braulke et al., 1990b ). These 
substances are thought to modulate the recycling of MPR-300 between the 
intracellular and cell surface pools, increasing the externalization rate while the 
internalization rate remains unchanged (Braulke et al., 1990a; Braulke et al., 
1990b ). As signal transduction pathways can be activated by many cell surface 
receptor-ligand interactions, an endothelial-associated molecule might also 
modulate the distribution of MPR-300 by activating one of these pathways. 
Such a mechanism for the action of the endothelial-derived factor offers one 
explanation for the apparent requirement for T cell pre-activation. Resting T 
cells have a poorly developed cytoplasm, with few discemable organelles, and 
MPR-300 is scattered diffusely through small cytoplasmic vesicles, as well as in 
the cytosol itself (Olsen et al., 1990). Lysosomal enzyme transport and 
intracellular movement of MPR-300 in resting T cells have not been examined, 
but very likely differ from that summarized in Fig. 1.15, given the poorly 
developed organelle system of these cells. If the endothelial-derived signal acts 
by modifying the intracellular movement of MPR-300 between the trans Golgi 
network, prelysosomal compartment and plasma membrane, then quiescent T 
cells may be physically incapable of responding. In contrast, activated 
lymphocytes possess highly developed cytoplasmic structures, including an 
extensive RER, ·conspicuous Golgi complexes, and many cytoplasmic vesicles. 
The distribution of MPR-300 resembles that of other cell types, being localized 
predominantly in the Golgi (Olsen et al., 1990). Activation may therefore be 
necessary to establish MPR-300 recycling pathways between the Golgi/TGN 
and the prelysosomal compartment, which are then available for modulation 
by the endothelial-derived signal. 
6.5 Is activation a requirement for T cell extravasation? 
The requirement for pre-activation shown by human T cells suggests that, if 
lymphocyte extravasation does involve cell surface-bound lysosomal enzymes, 
movement into extravascular tissues is limited to recently activated T cells. T 
cells in most of the adhesion experiments were used 6-8 days after the onset of 
Con A stimulation. In a preliminary experiment, however, T cell blasts 
stimulated for only 3 days were not affected by adhesion to endothelium, 
suggesting a specific temporal relationship between activation and the ability to 
upregulate MPR-300 expression in response to an endothelial-derived signal. If 
this is correct, then our hypothesis suggests that activated T cells at the peak of 
blastogenesis are less capable of entering extravascular tissues than are cells 
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that have passed this peak and are returning to a small lymphocyte 
morphology. 
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Antigen recognition mainly occurs within secondary lymphoid tissues, and 
responsive lymphocytes undergo blastogenesis, which peaks 3-4 days after 
immunization. Some of these cells leave the lymph node, and have been 
observed in the thoracic duct 4-5 days after immunization. By day 6, most 
activated cells have either left the lymph node or reverted to small lymphocytes 
(Asherson et al. (1973) and references therein). This is consistent with the 
pattern of induction of MPR-300 expression on the lymphocyte surface: 
expression of MPR-300 and lysosomal enzymes is unnecessary on T cells at 3 
days stimulation, as such cells in vivo are still located within the lymph node. It 
seems plausible that the ability to upregulate MPR-300 following adhesion to 
the vascular endothelium should be a characteristic of lymphocytes that have 
been released from the lymph node. 
T cell blasts have, however, a clear ability to enter extravascular tissues. MBP-
specific T cell lines stimulated with antigen for 3 days and injected 
intravenously, enter the CNS of the recipient within 24 h (Hickey et al., 1991; 
Ludowyk et al.,-1992). T lymphoblasts generated in vivo in lymph nodes 
draining a site of antigen stimulation, and µ1jected 3-4 days after immunization 
into syngeneic recipients, also accumulate in inflamed skin (Asherson et al., 
1973; Rose et al., 1976). These experimental systems are not physiological, in 
that lymphoblasts are made available in the circulation in greater numbers than 
they would normally be, and at an earlier stage in their development. 
However, they clearly indicate that the mechanisms exist for entry of T 
lymphoblasts into extravascular sites, whether or not they are actually available 
in the circulation. As T cell blasts have the ability to migrate into extravascular 
tissues, then either (a) they do so independently of the proposed MPR-
300 /lysosomal enzyme mechanism; (b) the preliminary data, suggesting that 3 
day T cell blasts do not express MPR-300 after adhesion to endothelium, is 
incorrect; or (c) as activated T cells probably acquire the ability to express MPR-
300 at the cell surface at some point between 3 and 6 days stimulation, the time 
elapsed between the isolation of blast cells and their entry into extravascular 
tissues in the recipients was sufficient to allow the expression of MPR-300. To 
resolve this question, it will be necessary to explore more thoroughly the ability 
of activated T lymphocytes to respond to the endothelial-derived signal with 
increased expression of MPR-300, over the period of blastogenesis. 
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Entry .. 6f T cells into inflammatory sites, particularly those involving DTH 
reactions or chronic inflammation, involves small, recirculating lymphocytes as 
well as lymphoblasts (Parrott and Wilkinson, 1981). While this seems 
inconsistent with the proposed requirement for recent T cell activation, the 
majority of small lymphocytes present in these lesions have more recently been 
shown to express the CD45RO+ antigen (Kingsley et al., 1988; Pitzalis et al., 
1988; Pitzalis et al., 1987; Volpes et al., 1991t and their presence has been 
demonstrated to result from the preferential migration of this subset into the 
lesion (Pitzalis et al., 1991; Sterry et al., 1990). For several years after the 
discovery that T cells can be divided into two relatively distinct populations 
based on their expression of two isoforms of the CD45 antigen (designated 
CD45RO and CD45RA in the human), the CD45RA + and CD45RO+ 
populations were widely thought to represent maturation steps, being naive 
and memory T cells, respectively. Activation of CD45RA + T cells results in a 
phenotypic change to CD45RO+, along with increased expression of adhesion 
molecules, MHC class II and IL-2 receptors, and it was assumed that long-lived 
CD45RO+ memory T cells developed from activated T cells (Mackay, 1993). As 
several groups have demonstrated the reversion of CD45RO+ T cells to the 
CD4SRA+ phenotype (Bell and Sparshott, 1990; Rothstein et al., 1991; Warren 
and Skipsey, 1991), this cell surface antigen has come to be seen more as a 
marker for cellular activation than for memory (Bell, 1992; Lightstone and 
Marvel, 1993; Mackay, 1992; Mackay, 1993). It is likely that the CD45RO 
isoform indicates activated cells and their progeny, which may then revert to 
CD45RA + resting cells at a subsequent stage. Thus, the CD45RO+ small 
lymphocyte population appears to be an intermediate stage between activated 
(CD45RO+) and resting (CD4SRA+) T cells, while the CD4SRA+ population 
includes both naive and previously activated cells (Mackay, 1993). 
According to this interpretation, the small CD45RO+ T cells which 
preferentially enter inflamed lesions are previously activated cells, falling in the 
intermediate stage between T cell blasts and resting cells. As MPR-300 
expression is inducible on T cells 6-8 days after the onset of Con A-stimulation, 
and possibly longer, migration of these small lymphocytes into inflamed sites 
could be compatible with our hypothesis if they include the most recently 
activated members of the CD45RO+ population. In support of this, small 
CD45RO+ T cells entering cutaneous suction blisters created over DTH lesions 
expressed higher levels of the CD45RO antigen than did peripheral blood T 
cells (Pitzalis et al., 1991). As expression of CD45RO has been observed to 
decrease with time after activation (Warren and Skipsey, 1991), the blister cells 
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may re.present a more recently activated population than in the blood as a 
whole. Masuyama et al., (1992) also showed that the 1 °/o of peripheral blood T 
cells able to migrate through an endothelial monolayer in vitro were recently 
activated, based on their expression of high levels of CD26, position in the cell 
cycle (G1 phase) and their active synthesis of RNA. As a result, they proposed 
that the small subpopulation of peripheral blood T cells with the ability to 
adhere to endothelium and penetrate vessel walls in vivo must be activated to 
some extent. Thus, the small CD45RO+ T cells which enter non-lymphoid 
tissues may represent the most activated subset of the CD45RO+ subpopulation 
available in the blood, and hence may have the ability to upregulate cell surface 
MPR-300 expression after adhesion to endothelium. It would be informative to 
determine whether T cells retain the ability to express MPR-300 at the cell 
surface for an extended period after activation. If the hypothesis that lysosomal 
enzymes attached to cell surface MPR-300 are involved in basement membrane 
degradation proves to be correct, then the ability of T cells to upregulate cell 
surface expression of MPR-300 in response to endothelial adhesion could be an 
indicator of their ability to extravasate. 
6.6 Binding of lysosomal enzymes to cell surface MPR-300 
According to the hypothesis proposed by ~arish and coworkers, cell surface 
expression of MPR-300 is not, of itself, sufficient to mediate basement 
membrane degradation. The presence of lysosomal enzymes in the 
extracellular space, with intact M6P markers and capable of activity under 
extracellular conditions, is also essential. This enzyme pool must also be large 
enough to saturate the constantly re-internalizing pool of cell surface MPR-300. 
It is not as yet known whether such a pool of lysosomal enzymes is available to 
extravasating T cells. 
Lysosomal enzymes could be secreted by the extravasating cells themselves. In 
the case of T cells, this could be induced by either of the two activating signals 
required for upregulation of MPR-300 expression. Biosynthesis of lysosomal 
enzymes by T cells increases after activation (Olsen et al., 1990). Hence, 
saturation of MPRs in the Golgi/TGN (the sorting site) could lead to secretion 
of lysosomal enzymes via the secretory pathway. Enzyme secretion could also 
arise from a change in the relative proportions of MPR-300 and MPR-46 in the 
Golgi/TGN. While both MPRs carry newly synthesized enzymes to the 
acidified prelysosomal compartment, MPR-46 has also been implicated directly 
in their secretion (Section 1.13). Thus, an increase in the proportion of MPR-46 
at the sorting site, induced by activation and/ or the endothelial-derived signal, 
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could enhance the secretion of lysosomal enzymes. The intracellular expression 
of MPR-46 was not examined in this study, as the attempt to produce mAbs to 
this receptor was unsuccessful. However, it would be interesting to compare 
the intracellular expression of MPR-46 in activated T cells before and after 
adhesion to endothelium. It is also possible that the increase in cell surface 
MPR-300 observed after binding to endothelial cells, which may have arisen 
from a diversion of intracellular receptors to the plasma membrane, altered the 
balance between MPR-300 and MPR-46 in the Golgi/TGN sufficiently to 
promote secretion of lysosomal enzymes. However, other studies suggest this 
is unlikely, as M6P, IGF-II, growth factors and other substances which induce a 
low level redistribution of MPR-300 to the cell surface do not affect lysosomal 
enzyme targeting (Braulke et al., 1990a). 
An extracellular pool of lysosomal enzymes could also be supplied by other 
cells in the local environment. Endothelial cells, for example, produce several 
matrix-degrading enzyme activities, including uPA, and collagenases, 
gelatinases and a stromelysin (Laug et al., 1985; Menashi et al., 1993), and a 
sulfatase (Bartlett et al., 1995b ). They may also secrete lysosomal enzymes, 
which would then be available to bind to cell surface MPR-300 expressed on 
extravasating T cells. It is feasible that secretion of lysosomal enzymes by 
endothelium could be induced by a cell contact-dependent mechanism, much 
as MPR-300 upregulation on T cells is induced. It is also potentially significant 
that PMA-stimulated microvascular endothelial cells undergo a rapid, 60°/o 
increase in cell surface MPR-300, an effect which is reversed on withdrawal of 
the stimulus (Hu et al., 1990). At sites of inflammation, activated endothelium 
could itself bind extracellular lysosomal enzymes to cell surface MPR-300 and 
contribute to basement membrane degradation. 
6.7 Relevance of this model to extravasation by other leukocytes 
It is not clear from this study whether this model for T lymphocyte 
extravasation can be applied to other leukocytes. In the rat, neither circulating 
neutrophils nor monocytes expressed MPR-300, nor did either cell type within 
the peritoneal exudate. Bartlett et al. (1994) have recently shown, however, that 
M6P inhibited the thioglycollate-induced entry of neutrophils into the murine 
peritoneal cavity. Extravasating neutrophils, like lymphocytes, are subject to 
activating stimuli after adhering to the vascular endothelium, which trigger the 
functional activation of integrins and permit tight adhesion (Zimmerman et al., 
1992), and the possibility that neutrophil activation induces cell surface MPR-
300 expression was discussed in Section 4.4. It is feasible then that cell surface 
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expression of MPR-300 could be induced transiently on adherent neutrophils, 
as it was on T lymphocytes. It would be worthwhile to investigate this 
possibility by examining the expression of MPR-300 on the plasma membrane 
of neutrophils after adhesion to endothelium. 
Human peripheral blood monocytes did not express MPR-300 at the cell 
surface, and there is no evidence to suggest that M6P influences monocyte 
entry into extravascular tissues. Cells of this lineage are, however, capable of 
expressing MPR-300 at the cell surface, as it is expressed on rabbit alveolar 
macrophages (Shepherd et al., 1984) and the U937 monocyte-like cell line 
(Bleekemolen et al., 1988). As adherent monocytes also receive activating 
stimuli from endothelium (Beekhuizen and van Furth, 1993), it may also be 
worthwhile to examine expression of MPR-300 on adherent monocytes. 
6.8 Future work 
Studies presented in this thesis support the hypothesis, proposed by Parish et 
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al. (1990), that extravasating lymphocytes degrade the basement membrane by 
means of cell surface-expressed lysosomal enzymes, as MPR-300 (the lysosomal 
enzyme receptor) was found to be inducible on the cell surface of recently 
activated T cells by an endothelial-derived. signal. An important unanswered 
question is whether the increased expression of MPR-300 on adherent T cells 
was matched by secretion of lysosomal enzymes. Lysosomal enzymes with 
intact M6P markers could be secreted by the T cells themselves, or by other 
cells in the vicinity, such as endothelial cells. As MPR-300 is induced on T cells 
after adhesion to endothelial cells, it is possible that lysosomal enzyme 
secretion could be similarly triggered on either cell type by a contact-dependent 
interaction. 
Another area in need of further study is the proposed requirement for both an 
activating and an endothelial-derived signal for the induction of MPR-300 
expression on the T cell surface. While this appeared to be necessary for 
human T cells, rat T cells expressed MPR-300 after stimulation with Con A 
alone. As interaction with endothelial cells induced no further expression of 
MPR-300 on Con A-stimulated rat cells, this lectin was proposed to supply both 
signals to rat, but not human, T cells. Comparison of Con A with more 
physiological means of T cell activation should help to clarify whether 
activation alone is sufficient to induce MPR-300 expression on the rat T cell 
surface, and if it is not, whether a second, endothelial-derived signal is effective 
in doing so. It has already been shown that in vitro antigen-stimulation does 
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not induce MPR-300 expression on a MBP-specific rat T cell line (D. Willenborg, 
unpublished observations), and T cell blasts activated in vivo could also be 
examined. Activated T cells could be generated in lymph nodes by 
immunizing rats with a contact-sensitizing antigen (Asherson and Allwood, 
1972), and lymph node cell suspensions examined for co-expression of MPR-
300 and activation markers. Antigen-stimulated T cells from both sources 
could then be used in the in vitro endothelial cell adhesion assay, or examined 
for expression of MPR-300 after extravasation into an extravascular site. Koster 
and coworkers have demonstrated that T cell blasts enter the inflamed 
peritoneal cavity (Koster and McGregor, 1971; Koster et al., 1971), thus antigen-
stimulated, fluorescently-labelled T cells could be injected into rats with 
induced peritoneal inflammation, and their appearance in the peritoneal cavity 
monitored. Expression of MPR-300 on the cell surface after, but not before, 
entry into the peritoneal cavity would provide additional evidence that events 
during the extravasation process induce the expression of MPR-300 on pre-
activated T cells. 
Another area not addressed in this study is the effect of cytokine-stimulation on 
the ability of endothelial cells to induce MPR-300 expression of the surface of 
adherent T cells. Leukocytes enter inflamed tissues more readily than they do 
normal, non-lymphoid tissues, this being reflected in the increased expression 
by cytokine-stimulated endothelial cells of tethering molecules, such as the 
selectins, and chemotactic factors capable of triggering integrin-mediated 
binding. Cytokine-stimulated endothelial cells may thus prove more effective 
than unstimulated endothelium in inducing MPR-300 expression on adherent T 
cells. 
Finally, identifying the endothelial-derived signal should prove to be an 
interesting study. In recent years, the vascular endothelium has been 
recognized as playing an active role in the extravasation process, expressing 
selectins responsible for the initial capture and rolling of leukocytes along the 
endothelium, and triggering the functional activation of leukocyte integrins. 
The effect of endothelial cells on the expression of MPR-300 by adherent T cells 
introduces the possibility that the vascular endothelium is also involved in 
triggering the expression of hydrolytic enzymes by adherent leukocytes, 
enabling them to degrade the subendothelial basement membrane and so 
continue their passage through the vascular wall. 
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